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Summary 
Rabies, the archetypal lyssavirus, is one of the most feared viruses known to man and 
globally, is the cause of more than 55,000 deaths per year. Alongside rabies virus, 
numerous related lyssaviruses exist that are also capable of causing fatal disease, 
clinically indistinguishable from rabies. Whilst the human burden of these non-rabies 
lyssaviruses remains unknown, fatalities have been reported.  
 
The lyssavirus glycoprotein is the sole target for virus neutralising antibodies and several 
amino acid epitopes have been linked to virus neutralisation. Lyssaviruses are 
genetically and antigenically categorised into phylogroups that indicate the level of 
protection afforded by current vaccines. It is generally accepted that an antibody 
response to the currently available rabies vaccines affords protection against all viruses 
that are categorised into phylogroup I. However, this antibody response does not protect 
against lyssavirus species within phylogroups II and III. Indeed, experimental data has 
shown that the antibody repertoire induced by rabies virus vaccines is unable to 
neutralise viruses in these phylogroups. In this study we have generated lentivirus 
pseudotypes representing all currently defined lyssaviruses as well as including chimeric 
lyssavirus glycoproteins that have had their antigenic sites swapped between phylogroup 
I and II viruses. Using the wildtype lyssavirus pseudotypes we have confirmed a strong 
level of intra-phylogroup neutralisation in addition to very limited inter-phylogroup 
neutralisation. The antigenic site swap constructs have shown an alteration in both 
glycoprotein functionality alongside altered neutralisation profiles using a variety of 
vaccine induced and divergent lyssavirus specific sera.  
 
Promising cross protective candidates have been cloned into a vaccine strain full length 
backbone and reverse genetics has enabled rescue of these viruses. The growth kinetics 
of recombinant viruses have been studied in vitro and an investigation into the 
pathogenicity and degree of vaccine induced protection against these viruses in vivo has 
been conducted.  
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Chapter 1: Introduction 
1.1 Lyssaviruses 
The lyssaviruses constitute an important group of viruses that are of significance to both 
human and animal health. All viruses within this genus are highly neurotropic and are 
capable of causing a fatal encephalitis, known as rabies.  The prototypic lyssavirus is 
rabies virus (RABV) which is primarily transmitted through the bite of an infected dog 
and causes a higher burden of disease in both humans and animals than any other 
lyssavirus. Indeed, the term ‘lyssa’ is of Greek origin and is believed to refer to a ‘raging 
dog’ (Neville, 2004). Of the remaining lyssaviruses, all have been detected in bats with 
only two exceptions, Mokola virus and Ikoma lyssavirus. Despite safe and effective 
prophylactic and post-exposure tools being available RABV remains endemic across 
much of Africa and the Indian subcontinent. Members of the lyssavirus genus are able to 
infect and cause disease in a very wide host range, with theoretically all mammalian 
species being susceptible to infection (Rupprecht et al., 2008). Susceptibility to infection 
with these viruses does vary with several factors being hypothesised to contribute to the 
duration of the incubation period, progression of disease and overall outcome of 
infection including: site of wound, virus dose, infecting strain and immunocompetence 
of the host. Despite the availability of tools to control rabies infection, the presence of 
virus in sylvatic populations has made elimination in certain mammalian species 
difficult and eradication problematic. From a human perspective, a lack of awareness of 
the disease and variation in incubation period following infection can mean that 
appropriate prophylactic tools are not sought and fatalities occur as where clinical 
disease develops, infection with lyssaviruses is invariably fatal. In 2010 the WHO 
estimated that between 26,400 and 61,000 people died from rabies, with approximately 
33,000 deaths in Asia, 26,000 deaths in Africa and less than 100 deaths in Latin 
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America, North America and Europe combined (WHO, 2005; 2013). 
 
1.1.1 Classification 
Lyssaviruses are classified within the Family Rhabdoviridae, Order Mononegavirales. 
This Order contains three further families: the Bornaviridae, the Filoviridae and the 
Paramyxoviridae. All viruses within this Order contain linear, non-segmented, negative-
sense, single-stranded ribonucleic acid (RNA) genomes. As such, for replication to 
occur, first viral mRNAs are transcribed, and following the accumulation of viral 
proteins within an infected cell, the antigenome sense RNA is generated as a full length 
positive sense replicative intermediate which acts as a template for replication to 
produce the negative sense genome (Whelan et al., 2004). Transcription and replication 
tend to occur in the cytoplasm of infected cells for most members of the 
Mononegavirales with the exception of bornaviruses, nyavirus and the 
nucleorhabdoviruses which carry out transcription and replication in the host cell 
nucleus (Easton & Pringle, 2012). The majority of viruses classified within the 
Mononegavirales encode 5-10 genes in their genomes, although some have evolved to 
generate more through maximisation of coding potential (Pringle & Easton, 1997). 
Genetic reassortment is poorly characterised for most members of the Mononegavirales, 
most likely because the RNA genome is almost always very tightly encapsidated thus 
limiting the potential for hybridisation of an alternative template (Mebatsion et al., 
1996b). So far there have been two documented cases of genetic reassortment in 
Mononegavirales; one between two deletion mutants of Respiratory Syncytial Virus 
(RSV) which were able to produce just one reassortant virus despite being under optimal 
laboratory controlled conditions for reassortment (Spann et al., 2003) and another case 
which detected two potential recombination events in a panel of 44 rabies viruses, both 
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within the polymerase protein (Liu et al., 2011).  
 
Within the Mononegavirales, different members of the Rhabdoviridae are able to infect 
a wide range of hosts including mammals, invertebrates, plants and fish, although to date 
only lyssaviruses and vesiculoviruses have been reported as the cause of clinical disease 
in animals and humans (Table 1.1). Alongside this, novel rhabdoviruses continue to be 
reported with Oita Rhabdovirus being isolated from a horseshoe bat being able to cause 
fatal encephalitis in mice up to 3 weeks of age (Iwasaki et al., 2004), a human pathogen, 
Bas Congo virus, was found to cause a fatal haemorrhagic disease in humans (Grard et 
al., 2012) and Fikirini virus which was isolated from a Hipposideros vittatus bat in 
Kenya (Kading et al., 2013) being recently described. 
 
1.1.1.1 Lyssavirus Phylogroup Classification 
Within the lyssavirus genus, viruses are classified according to both genetic and 
antigenic data. Recently, there has been a shift in nomenclature from the definition of 
lyssavirus genotypes to that of lyssavirus species (ICTV, 2012). In addition to the 
separation of genetically distinct viruses into species, these viruses can also be divided 
into phylogroups using antigenic data (Horton et al., 2010; ICTV, 2012; Nadin-Davis, 
2007) (Figure 1.1).  
 
This differentiation is mainly based on the degree of cross protection afforded by the 
current rabies vaccines between each of the viruses characterised. Genetic data allow 
reliable quantitative comparison of lyssavirus divergence (Marston et al., 2007) and 
sequence data are available for at least one isolate from all 14 virus species classified 
within the lyssavirus genus. Across the open reading frame (ORF) encoding the G  
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Table 1.1: Rhabdovirus taxonomy, species, hosts and vector species. Adapted from 
(Healy et al., 2013a) 
Genus 
Number 
of 
species 
Species 
Primary 
hosts 
Vector 
Ephemerovirus 5 
Bovine ephemeral fever 
virus 
Adelaide river virus 
Berrimah virus 
Kotonkan virus 
Obodhiang virus 
Cattle Arthropods 
Lyssavirus 14 
Rabies virus (RABV) 
Duvenhage virus (DUVV) 
European bat lyssavirus 
type 1 (EBLV-1) 
European bat lyssavirus 
type-2 (EBLV-2) 
Mokola virus (MOKV) 
Lagos bat virus (LBV) 
Irkut virus (IRKV) 
Khujand virus (KHUV) 
Shimoni virus (SHIBV) 
West Caucasian bat virus 
(WCBV) 
Aravan virus (ARAV) 
Australian bat lyssavirus 
(ABLV) 
Bokeloh bat lyssavirus 
(BBLV) 
Ikoma virus (IKOV) 
Dogs 
Humans 
Bats 
N/A 
Vesiculovirus 10 
Vesicular stomatitis 
Alagoas virus 
Vesicular stomatitis 
Indiana virus 
Vesicular stomatitis New 
Jersey virus 
Chandipura virus 
Isfahan virus 
Carajas virus 
Cocal virus 
Maraba virus 
Piry virus 
Cattle 
Arthropo
ds 
Fish 
Arthropods/ 
Annelids 
Cytorhabdovir
us 
9 
Lettuce necrotic yellows 
virus 
Northern cereal mosaic 
Plants 
Aphids 
Arthropods 
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virus 
Strawberry crinkle virus 
Barley yellow striate 
mosaic virus 
Broccoli necrotic yellow 
virus 
Festuca leaf streak virus 
Lettuce yellow mottle 
virus 
Sonchus virus 
Wheat American striate 
mosaic virus 
Nucleorhabdov
irus 
11 
Potato yellow dwarf virus 
Maize mosaic virus 
Sowthistle yellow vein 
virus 
Datura yellow vein virus 
Eggplant mottled dwarf 
virus 
Maize fine streak virus 
Maize Iranian mosaic 
virus 
Rice yellow stunt virus 
Sonchus yellow net virus 
Sowthistle yellow vein 
virus 
Taro vein chlorosis virus 
Plants Arthropods 
Novirhabdovir
us 
4 
Infectious haematopoietic 
necrosis virus 
Viral haemorrhagic 
septicaemia virus 
Snakehead virus 
Hirame rhabdovirus 
Fish 
Link to fish 
parasites 
Sigmavirus 7 
Drosophila melanogaster 
sigmavirus 
Drosophila affinis 
Sigmavirus 
Drosophila ananassae 
Sigmavirus 
Drosophila immigrans 
Sigmavirus 
Drosophila obscura 
Sigmavirus 
Drosophila tristis 
Sigmavirus 
Drosophila stabulans 
sigmavirus 
 
 
 
Fruit flies 
Arthropods 
Perhabdovirus 3 
Perch rhabdovirus 
Sea trout rhabdovirus 
 
Fish 
Unknown 
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Anguillid rhabdovirus 
Tibrovirus 2 
Tibrogargan virus 
Coastal Plains virus 
Ticks 
Cattle 
Arthropods 
Tupavirus 2 
Durham virus 
Tupaia virus 
Birds Unknown 
Unassigned 4 
Flanders virus 
Moussa virus 
Ngaingan virus 
Wongabel virus 
Birds 
Mosquito 
Macropo
d/Midges 
Unknown 
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Figure 1.1: Bayesian phylogenetic analysis of glycoprotein ectodomain sequences. 
Representative lyssavirus species glycoproteins were aligned using BEAST (v1.4.8). 
The GTR+I model of nucleotide substitution and a chain length of 5 million were used. 
The maximum clade credibility tree was chosen using Tree annotator (v1.4.8) and 
viewed using Figtree (v1.1.2) estimated samples sizes were >100 and posterior 
probabilities at key nodes are shown. Scale bar represents substitutions per site. 
Accession numbers for each of the lyssavirus species analysed in this study are: ABLV 
AF801020, RABV CVS-11 EU352767, RABV Pitman Moore AJ871962, RABV Flury-
HEP GU565704, BBLV JF311903, KHUV EF614261, EBLV-2 EF 157977, ARAV 
EF614259, DUVV EU293119, EBLV-1 EU293109 and EU293120, IRKV EF614260, 
MOKV HM623780 and EU293118, SHIBV GU170201, LBV ‘B’ EF547431, LBV ‘C’ 
EF547425, LBV ‘D’ GU170202, LBV ‘A’ EF547432, WCBV EF614258 and IKOV 
JN800509. Taken from (Evans et al., 2012).  
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protein the lyssaviruses are at most 50% divergent at the nucleotide level while sharing 
only 46% identity at the amino acid level, as seen in Table 1.2. 
 
There is a low degree of cross neutralisation between phylogroups I and II and also 
between both phylogroups and WBCV (Horton et al., 2010). In vivo vaccine challenge 
experiments have shown reduced or no efficacy of current licensed rabies vaccines 
against viruses in phylogroup II (MOKV, LBV, SHIBV) (Badrane et al., 2001) and 
phylogroup III (WCBV) (Hanlon et al., 2005; Horton et al., 2014). There is also 
evidence for variable vaccine efficacy against some viruses in phylogroup I (Brookes et 
al., 2006; Brookes et al., 2005; Fekadu et al., 1988; Hanlon et al., 2005) which suggests 
a gradual loss of vaccine protection corresponding to antigenic distance from vaccine 
strains. 
 
1.1.2 Lyssavirus Genome Organisation and Diversity 
All lyssaviruses are enveloped, deriving their envelope from the plasma membrane of 
the infected host cell upon budding; they exhibit the classic rhabdoviral bullet-like 
morphology. They generally measure ~75nm by 180nm (Warrell & Warrell, 2004). The 
genome organisation of members of the lyssavirus genus is relatively simple, consisting 
of between 11,000 and 12,000 nucleotides which encode just five genes: N, P, M, G and 
L (Dietzschold et al., 2008). The genes all have a very conserved sequence across the 
order. The nucleoprotein (N) tends to be at the 3’ end followed by the phosphoprotein 
(P) and matrix protein (M), this is followed by the glycoprotein (G) and the large 
polymerase (L) is always at the 5’ end. This conserved order of genes may be an 
adaptation to enable control of protein expression (Hodges et al., 2012). The genome 
arrangements for a representative of each of the genera within the Rhabdoviridae are  
Chapter 1: Introduction 
31 
 
 
T
a
b
le
 1
.2
: 
N
u
cl
eo
ti
d
e 
a
n
d
 a
m
in
o
 a
ci
d
 i
d
en
ti
ty
 o
f 
th
e 
ly
ss
a
v
ir
u
s 
G
 p
ro
te
in
. 
P
er
ce
n
ta
g
e 
id
en
ti
ti
es
 a
re
 s
h
o
w
n
. 
W
h
er
e 
id
en
ti
ty
 i
s 
le
ss
 t
h
an
 o
r 
eq
u
al
 t
o
 6
0
%
 t
h
ey
 a
re
 s
h
ad
ed
 g
re
en
. 
V
ir
u
se
s 
th
at
 h
av
e 
b
ee
n
 t
en
ta
ti
v
el
y
 c
la
ss
if
ie
d
 i
n
to
 p
h
y
lo
g
ro
u
p
s 
ar
e 
sh
ad
ed
 
ac
co
rd
in
g
ly
. 
T
ak
en
 f
ro
m
 (
E
v
an
s 
et
 a
l.
, 
2
0
1
2
) 
Chapter 1: Introduction 
32 
 
displayed in Figure 1.2. 
 
1.1.2.1 The Nucleoprotein 
The nucleoprotein (N) is the most well conserved of the lyssavirus proteins (Mannen et 
al., 1991) so is the main area studied in the determination of evolutionary relationships 
between lyssavirus isolates (Sacramento et al., 1991). It is also the main target of 
diagnostic, epidemiological and immunological studies (Bourhy et al., 1993; Kissi et al., 
1995). 
 
The protein itself is approximately 450 amino acids in length and one of its main 
functions is the encapsidation of the viral genome. The core of the virus genome; the 
ribonucleoprotein complex (RNP) consists of the genomic RNA tightly encapsidated by 
N in association with the phosphoprotein and large polymerase (Tordo, 1996) and is the 
minimal essential replication unit (Schnell et al., 2010). 
 
N also plays a role in the regulation of transcription and replication (Kissi et al., 1995). 
Accumulation of N in infected cells is thought to trigger a switch from transcription of 
the monocistronic messenger RNAs (mRNA) to transcription of the genome-length 
positive sense template RNA. It is this switch which induces replication of the negative 
sense RNA genome (Tordo et al., 1988). 
 
The N protein has also been implicated in the induction of B cell proliferation and T 
helper cell (Th) responses, both of which can induce long lasting humoral immunity to 
RABVs (Koser et al., 2004).  
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Figure 1.2: Genome organisation and virion morphology within the family 
Rhabdoviridae. (A) A schematic depicting the genome organisation for each genus 
within the family Rhabdoviridae. Gene open reading frame (ORF) sizes are not to scale 
and the full genome lengths have been standardised. Genome lengths and examples of a 
virus for each genus have been given. Genes additional to the minimal 5 are highlighted 
in green. (B) Schematic depiction of a rhabdoviral virion. The RNP core is shown in 
yellow with the P (green) and L (blue) surrounded by the matrix (pale blue) which is 
interspersed with numerous glycoproteins (purple) Adapted from (Healy et al., 2013a).   
Chapter 1: Introduction 
34 
 
1.1.2.2 The Phosphoprotein 
The phosphoprotein (P) gene encodes a protein of between 297 and 303 amino acids 
(Tordo, 1996). It exists in two forms with a molecular weight of 38-41 kDa, depending 
on the degree of phosphorylation (Gupta et al., 2000). It has been reported to play a role 
in viral transcription and also pathogenicity (Tan et al., 2007). P is an essential 
component for the function of the large polymerase (L) protein (Marston et al., 2007). It 
is also able to initiate interaction with the cytoplasmic dynein light chain LC8 which 
may contribute to the axonal transport of RABV in infected neurones (Lo et al., 2001) 
and it may also play a role in down regulation of innate host immune responses post 
infection (Brzozka et al., 2006). 
 
1.1.2.3. The Matrix protein 
The matrix (M) is a small protein; 23-24 kDa which plays multiple roles within the 
lyssavirus replication cycle. It is the main structural component of the virus, being 
proposed to form a layer between the glycoprotein and the RNP core which holds the 
virion in its distinctive bullet-shaped form (Graham et al., 2008). It does this by 
interacting with the cytoplasmic tail of the glycoprotein at the cell membrane and 
promotes virus assembly and budding (Mebatsion et al., 1999). It has also been 
suggested that M may play a role in regulation of the balance between transcription and 
replication of the viral genome (Finke et al., 2003). Like P, it is thought M may be able 
to down regulate some host gene expression (Komarova et al., 2007) and may also be 
involved in the induction of apoptosis of infected cells (Kassis et al., 2004; Morimoto et 
al., 1999). 
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1.1.2.4. The Glycoprotein 
The glycoprotein (G) is composed of 512 to 524 amino acids (Marston et al., 2007) and 
65kDa in weight (Tordo, 1996). It is responsible for numerous functions as it is the only 
viral protein present on the virion surface. For this reason it plays an essential role in 
controlling virus and cell interactions (Rupprecht et al., 2002) including: determination 
of cell tropism (Wunner et al., 1984), fusion of the viral membrane and host cell 
endosome to release the nucleocapsid into the host cell cytoplasm (Gaudin et al., 1993) 
and formation of the virion envelope by its interaction with M (Mebatsion et al., 1999). 
The variation in the sequence of G between lyssavirus isolates is thought to play a role in 
the differing degrees of pathogenicity seen between different RABV strains or lyssavirus 
species (Faber et al., 2005; Morimoto et al., 2000; Yan et al., 2002). 
 
The G protein is the main immunogenic component of the virion, thus the primary target 
for virus neutralising antibodies (VNAs) (Benmansour et al., 1991; Dietzschold et al., 
1982). G is also able to stimulate cytotoxic T cells (Tc) (Macfarlan et al., 1986) and in 
combination with the induction of VNAs is the major protein responsible for the 
induction of protective immunity against challenge (Wiktor, 1985). 
 
1.1.2.4.1 Antigenic Sites on the Glycoprotein 
Present on the surface of the virion, the lyssavirus G protein is the sole viral component 
responsible for induction of a host antibody response and as such is the target of host 
neutralising antibodies (Gaudin et al., 1992). The regions of the G protein responsible 
for the differences in antigenicity seen are ill defined. The G protein is relatively 
conserved in length across the genus with an ORF encoding between 512 and 534 amino 
acids. Furthermore all lyssavirus proteins contain 14 highly conserved cysteine residues 
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alongside the antigenic domains that contribute to the structure of the protein (Figure 
1.3).  
 
Currently, defined antigenic domains within the G protein include four major antigenic 
sites and one minor antigenic site. Historically, these have been defined through 
mapping of monoclonal antibody (mAb) binding sites as shown in Table 1.3. 
 
The positions and a consensus amino acid sequence for each antigenic site are detailed in 
Table 1.4.  
 
Antigenic site I is a region containing both conformational and linear epitopes as it is 
delineated by the monoclonal antibody mAb 509-6 that recognises a conformational 
epitope as well as antibody CR57 that recognises a linear epitope (Benmansour et al., 
1991). This site also appears to be the region recognised by the potent neutralising 
antibody, 62-7-13, a candidate antibody that has been proposed for inclusion in a 
monoclonal antibody based passive immunisation cocktail (Both et al., 2013; Muller et 
al., 2009).  
 
Antigenic site II has two domains, IIa and IIb, and is thought to be present as a 
discontinuous conformational epitope (Benmansour et al., 1991). Antigenic site II is 
proposed to be recognised by the neutralising antibody, E559 (Muller et al., 2009).  
 
Antigenic site III is continuous, though no site specific mAbs are able to bind unfolded 
protein which indicates that this epitope forms part of a loop on the protein surface and  
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Figure 1.3: Schematic representation of the lyssavirus G protein. Defined antigenic 
sites and conserved cysteine residues are shown. C residues are coloured according to 
proposed linkages within the mature protein. TM: transmembrane; NH2: amino 
terminus; COOH: Carboxyl-terminus. Taken from (Evans et al., 2012). 
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Table 1.3: Methods by which each of the proposed lyssavirus antigenic sites were 
identified. Amino acid position numbering is given following the removal of the signal 
peptide. The reference describing each specific mAb is given in superscript. 
Antigenic 
Site 
Position Identification Specific mAbs 
Viral 
Source 
Reference 
I 226-231 mAb mapping 509-6
a,b
 CVS-11 
(Lafon et al., 
1983)
a
 
(Benmansour et 
al., 1991)
b
 
II 
IIb – 
34-42 
 
IIa – 
198-200 
mAb mapping 
231-11
a
 
220-8
a
 
101-1
a,c
 
162-3
a
 
719-3
a,c
 
226-11
a
 
240-3
a 
 
46D2
b
 
52A4
b
 
49C2
b
 
7B1
c
 
19C5
c
 
24A1
c
 
25A1
c
 
25A2
c
 
25B4
c
 
45C5
c
 
PVE
c
 
PVK
c 
 
CVS-11 
ERA 
(Lafon et al., 
1983)
a
 
(Prehaud et al., 
1988)
c
 
(Benmansour et 
al., 1991)
b
 
III 330-338 mAb mapping 
194-2
a,d,e
 
248-8
a,d,f,e
 
718-4
a
 
507-1
a,e
 
50AC-1
f
 
50AD-1
f
 
21B4
e
 
CVS-11 
(Lafon et al., 
1983)
a
 
(Dietzschold et 
al., 1983)
d
 
(Seif et al., 1985)
e
 
(Coulon et al., 
1998)
f
 
IV 
251 or 
263-264 
mAb mapping 
110-3
g 
RG129
h 
15-15
i
 
CVS-11 
ERA 
HEP-
Flury 
RC-HL 
(Bunschoten et 
al., 1989)
g 
(Ni et al., 1995)
h 
(Luo et al., 1997)
i
 
a 342-343 mAb mapping 
40E1
b
 
48C5
b
 
40A1
b
 
49C3
b
 
20A2
b
 
11C6
b
 
CVS-11 
(Benmansour et 
al., 1991)
b
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Table 1.4: Amino acid sequence of the lyssavirus antigenic sites. The amino acid 
sequences are given (numbering starts at the beginning of the ORF). The residues 
coloured in red are those that differ from the RABV sequence, given in the top row. 
Taken from (Evans et al., 2012). 
Virus 
Phylo-
group 
Site II b       
(53-61) 
Site 
II a    
(217-
219) 
Site I     
(245-
250) 
Site 
IV       
(282-
283) 
Site III       
(349-357) 
Site 
'a'      
(361-
362) 
Accession 
Number 
RABV I GCTNLSEFS KRA KLCGVL FH KSVRTWNEI KG RABV_CVS 
GQ918139.1 
ABLV I GCTSLSGFS KKA KLCGIS FN KSVRTWDEI KG ABLV 
AF418014.1 
ARAV I GCTNLSGFT KKA KLCGVM FH KSVREWTEV KG ARAV 
EF614259.1 
BBLV I GCTTLTVFS KKA KLCGVS FH KSIRQWTEI KG BBLV 
JF311903.1 
DUVV I GCTTLTPFS KKA RLCGIS FH KSVREWKEI KG DUVV_RV131 
AY062055.1 
EBLV-1 I GCTTLTPFS KKA RLCGVP  FH KSVREWKEV KG EBLV-1_RV20 
AY062061.1  
EBLV-2 I GCTTLTVFS  KKA KLCGIS  FH KSIREWTDV KG EBLV-
2_RV628 
AY721613.1 
IRKV I GCTTLTAFN  KKA KLCGMA  DR KSIREWKEI KG IRKV 
EF614260.1  
KHUV I GCTTLSGFT KRA KLCGVS FH KSIREWSEI KG KHUV 
EF614261.1 
LBV A II GCSETSSFT RKA TLCGKP NR KRVDNWVDI KG LBV_RV767 
LBV B II GCGTSSVFS KKS TLCGKP NR LRVDSWNDI KG LBV_NIG1956 
EF547431.1 
LBV C II GCSDTATFS KKS TLCGKP NR LRVDSWNDI KG LBV_RV3 
AY062049.1 
LBV D II GCSTSTSFS RKA TLCGKP NR RRVDNWTDI KG LBV_KE576 
GU170202.1 
MOKV II GCNAETPFT QKA TLCGKP  DR KRVDKWTDI KG MOKV_RV4 
AY062051.2 
SHIV II GCSSSSTFS KKS TLCGKP NR KRVDRWEEI  KG SHIV 
GU170201.1 
WCBV III YCTTEQSIT KLV SICGRQ IK IKVENWSEV KG WCBV 
EF614258.1 
IKOV III GCNEGSKVS ILL IICGKS VK KSVDNWTDI PI IKOV 
JN800529 
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is this tertiary structure which enables recognition by antibodies or neuronal receptors 
(Benmansour et al., 1991).  
 
The location of antigenic site IV is currently undefined. Studies have suggested that site 
IV is present at residues 263-264 so consists of only two amino acids and is continuous 
though it contains overlapping linear epitopes (Ni et al., 1995). It has also been 
suggested that site IV contains overlapping linear epitopes with key residues at 251 and 
264 (Both, 2013) though another study suggested that site IV comprises only of residue 
251 (Liu et al., 2013a). This suggests that a more conclusive investigation into the exact 
location of antigenic site IV may be required. For the purposes of this investigation, 
antigenic site IV has been defined as residues 263-264. Minor site ‘a’ is located in close 
proximity to site III but contains no overlapping epitopes and consists of only two amino 
acids (Benmansour et al., 1991).  
 
1.1.2.5 The Large Polymerase 
The polymerase (L) is the largest of the rhabdoviral proteins at around 2142 amino acids 
and it represents 54% of the viral genome (Koser et al., 2004). It is responsible for the 
viral transcription activities with four main functions: as an RNA dependent RNA 
polymerase (RdRp), mRNA methyltransferase, mRNA guanylyltransferase and a 
poly(A) synthetase (Wunner, 1991). The overall sequence of rhabdoviral L proteins is 
fairly homologous to other Mononegavirales including vesicular stomatitis virus (VSV) 
and Sendai virus however some regions show considerable variability, likely due to the 
multifunctional nature of L (Poch et al., 1990). 
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1.1.2.6 Genomic Diversity  
A great deal of diversity between lyssavirus genomes has been observed and two 
elements of lyssavirus virology that determine variation are the presence of defective 
interfering (DI) particles and viral quasispecies. Virus quasispecies are variant RNA 
species present in all RNA virus populations and are generated as a result of the error 
prone nature of the RNA dependant RNA polymerase (Vignuzzi et al., 2006). Virus 
species that contribute to a virus population may include those with single mutations, 
those with multiple mutations and those that have had complete deletions of stretches of 
the genome; DI particles (Finke & Conzelmann, 1999; Wunner & Clark, 1980). The 
latter are believed to only be generated in isolates following extensive in vitro passage 
but can contribute significantly to pathogenesis (Perrault, 1980). The former will, no 
doubt affect viral fitness but as yet determining the dynamics of how this occurs remains 
to be defined. 
 
The role of single/multiple mutations within dominant virus populations have been 
investigated in several studies. Growth of a human RABV isolate in cell culture was 
investigated and significant intrinsic heterogeneity within the glycoprotein sequence was 
observed (Benmansour et al., 1992). When comparing a dog derived street RABV 
isolate with CVS, a 10% divergence in amino acid composition was observed; however, 
in the ectodomain there was only a 6% divergence which may suggest that some 
structural features may restrict divergence in this region. Additional evidence comes 
from sequencing of viral clones; only one third of clones isolated from the brain of a 
rabid dog exhibited the consensus sequence, the remaining two thirds showed between 
one to three amino acid substitutions. It is suggested that the nature of these 
heterogeneous populations enables the virus to rapidly adapt to changes in the 
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environment. Deep sequencing techniques are increasingly being used to analyse the full 
range of sequences present in a viral population to further our understanding of variation 
among viral quasispecies. 
 
1.1.3 Life Cycle 
Rabies is most commonly transmitted via infected saliva transfer from an animal bite. It 
is thought that the virus initially replicates in muscle cells at the site of the wound 
(Bellinger et al., 1983) then is able to enter either motor or sensory nerves to travel by 
retrograde transport along axons to the central nervous system (CNS) (Lo et al., 2001; 
Mrak & Young, 1993). Virus RNPs are able to travel along axons in a retrograde fashion 
at a rate of 50-100mm/day (Tsiang et al., 1991). The mechanism of axonal transport may 
in part be due to interactions between the P protein and actin and microtubule networks 
including the microtubule motor molecule, dynein LC8 (Jacob et al., 2000; Raux et al., 
2000). The virus is able to spread rapidly within the CNS due to the ubiquitous nature of 
the proposed receptors whilst movement in the periphery appears limited which restricts 
the spread of virus in these areas (Ugolini, 2008). Once the virus reaches the brain it 
continues to replicate and spread through the tissue via cell to cell transmission or trans-
synaptic spread. From the brain the virus is able to travel along neurones to the salivary 
glands for onward transmission and also to many other areas of the body (Jackson et al., 
1999). 
 
1.1.3.1 Adsorption 
The lyssavirus glycoprotein is the main viral protein that enables virion attachment and 
entry into host cells. Currently, whilst there are postulated to be as yet undefined 
receptors utilised by lyssaviruses for cell entry, several receptor molecules have been 
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proposed to be involved in virus binding and entry (Lafon, 2005). Once the virus has 
entered the host it may either enter the nervous system directly or may initially replicate 
in the muscle tissue surrounding the locus of infection before entering the nervous 
system. The exact sites of virus replication prior to entering the central nervous system 
(CNS) are yet to be defined, however, the suggestion of low level replication in the non-
neuronal tissue following infection may provide some explanation for the long 
incubation periods which have been reported (Lafon, 2005). It has been demonstrated in 
vitro that the virus is able to enter motor nerves via neuromuscular junctions (NMJs). As 
well as this, viral antigen has been shown to be present in proprioceptors, sensory 
spindles and stretch receptors in vitro (Lewis et al., 2000). 
 
The virus is able to enter neural tissues via one/a combination of three proposed 
receptors which are present in all mammals: the neural cell adhesion molecule (NCAM) 
which is present in NMJs at post-synaptic membranes (Thoulouze et al., 1998), the 
nicotinic acetylcholine receptor (nAchR) which is involved in interneuronal signalling 
within both the peripheral and central nervous systems (Gastka et al., 1996) and 
p75NTR which is a neurotrophin receptor responsible for apoptosis, axonal elongation 
and synaptic transmission (Dechant & Barde, 2002). Each of these three proposed 
receptors are not only expressed in the CNS but can be expressed on cells in the dermis; 
NCAM and p75NTR are expressed from dermal fibroblasts associated with hair follicles 
(Botchkareva et al., 1999; Muller-Rover et al., 1998) whilst nAchR has been detected in 
the squamous epithelium (Arredondo et al., 2002). This suggests that they may be 
available around sites of infection as a route to the CNS for the virus; however the extent 
to which rabies and the lyssaviruses utilise each of these proposed receptors is 
undefined. 
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1.1.3.2 Penetration and Uncoating 
Upon attachment of the virus to a permissive cell it proceeds to enter via fusion of the 
viral envelope with the plasma membrane of the cell (Wunner & Conzelmann, 2013). 
The virus is also able to enter cells through attachment and engulfment by coated pits 
(viropexis) or via internalisation of vesicles (pinocytosis), both of which can result in the 
internalisation of multiple virions simultaneously (Tsiang, 1993). Once internalised the 
G protein initiates fusion of the viral envelope with the endosomal membrane to release 
the RNP into the endosomal vesicles (Wunner & Conzelmann, 2013). Lysosomes then 
fuse with these vesicles to release the RNP into the cell cytoplasm (Gosztonyi, 1994) to 
initiate transcription (Finke & Conzelmann, 2005b). 
 
1.1.3.3 Primary Transcription 
The lyssavirus genome consists of a strand of linear, negative sense, single stranded 
RNA. This means virus replication requires transcription of mRNA. The L protein, as an 
RdRp initiates transcription of the genomic RNA to produce leader RNA which is an 
exact complement of the 3’ end of the genome RNA. It is phosphorylated at the 5’ end 
but has no 3’ poly(A) tail. Five complementary positive sense mRNAs are also 
transcribed which are capped at the 5’ end and polyadenylated at the 3’ end, each 
corresponding to one of the five viral genes (Banerjee, 1987). The transcripts are 
generated in consecutive mono-cistronic fashion with the sequential nature of 
transcription controlled by the transcriptional complex. This complex is able to 
recognise the start, stop and polyadenylation signals which flank each cistron. A gradient 
effect of transcriptional efficiency has been observed from the 3’ to 5’ genes. This 
process allows structural proteins at the 3’ end of the genome e.g. N to be produced in 
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higher concentrations than the  5’ proximal genes  (Tordo & Kouknetzoff, 1993). 
 
1.1.3.4 Translation and Protein Processing 
The viral mRNAs are translated using the host cell machinery. The N, M, P and L 
proteins are translated on free ribosomes within the cytoplasm whereas the mRNA 
encoding G is translated on membrane bound ribosomes (Tordo, 1996). Completion of 
the G processing is carried out co-translationally: firstly core glycosylation occurs in the 
rough endoplasmic reticulum (RER) and this is followed by final processing of the 
carbohydrate side chains in the RER and Golgi body (Shakin-Eshleman et al., 1992). 
The now glycosylated transmembrane G protein is transported to the cell membrane, the 
glycosylated ectodomain protruding from the exterior of the cell (Tordo, 1996). 
 
1.1.3.5 Replication 
Although the exact mechanisms that drive a switch from transcription to replication 
remain unclear, at some stage following infection a switch occurs to drive the generation 
of a positive strand full length genome replicative intermediate. This replication is 
dependent on continued synthesis of viral N protein. Once a full length antigenome has 
been produced, this acts as the template for genome replication to produce nascent 
genome sense RNA. During the switch from primary transcription to genome replication 
the activity of the viral polymerase changes from a transcriptive to a replicative mode. 
As the positive sense RNA is synthesised it is immediately associated with the newly 
generated N protein to form positive sense RNP and it is this which acts as the template 
for replication. Negative sense genome is then amplified; again with the negative sense 
RNA being immediately encapsidated by the N protein. Once the negative sense RNP 
has been amplified this acts as a template for secondary transcription which results in 
Chapter 1: Introduction 
46 
 
amplification of all viral proteins for subsequent virion assembly (Banerjee, 1987). 
 
1.1.3.6 Assembly 
The process of RABV morphogenesis starts with the formation of the RNP during 
replication. M then associates with the RNP complex in the cell cytoplasm and down-
regulates RNA transcription while up-regulating replication (Finke & Conzelmann, 
2003). M initiates tight coiling of the RNP complex and localises the coiled RNP-M at 
the cell membrane. At the membrane of the cell the M protein bridges the RNP and the 
cytoplasmic tails of G and as the components assemble the polymerase activity of L is 
halted by M within the very tightly coiled RNP and virus budding is initiated (Wunner & 
Conzelmann, 2013). 
 
1.1.3.7 Budding 
Once the RNP-M complex has associated with the transmembrane G proteins at the cell 
membrane, the mature virions bud through the cell membrane, acquiring their lipid 
bilayer envelope during the process (Wunner & Conzelmann, 2013). The interaction of 
the G cytoplasmic tail with the M protein within the virion is thought to hold the virus in 
its classic bullet-like morphology. It is possible that the RNP-M complex is able to bud 
though the cell membrane in areas where no viral G trimers are expressed and in this 
case the viral particles produced are non-infectious (Mebatsion et al., 1996a). It has also 
been observed that virions may bud through the endoplasmic reticulum or Golgi body 
within the cells (Lahaye et al., 2009) into the lumen of vesicles produced by these 
membranes. In this case it is possible that these vesicles would be secreted from the 
infected cells by the normal secretory pathway (Wunner & Conzelmann, 2013). 
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1.1.4 Epidemiology 
RABV is distributed globally with only a few, principally island nations, being free of 
disease. Concerted vaccination campaigns with domestic animals across both the USA 
and Western Europe have now eliminated the burden of rabies from domestic terrestrial 
carnivore populations. In the USA, sylvatic rabies remains a constant threat to human 
populations with racoons, skunks and foxes acting as reservoirs for the classic rabies 
viruses but with bats causing increasingly more human infections (Blanton et al., 2011). 
Extensive wildlife vaccination campaigns have managed to eliminate sylvatic rabies 
from Western Europe. However, globally the existence of lyssaviruses circulating in 
Chiropteran reservoirs remains and so a complete eradication of rabies virus is thought 
to be unrealistic (Rupprecht et al., 2008). Within the USA, bat species maintain RABV 
whilst, in contrast across the Old World, classical RABV appears to be totally absent 
from bat populations whilst several non-rabies lyssaviruses persist. These populations of 
bats are very difficult to access, and across the EU, are protected by law (Freuling et al., 
2012) making eradication of lyssaviruses an unfeasible target. 
 
From an epidemiological perspective, within Europe, alongside RABV in terrestrial 
wildlife populations three other lyssavirus species have been genetically characterised: 
European Bat Lyssavirus type-1 (EBLV-1), European Bat Lyssavirus type-2 (EBLV-2) 
and Bokeloh Bat Lyssavirus (BBLV).   
 
EBLV-1 is genetically classified into two lineages; EBLV-1a is found throughout 
northern Europe and EBLV-1b has been detected in southern Germany, France and 
Spain. Both EBLV-1 lineages are associated with infection of Eptesicus fuscus, the 
Serotine bat. Infection of other bat species such as the Meridional Serotine (E. 
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isabellinus) may suggest the circulation of a third lineage of EBLV-1 (Banyard et al., 
2011; Vazquez Moron et al., 2011).  EBLV-1 cross species transmission (CST) events 
have occurred at a very low frequency although to date independent terrestrial 
transmission pathways have not been established (Dacheux et al., 2009; Muller et al., 
2004; Tjornehoj et al., 2006).  
 
In contrast, EBLV-2 is predominantly associated with infection of Myotis daubentonii, 
the Daubenton’s bat, across much of northern Europe and no cross species transmission 
events have been reported in terrestrial species although two fatal human cases have 
occurred (Fooks et al., 2003; Lumio et al., 1986).  
 
The first isolate of BBLV was obtained from a Natterer’s bat (Myotis natterei) in 
Germany in November 2009 (Freuling et al., 2011). Since then two further detections 
have been reported including another in  Germany (Freuling et al., 2013) and an isolate 
from France (Picard-Meyer et al., 2013). Evidence for a further lyssavirus has been 
reported in Spain in a common bent-wing bat (Miniopterus schreibersi). Although only a 
short stretch of genetic data has been determined for this virus it has been named Lleida 
bat virus (LLEBV). Initial sequencing of the N gene suggests considerable genetic 
divergence from the current European lyssaviruses (Arechiga Ceballos et al., 2013). 
 
A further four Eurasian lyssaviruses have been described, predominantly from single 
virus isolates from different bat species. These include Aravan virus (ARAV) isolated 
from a Lesser-mouse Eared bat (Myotis blythi) in Kyrgyzstan (Botvinkin et al., 2003), 
Khujand virus (KHUV) isolated from a whiskered bat (Myotis mystacinus) in Tajikistan 
(Kuzmin et al., 2008b), Irkut virus (IRKV) isolated from a Greater Tube-nosed bat 
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(Murina leucogaster) in Eastern Siberia (Botvinkin et al., 2003) and West Caucasian Bat 
virus (WCBV) isolated from a common bent-wing bat (Miniopterus schreibersi) in the 
Caucasus mountains in Russia (Botvinkin et al., 2003). Phylogenetic classification of 
these Eurasian isolates has shown them to be distinct species within the lyssavirus genus 
with WCBV being the most genetically divergent (Horton et al., 2010). Of these, only 
Irkut virus has been isolated on more than one occasion (Liu et al., 2013b) and has been 
associated with human fatality (Belikov et al., 2009). 
 
In other parts of the world several other, predominantly bat associated lyssaviruses occur 
(Banyard et al., 2011). In Australia, Australian bat lyssavirus (ABLV) has been isolated 
from five different bat species since its initial isolation in 1996 (McCall et al., 2000) and 
has also been implicated in three human fatalities (Allworth et al., 1996; Hanna et al., 
2000; Weir et al., 2013). There have also been two confirmed cases of horse infection 
with ABLV in Queensland (Symons, 2013) which have raised concerns about a 
theoretical yet possible risk of transmission of ABLV infection from horses to humans.  
 
Across Africa a number of bat lyssaviruses have been detected. The most frequently 
reported is Lagos bat virus (LBV) which has been isolated from multiple bat species 
distributed across sub-Saharan Africa (Hayman et al., 2008). There are currently four 
defined lineages of LBV; lineage A consists of Kenyan (2007), Senegalese (1985) and a 
French (1999) isolates, lineage B contains only the original Nigerian (1956) isolate, 
lineage C contains isolates from Zimbabwe, South Africa and the Central African 
Republic and lineage D contains a single isolate identified in an Egyptian fruit bat in 
Kenya (Kuzmin et al., 2010; Markotter et al., 2008). It has been suggested that Lagos 
bat virus isolates could be subdivided into several genotypes or lineages based on 
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criteria adopted by the ICTV whereby all isolates belonging to the same species have 
identities of greater than 80-82%. LBV isolates can be more divergent than this, within 
the variable glycoprotein, across each lineage and as such may ultimately be re-
classified.   
 
Duvenhage virus (DUVV) was initially isolated from a fatal human infection following a 
bat bite and was subsequently isolated from a number of bat species, mainly Nycteris 
species in South Africa and Zimbabwe. There have been two further cases of DUVV 
infection in humans, both of African origin (Paweska et al., 2006). Only a single isolate 
of Shimoni bat virus (SHIBV) exists and was isolated in 2009 from a Hipposideros 
vittatus bat in Kenya (Kuzmin et al., 2010).  
 
Mokola virus (MOKV) is an African lyssavirus which is only one of two lyssavirus 
species that have not been detected within bat species. MOKV has been isolated from a 
range of mammals including a shrew, domestic cats and a dog. Most of the isolates have 
been from South Africa and neighbouring Zimbabwe but there have also been sporadic 
isolations from Nigeria, Cameroon, Central African Republic and Ethiopia. 
Interestingly, sera from LBV positive bats have been shown to neutralise MOKV 
making an assessment of the range of species infected with MOKV difficult and as a 
result bats cannot be ruled out as a reservoir for MOKV (Kgaladi et al., 2013). There 
have been two recorded human cases of MOKV infection (Familusi & Moore, 1972; 
Familusi et al., 1972).  
 
The most recent African lyssavirus to be identified is Ikoma lyssavirus (IKOV). IKOV 
was isolated from an African civet and is the second non-rabies lyssavirus to have been 
Chapter 1: Introduction 
51 
 
isolated only from a terrestrial carnivore species although its origin within Chiropteran 
species is assumed from the circumstances within which it was detected (Marston et al., 
2012b). IKOV is genetically divergent from all the other lyssaviruses (Marston et al., 
2012a). 
 
1.1.5 Infection with lyssaviruses 
Several aspects of lyssavirus virology remain unclear with the events that lead to either 
an established infection and death, or so called abortive infections being largely 
undefined. Alongside this, recent studies have suggested that in some instances infection 
and clearance by an undefined immune mechanism may also occur (Gilbert et al., 2012). 
What is understood following an exposure to a lyssavirus is detailed below. 
  
1.1.5.1 Transmission 
The most common route of infection with a lyssavirus is via the mechanistic action of a 
bite from an infected animal which contains live virus in its saliva. Historically, this 
mechanism was first described over 200 years ago by experimental work in 1804 by 
Zinke (Zinke, 1804). Alongside this early observation, it was later determined that these 
viruses are unable to cross an intact dermal barrier. However, if the skin is broken, the 
risk of infection is greatly increased. Lyssaviruses can also infect hosts via mucous 
membranes including the nasal lining, oral cavity, conjunctivae, external genital organs 
and the anus. There have also been reports of infection via inhalation of virus via the 
aerosol route (Constantine, 1962; Johnson et al., 2006) although conclusive evidence to 
validate this route of infection is lacking. Human-to-human transmission has only been 
reported very rarely with transmission of bodily fluids being implicated as the source of 
virus (Fekadu et al., 1996). Alongside this, there have been occurrences of infection 
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through transplantation of infected tissue. A case in 2004 resulted in three rabies 
fatalities when an infected donor supplied a liver section, a kidney and a section of artery 
to three separate recipients. Within 30 days of transplantation all three recipients had 
returned to the hospital with rapidly progressing neurological disease, which was 
diagnosed post mortem as rabies infection (Burton et al., 2005). A further case in 
Germany resulted in the deaths of three individuals following organ donation (Johnson 
et al., 2005). Corneal transplantation has also facilitated infection in the recipient 
following surgery (Javadi et al., 1996). 
 
1.1.5.2 Incubation Period 
The incubation period of rabies virus is widely accepted to be between 20-90 days, 
however, there have been reports of extreme cases of incubation periods ranging 
between 14-19 years although in these cases the possibility of a secondary infection 
cannot be discounted (Fishbein, 1991). Recent human cases in the UK have highlighted 
incubation periods of up to two and a half years (Hunter et al., 2010). Regardless, it is 
clear that the incubation period following infection can vary greatly depending on a 
range of factors. Due to the neurotropic nature of the virus, a bite/site of infection that is 
highly innervated (e.g. face and hands) can lead to a much shorter incubation period or 
faster progression of disease than infection at a less densely innervated area. Alongside 
this, the presence/absence of permissive receptors in the tissue surrounding the infection 
site can affect viral entry and spread, hence increasing the incubation period. Muscular 
nicotinic acetylcholine receptors (a proposed receptor for rabies virus) have been 
identified at post synaptic muscle membranes which may enable the amplification of 
virus before it enters the nervous system (Lafon, 2005). The dose of infective virus also 
plays a role in determining incubation period (Ugolini, 2008). As well as this the 
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immune status and age of an individual can influence incubation as incubation periods in 
paediatric cases are shorter than those in adults, presumably due to their smaller stature 
(Warrell, 2008).  
 
Incubation periods following exposure to non-rabies lyssavirus are also poorly defined 
as possible exposure times are often difficult to determine. In particular it is recognised 
that bat bites may go totally unnoticed leading to cryptic cases of rabies (Messenger et 
al., 2003). A case of EBLV-1 infection in a human recorded an incubation period of 45 
days (Botvinkin et al., 2006). Further to this, a case of EBLV-2 infection in a bat handler 
reported a 19 week incubation period, however, the patient had a documented history of 
bat bites which may have confounded determination of the incubation period (Fooks et 
al., 2003). DUVV infection has been reported to have an incubation period of around 4 
weeks (Meredith et al., 1971; Paweska et al., 2006) whereas ABLV may have a much 
longer incubation period as a case in 1998 reported onset of clinical disease 20 months 
after exposure to a bat (Hanna et al., 2000; Johnson et al., 2008). Interestingly, infection 
of bats with lyssaviruses has also suggested inordinately long incubation periods. For 
example, a Daubenton’s bat kept in isolation in a bat rehabilitation centre was seen to be 
asymptomatic for a period of 9 months before developing aggressive behaviour that was 
diagnosed, following termination, as EBLV-2 infection (Pajamo et al., 2008). 
 
The principal mechanisms of lyssavirus pathogenesis within the peripheral and central 
nervous system (P/CNS) remain poorly defined and mice brains infected with rabies 
virus show little morphological damage (Song et al., 2013). Once in the CNS the virus 
may alter neurotransmission and normal neural function. It has been demonstrated that 
there is a reduction in the expression of housekeeping genes in RABV infected neurones 
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(Prosniak et al., 2001). This results in a reduction of protein synthesis and subsequently 
affects neuronal activity. It has also been suggested that the presence of the G protein on 
the surface of infected cells may disrupt ion channels, supported by the observation of 
electrophysiological disturbances in RABV infected murine brains (Dietzschold et al., 
2005). 
 
1.1.5.3 Immune Response 
The first line of defence against infection is the innate immune response. This response 
has been shown to have little impact in rabies infection (Chopy et al., 2011). Initially, 
during migration from the periphery to the CNS, rabies activates the innate immune 
sensors retinoic acid-inducible gene I (RIG-I) and melanoma-associated gene 5 (MDA-
5), both of which are cytoplasmic helicases (Loo et al., 2008). RIG-I recognises and 
binds to both ssRNA and dsRNA whereas MDA-5 recognises long dsRNA fragments 
(Jensen & Thomsen, 2012). These interactions induce the recruitment of intracellular 
adaptor proteins which initiate transcription and expression of type I interferon (IFN) 
(Kawai & Akira, 2008). The type I IFN response is generally responsible for inducing an 
anti-viral environment within the infected host however rabies has developed a number 
of mechanisms to circumvent the type I IFN response, thus abrogating the impact of the 
innate immune response in rabies infection (Chopy et al., 2011). The IFN response 
upregulates the expression of FasL and B7-H1 on migratory T cells. These molecules are 
responsible for limiting the effects of migratory T cells within the CNS as they induce 
apoptosis in T cells expressing the corresponding ligands: PD-1, Fas and CD8. The IFNs 
released in response to RABV infection upregulate the expression of FasL and B7-H1 on 
migratory T cells which enhance apoptosis of T cells both within the periphery and the 
CNS of the infected host, thus enhancing survival of rabies virus (Lafon, 2011).  
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In addition to the RIG-I like receptors (RLRs) mentioned, toll-like receptors (TLRs) also 
respond to the presence of pathogen associated molecular patterns (PAMPs). TLR3 is of 
particular significance in rabies infection as it recognises both dsRNA and the envelope 
glycoprotein (Jensen & Thomsen, 2012). TLR3 is found in intracellular compartments of 
both dendritic cells (DCs) and neuronal cells so is able to recognise viruses which enter 
cells via the endocytic pathway, as RABV does. During the infection process, TLR3 
recognising its ligand would result in the activation of various transcription factors 
including NF-κB which would result in downstream activation of IFN-α/β, however, 
during RABV infection TLR3 is sequestered into perinuclear inclusion bodies within 
infected neurones (Menager et al., 2009). This sequestration of TLR3 results in a 
reduction of innate immune response activation as well as a reduction in the activation of 
apoptosis of infected cells (Lafon, 2011), all of which combine to promote the survival 
of RABV in the infected CNS. 
 
Due to the invariably 100% fatality rate of rabies infection once clinical symptoms 
present, a pre-exposure immunisation is recommended for all those at risk of infection 
including scientists working with the virus, bat workers and travellers to endemic areas. 
Four days after vaccination immunoglobulin M (IgM) becomes detectable and this is 
followed by the IgG response three days later. It has been shown that Ig responses 
persist up to two years and it is IgG which provides the most effective level of 
protection. This is likely due to IgM being unable to penetrate tissue (Johnson et al., 
2010; Turner, 1978).  
 
The vital importance of neutralising antibodies in a protective immune response was 
demonstrated using gene knockout mice. Those lacking B cells and those lacking both T 
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and B cells were susceptible to attenuated strains of RABV whereas those lacking only 
CD8 T cells were not susceptible to infection (Hooper et al., 1998). In humans, 
detectable antibody levels do not generally develop until days after the onset of clinical 
disease. It was found that out of eleven human cases studied in Thailand, only three 
produced detectable, yet low, neutralising antibody levels. The cerebrospinal fluid (CSF) 
of six of these patients was investigated yet none contained detectable antibody 
(Kasempimolporn et al., 1991). Similarly, in a sample of twenty rabies cases in the USA 
between 1980 and 1996, none had detectable antibody levels upon presentation to 
hospital however more than 50% of these patients had generated detectable titre within 
ten days from admission. In addition, just two of fourteen selected patients from this 
sample showed detectable antibody levels in the CSF (Noah et al., 1998). A similar 
pattern has been observed in two documented RABV cases imported into the UK. One 
patient did not develop detectable serum antibody until sixteen days after hospital 
admission (Solomon et al., 2005) whereas the second patient developed antibodies in 
both the serum and CSF however this did not occur until the second week post hospital 
admission (Johnson et al., 2010). An indigenous case of EBLV-2 infection in the UK did 
not develop any detectable antibodies throughout the course of clinical infection 
(Nathwani et al., 2003).  
 
It is likely that this late development of neutralising antibodies in the periphery and 
therefore a lack of antibody response at the site of infection combined with low to non-
existent levels of neutralising antibody in the brain, where it is most needed, contribute 
to the devastatingly high degree of mortality in rabies infections (Johnson et al., 2010). 
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1.1.5.4 Human Infection 
In human infection, where disease progression has been characterised, the development 
of clinical disease following lyssavirus infection is indistinguishable from that caused by 
RABV. Indeed, in areas where RABV is endemic, a patient presenting with idiopathic 
neurological symptoms should not have rabies ruled out and an absence of bite history 
should not rule out the possibility of rabies in a differential diagnosis (Rupprecht, 1996). 
It has been shown that misdiagnosis of neurological disease occurs with misdiagnosis of 
rabies as malaria being one example (Mallewa et al., 2007). Although infection via a 
bite from a rabid animal is the most common route of infection other routes must be 
considered; infection may occur through infected saliva contact with exposed scratches 
or an open wound as well as exposure with mucous membranes.  
 
The 2-20 day prodromal phase of a RABV or lyssavirus infection are easy to confuse 
with many other diseases as the patient often presents with weakness, malaise, fever, 
headaches, urinary problems and paraesthesia at the site of infection which leads to 
ascending paralysis. For this reason other diseases such as Guillain-Barre syndrome are 
included in a differential diagnosis (Grattan-Smith et al., 1992; Plotkin, 2000). From the 
point of clinical onset, the likelihood of recovery is effectively zero. Approximately 80% 
of individuals then go on to develop the classic ‘furious’ form of rabies that can be 
characterised by hydrophobia and respiratory convulsions whilst the remainder may 
develop a ‘dumb’ or ‘paralytic’ form of disease (Toacsen & Moraru, 1985). The reason 
for these different clinical courses is not yet defined but may be related to the source of 
infection i.e. a low level dermal bite from a bat versus a deep intramuscular bite from a 
dog, genetics of the host or genetics of the virus itself. Death most often results from 
respiratory failure as a result of the spasms brought on by hydrophobia or cardiovascular 
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failure (Leung et al., 2007). 
 
1.1.5.5 Animal Infection  
It appears that there are no species specific symptoms but similar to human infection, 
there is a prodromal phase where the animal appears lethargic and exhibits some 
weakness. It has been observed that domesticated animals may show less interest in their 
owners whereas wild animals may actively seek contact with humans (Niezgoda et al., 
2002). Animal infection also follows the dumb or furious forms of disease but 
individuals may present with features of both. Clinical progression may be linked to the 
site of viral replication within the CNS which may be linked to the site of infection and 
the dose of virus transmitted (Healy et al., 2013b). In animals exhibiting signs consistent 
with furious rabies there is often a short prodromal phase where the animal may appear 
to have heightened alertness and this is followed by a neurological phase with signs 
similar to those seen in human infection. Rabid animals have been observed to become 
hyper-reactive to external stimuli, including noise, light or touch and may attack other 
humans, animals or inanimate objects. It is presumed that animals also experience 
paraesthesia at the site of infection as excessive grooming and scratching has been 
observed which can lead to self-mutilation. Death results from organ failure and 
respiratory arrest. Paralytic rabies in both domesticated and wild dogs starts with a 
clinical presentation of lethargy and a lack of coordination. This leads to weakness in the 
hind limbs and subsequent motor paralysis that spreads eventually to the mandible 
which results in cessation of the swallowing reflex. This is the final stage of disease 
before death (Hanlon, 2013). 
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1.1.5.6 Seropositivity to rabies in mammals 
With infection, following the onset of clinical disease, leading invariably to death the 
presence of healthy seropositive animals remains a quandary. The question of whether 
bats possess a level of tolerance to rabies infection/disease has often been raised and 
numerous studies have detailed high levels of  seropositivity in bats; for example a study 
of Brazilian free-tailed bats showed that 69% of those sampled had virus neutralising 
antibodies (VNA) to rabies virus but only 0.5% had active infection. This was 
determined by direct fluorescent antibody testing of brain samples (Steece & Altenbach, 
1989). This suggests that seroconversion may be common in natural infections but it is 
still unclear whether these infections lead to any CNS involvement which is 
subsequently resolved. 
 
In addition to seroconversion in bats, there have been multiple documented cases of 
seroconversion in other animals. A study in hyenas in the Serengeti over a period of 9 to 
13 years showed that 37% were seropositive with a further study following some of 
these hyenas demonstrating that half of these seropositive animals lost their VNA titres 
over time. The higher ranked animals tended to have high VNA and this may be due to 
the observed high bite rates and oral contacts with other hyenas involving lower ranked 
animals licking the open mouths of the higher ranked (East et al., 2001). During the 
period of the study, no clinical rabies disease was observed and no virus could be 
isolated from the saliva of the seropositive animals. The saliva did however yield RT-
PCR positive results for rabies RNA in half of the seropositive cases. Sequence analysis 
of the RNA isolated from the hyena saliva showed that the sequences were most closely 
related to dog strains in the Middle East and Europe. They were divergent compared to 
the commonly circulating strains of rabies virus in other mammals in the Serengeti. 
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Overall this suggests that there may be a role for low virulence strains of rabies in 
pathogenesis which may not cause clinical disease.  
 
In support of this evidence from animals there has been a recent documented case of 
seropositivity in humans. A study of two isolated communities in Peru looked at 
possible risk factors for rabies infection via a questionnaire and isolation of blood 
samples from participants. It was found that 11% of participants had VNA against rabies 
virus and 86% of these seropositive individuals reported having been bitten by a bat with 
only one seropositive individual having received PEP. This suggests that there may have 
been a number of non-fatal infections in these communities, most likely by vampire bats 
which circulate in these areas and are reported to feed off cattle kept by these 
communities (Gilbert et al., 2012). 
 
The findings of these studies are in opposition of the currently commonly held view that 
rabies causes clinical disease and death in cases of successful infection and suggest that 
further investigation into seropositivity in mammals must  be conducted before these 
phenomena can be fully understood. 
 
1.2 Current Prophylactic and Therapeutic tools 
1.2.1 Human Interventions 
The lyssaviruses represent the only group of viruses for which, following the 
development of clinical disease, the outcome of infection is invariably fatal (Fooks et al., 
2014). This feature of these viruses has made rabies virus one of the most feared 
infections in human history. Interestingly, the development of a medical intervention 
that ultimately involves the induction of a therapeutic coma has resulted in a small 
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number of cases where individuals have survived infection, albeit with permanent 
neurological sequealae (Jackson, 2013). This treatment, termed the Milwaukee Protocol 
(MP) where success has been seen, appears to work by reducing the activity of the 
patient’s nervous system which is hypothesised to enable the immune system to catch up 
with the progress of the virus through the nervous system and to neutralise the spread of 
virus (Willoughby et al., 2005). Whilst initially heralded as a breakthrough in the battle 
against rabies virus, the procedure has so far had a low survival rate with between one 
and three individuals surviving beyond 4 years without neurological sequelae (Jackson, 
2013; Willoughby, 2009). 
 
1.2.2 Pre and post exposure tools 
The continued failure of the MP to save individuals that have developed clinical rabies 
means that currently the only tools to prevent death prior to the development of clinical 
disease are vaccination and rabies immunoglobulin. Historically, nerve tissue based 
vaccines (NTVs) were used that were generated from desiccated brain and spinal cord 
material from infected animals. The early vaccines could stimulate  neuroallergenic 
responses in vaccinees which was problematic although later these live vaccines were 
inactivated with β-propiolactone to reduce reactogenicity (Bugyaki et al., 1979). Some 
reports suggest that these vaccines are still in use in some rabies endemic countries 
(Parviz et al., 2004) though the WHO advises against the use of these reactogenic 
vaccines. The advent of tissue culture techniques for the generation of vaccines led to 
the development of the human diploid cell vaccine (HDCV) (Wiktor et al., 1964) which 
involved adapting classic RABV strains to growth in human cell culture then subsequent 
inactivation. The HDCV was able to produce a highly protective immune response in 
most vaccinees but had high production costs which inhibited its use in many of the 
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developing countries that needed it most. Purified chick embryo cell vaccines (PCECV) 
and purified Vero rabies vaccines (PVRV) have been included in a number of studies 
using Intradermal (ID) vaccination regimens to reduce the cost of PEP (Ambrozaitis et 
al., 2006; Briggs et al., 2000).  
 
Vaccines can be used as pre-exposure immunisation for individuals at high risk of 
infection including veterinarians, laboratory workers and those travelling to rabies 
endemic countries as well as following potential exposure. The OIE and WHO specify 
that scientists working with rabies viruses must have a minimum antibody titre of 
0.5IU/ml post immunisation in order to be protected from accidental infection with 
classical rabies strains with boosters being recommended should an individual’s titre 
drop below this threshold. Additionally, for other at risk groups including bat workers, 
regular serological testing and  boosters when necessary are recommended (OIE, 2008). 
 
One potential drawback with the current RABV vaccines, however, is that they are 
unable to induce neutralising antibody responses that can protect against infection with 
all of the lyssaviruses. Whilst perhaps not significant for the global fight against rabies 
virus, the requirement for a vaccine that protects against all lyssaviruses is of importance 
for those at high risk from infection. Alongside those at high risk, the epidemiology of 
the non-rabies lyssaviruses is poorly understood and so the threat to human life has not 
been determined. The current RABV vaccines for both human and animal use are based 
on inactivated preparations of phylogroup I rabies strains. Studies have shown that with 
these vaccines little to no cross protection is afforded against phylogroup II or III viruses 
meaning that for a number of lyssaviruses there is no vaccine protection (Badrane et al., 
2001; Fooks, 2004; Hanlon et al., 2001). A number of studies have looked into viable 
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cross protective vaccine strategies, for example it has been shown using recombinant 
vaccinia viruses expressing the MOKV and WCBV G proteins that protection can be 
obtained for both viruses, both singly and in combination (Weyer et al., 2008). This 
shows that there may be potential to generate a pan-lyssavirus vaccine in the future 
(Evans et al., 2012; Fooks, 2004). In addition to pan-lyssavirus vaccines there is also 
ongoing development of live attenuated vaccines for use in human post exposure 
prophylaxis in order to avoid the need for multiple vaccinations before a protective titre 
is reached. An attenuated triple G variant of rabies has been generated which could 
potentially be used for human vaccination. The risk of the live vaccine reverting to 
virulence is negligible due to the inherent safety of the triple apathogenic G which has 
been shown to be dominant over the pathogenic G in co-infection studies (Faber et al., 
2009; Faber et al., 2002). In the meantime, while these vaccines are under development, 
intra dermal regimens are available which utilise the existing rabies vaccines but use 
60% less vaccine and are safer and more practicable than intramuscular methods 
(Warrell et al., 2008).  
 
Another feature of the existing rabies vaccines is that they can be used to protect against 
disease after exposure to the virus but before the development of clinical disease. The 
regimen used once an individual has experienced a potential exposure to virus is termed 
post exposure prophylaxis (PEP) and includes vaccination coupled with administration 
of rabies immunoglobulins (RIG). PEP should be administered as soon after the 
exposure as possible, to reduce the likelihood of the virus establishing a productive 
infection. Initially, in the case of a bite or scratch the WHO recommends washing the 
wound thoroughly with soap and water, and  it is thought that this simple action can 
increase survival by 50% (Rupprecht & Gibbons, 2004). Once the wound has been 
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thoroughly washed it is advisable to soak the site in 70% ethanol or iodine. It is 
important that the wound is not sutured. The next step is to administer PEP. Rabies 
immunoglobulins are applied to the wound and any nearby mucous membranes. The 
immunoglobulins are based on either vaccinated human rabies immunoglobulins (sera 
(HRIG) or neutralising antibodies generated in horses, equine rabies immunoglobulins 
(ERIG). HRIG is applied at a dose of 20 international units per kilogram (IU/kg) of body 
weight and ERIG is applied at a dose of 40 IU/kg. Once the RIG has been applied, a shot 
of rabies vaccine is administered at a site distant from the wound so that the RIG does 
not neutralise the virus in the vaccine. There are two main regimens for administration 
of RIG; the Essen regimen which is practised in Europe and North America and consists 
of 5 intramuscular doses of vaccine and the Zagreb 2-1-1 regimen which is more 
commonly used in some parts of Europe as the number of doses of vaccine is reduced 
compared to the Essen regimen (WHO, 2005). Despite PEP being effective in reducing 
the incidence of disease it is estimated that it is only used in 5% of cases due to its lack 
of availability which is related to its almost prohibitive cost (Both et al., 2012). There 
are however efforts to develop more affordable antibody cocktails to replace RIG, 
including mouse derived monoclonal antibody (mAb) cocktails (Muller et al., 2009) and 
plant derived antibodies (plantibodies) (Both et al., 2013). 
 
The WHO has identified five murine monoclonal antibodies (mAbs) which when used in 
combination have the potential to replace conventional RIG as they are capable of 
neutralising the same spectrum of lyssaviruses to a comparable titre (Muller et al., 
2009).  mAbs M777, M727, 1112-1 and E559 were shown to target antigenic site II and 
62-7-13 to target antigenic site I on the glycoprotein by sequencing and cross 
neutralisation experiments. Subsequent investigation into these mAbs as a potential 
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alternative therapy excluded 1112-1 due to licensing issues but cocktails of two to three 
of the remaining mAbs are currently under investigation (Muller et al., 2009). 
 
Alongside these therapeutic mAbs there are a number of others which have been 
identified as strongly neutralising, targeting the lyssavirus glycoprotein. mAb D8 was 
generated from mouse hybridomas against DUVV and found to strongly neutralise only 
DUVV in vitro, however its neutralisation profile was considered too narrow for 
inclusion in a therapeutic cocktail (Dr A C Banyard - unpublished observation). mAb D1 
was generated in the same manner as D8, via mouse hybridoma against Pasteur virus 
(PV) strain, a phylogroup I RABV and was found to target antigenic site III of non-
denatured rabies glycoprotein (Jallet et al., 1999). mAb D1, like D8 however has also 
not been considered for use in potential therapeutic cocktails. 
 
1.2.3 Vaccines for domestic and wild animals 
The vaccines used in animals, mainly for dogs as these are the species most associated 
with human infection, have been derived in a similar way to human counterparts. The 
first vaccines were derived from neural tissue but the reactogenicity of these vaccines 
drove development of embryonic chicken egg derived vaccines. These egg derived 
vaccines were effective in adult dogs but could cause clinical rabies in young dogs, cats 
and even cattle (Bunn, 1991). In order to reduce these vaccine associated deaths, the egg 
derived passage strains were further passaged in embryonated chicken eggs until, after 
205 passages the strain was safe for use intra-muscularly in cats,  puppies (>3 months) 
and cattle (Koprowski et al., 1954). Unfortunately this High Egg Passage (HEP) strain 
produced a number of vaccine-induced rabies cases in cats and was withdrawn. Current 
vaccines now recommended for routine parenteral vaccination of domestic animals 
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include cell culture vaccines (WHO, 2005). These killed vaccines are commonly 
inactivated with β-propiolactone and the preparations are often combined with other 
vaccines including canine distemper for dogs and feline parvovirus and calcivirus for 
cats. Due to the inactivation of the viruses, adjuvants are added to the vaccine 
preparation to increase the immune response (Dreesen, 2007).  
 
As well as vaccines based on fixed virus strains there are a number of genetically 
engineered vaccines designed to control rabies in wildlife. A successful oral vaccine 
composed of vaccinia virus expressing the RABV glycoprotein helped reduce concerns 
over the safety of live attenuated vaccines (Pastoret et al., 1988). In some parts of 
Canada, the USA, and across much of western Europe the application of oral vaccination 
campaigns has successfully eliminated terrestrial rabies which has, in turn, reduced the 
number of human cases in these areas (Blanton et al., 2011; Krebs et al., 2005). 
However, in many countries, especially across many parts of the USA, Africa, Asia, 
Latin America and Eurasia, RABV continues to circulate in certain wildlife populations 
and development of suitable bait formulations to try and eliminate these pockets of 
infection continues.  
 
1.3 Utilisation of lentiviral pseudotypes for glycoprotein expression  
Lentiviral pseudotype (PT) viruses were initially developed as vectors for gene therapy 
due to their ability to transduce non-proliferating cells (Naldini et al., 1996). Many of 
these initial vectors expressed the VSV glycoprotein on the PT surface as this enhanced 
the stability of the PT particles (Burns et al., 1993). The stability and high titres of these 
lentiviral VSV PT particles led to the development of the related rhabdoviral lyssavirus 
PTs, albeit for a very different purpose. Due to the lyssavirus G protein being the sole 
Chapter 1: Introduction 
67 
 
target of virus neutralising antibodies (Dietzschold et al., 1982) the expression of this 
protein alone on the PTs would enable investigation of the role that antibodies 
specifically targeting the glycoprotein play in a neutralising response (Wright et al., 
2008). 
 
Currently, lyssavirus PTs have been utilised to study the neutralisation profiles of a 
range of vaccinated human and animal sera against a small number of PTs representing 
CVS, EBLV-1 and EBLV-2. This study showed the utility of PTs for assessing VNAs in 
sera as an alternative to live virus neutralisation assays (Wright et al., 2008). The 
specificity and sensitivity of pseudotype neutralisation assays (PNA) in comparison to 
live virus neutralisation assays has been shown to be comparable and the inclusion of a 
range of different reporter genes including: luciferase, green fluorescent protein (GFP) 
and β-galactosidase (LacZ) has demonstrated the flexibility of this assay for use in a 
range of laboratory conditions (Wright et al., 2009). A multiplex PNA of LBV, MOKV 
and WCBV PTs has also been developed and used to screen a panel of African bat sera 
to determine seroprevalence against each of these viruses (Wright et al., 2010). 
 
These studies have shown the flexibility and accuracy of PTs to detect VNAs. In 
addition they have the added advantage of being able to be carried out in lower 
containment facilities than traditional virus neutralisation tests as PTs are replication 
deficient as they contain no rhabdovirus genome RNA (Temperton & Wright, 2009). 
 
Pseudotype viruses carry the genome and core of one virus and the envelope of another 
virus. The benefit of a lentiviral pseudotype is the inherent capability of lentiviruses to 
reverse transcribe their genomic RNA to create double stranded DNA (dsDNA) which is 
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then stably integrated into the host cell genome. This means that reporter genes carried 
by the PT are integrated into infected cells enabling quantification of PT particles by 
reporter gene expression.  
 
The pseudotype particles are generated by a triple transfection of three plasmids 
containing the replication complex, glycoprotein and a reporter gene. The retroviral 
structural proteins including p7, nucleocapsid and the matrix (GAG) and the enzymatic 
proteins including the protease, integrase and reverse transcriptase (POL) are encoded on 
the gag-pol plasmid, with the removal of the packaging signal to ensure these genes are 
not incorporated into the mature virions. The reporter gene plasmid encodes the reporter 
gene flanked by LTR regions that enable integration and transcription of the PT RNA 
genome. Upstream of the reporter gene is a packaging signal which ensures this gene is 
incorporated into the mature virion. The envelope plasmid contains the glycoprotein 
gene downstream of a promoter sequence. These plasmids are transfected into 
permissive cell lines, usually HEK293T cells and PT within the culture supernatant is 
harvested 48-72 hours later. 
 
The PT particles are generated by the host cell machinery. The cell transcribes and 
translates the transfected genes and the reporter gene is incorporated into the PT core, , 
in the form of an RNA dimer. The glycoprotein is glycosylated and sent to the cell 
plasma membrane so that when the PT capsid arrives at the membrane it is able to bud 
out of the cell taking the plasma membrane expressing G with it. These enveloped PT 
virions now contain the reporter gene and the lentiviral reverse transcriptase and 
integrase proteins within the core which is surrounded by a plasma membrane from 
which the G protrudes. These mature virions are then capable of infecting cells 
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expressing G specific receptors. Because the  
reporter construct is the only one to encode a packaging signal no other nucleic acids are 
present in the mature virion. This means that no viral proteins are generated in infected 
cells so no PT propagation occurs. This feature is the reason that PTs are such an 
effective vehicle to study lyssavirus neutralisation because they remove the requirement 
for working with live virus. This means that work can be done at a much lower 
containment level. 
 
1.4 Reverse Genetics Techniques 
The process of reverse genetics enables specific mutations to be engineered into viral 
genomes by a process of recovery of infectious virus from copy DNA (cDNA). Due to 
the different replication systems employed by DNA and RNA viruses, the process of 
reverse genetics was more readily applied to certain viruses than others. It was most 
quickly adapted to DNA viruses via heterologous recombination between plasmids 
containing specific viral sequences and the virus genome, or by directly transfecting 
cells with plasmids containing the required virus genome (Pekosz et al., 1999). The next 
group of viruses to have successful reverse genetics systems were the positive strand 
RNA viruses. This is because the viral genome is mRNA sense. This meant that by 
transfecting cells with plasmids or RNA transcribed from plasmids which contain, for 
example, the poliovirus genome, infectious poliovirus was able to be generated 
(Racaniello & Baltimore, 1981). The negative strand RNA viruses however have several 
features which make artificial manipulation of their genomes more difficult than for 
other viruses: firstly specific 5’ and 3’ ends are required for the replication and 
packaging of genome RNA. Secondly the viral RNA polymerase is required to 
transcribe mRNA and positive sense antigenome RNA and finally, both genome and 
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antigenome RNA are incorporated into RNP complexes (Pekosz et al., 1999). Another 
feature of negative sense RNA viruses which made development of reverse genetics 
systems more complex was the negative sense polarity of their genomes. These genomes 
are not able to act as a template to generate proteins; the viral RdRp must first transcribe 
the genome into positive sense. In addition, the transcription and replication of the 
genomes are dependent on sufficient quantities of cofactors being available, namely N 
protein to encapsidate the newly transcribed genomes. These features mean that 
particular systems have been developed in order to generate recombinant virus from 
cDNA, as shown in Figure 1.4. 
 
This reverse genetic system has allowed a much more in depth understanding of the 
negative stranded viruses, including the lyssaviruses. Additional genes have been 
incorporated into viral genomes, to enable expression of both heterologous viral proteins 
and fluorescence markers. In addition, the function of individual genes or gene segments 
has been investigated via truncation and epitope mutation. Reverse genetics can also be 
applied to the development of  novel vaccines and molecular tools (Finke & 
Conzelmann, 2005a). For the lyssaviruses, several recombinant approaches have been 
taken. A deletion mutant of RABV was generated that contained an alternative envelope 
alongside  multiple fluorescent proteins produced transgenes enabling the resulting virus 
to efficiently infect and label neuronal axons at the site of infection (Wickersham et al., 
2013). Furthermore, attenuated RABVs have been generated as potential vaccine 
formulations. Alteration of P gene expression has been investigated by changing the 
position of P relative to the 3’ genome terminus and by driving its expression from an 
internal ribosome delivery sites (IRES) (Marschalek et al., 2009)  (Brzozka et al., 2005).   
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Figure 1.4: The process of reverse genetics rescue of non-segmented negative 
strand RNA viruses. A. Helper plasmids under the transcriptional control of the T7 
polymerase, expressing the nucleoprotein (N), phosphoprotein (P), glycoprotein (G), 
large polymerase (L) and the cDNA clone are transfected into a cell which has 
previously been infected with a T7 polymerase expressing recombinant fowlpox virus. 
B. The antigenome (positive strand) sense T7 derived primary transcripts, are 
encapsidated by N protein and subsequently replicated to produce negative strand 
genomes; which are also encapsidated. The correct 3’ end of the RNA is generated by 
the Hepatitis Delta (Hepδ) ribozyme sequence. These serve as the template for viral 
transcription and with the expression of the five viral proteins an infectious cycle begins. 
C. Rescued virus released from the cell. Adapted from (Conzelmann, 1996).   
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It has been shown that the pathogenicity of these viruses is markedly reduced in mice 
(Marschalek et al., 2009; Rieder et al., 2011) but their ability to protect against challenge 
has yet to be determined (Pfaller et al., 2015). It is also possible for the glycoproteins to 
be switched between lyssaviruses so for example, a highly divergent glycoprotein can be 
incorporated into a vaccine strain in order to study neutralisation and glycoprotein 
function (Marston et al., 2013). 
 
1.5 Project Outline 
The aim of this project is primarily to investigate the lyssavirus glycoprotein and its 
ability to induce neutralising antibodies. As the sole target of neutralising antibodies, 
and due to the inability of current vaccines to neutralise all lyssaviruses, mutations to G 
were investigated. The functionality, immunogenicity and neutralisation of different 
lyssavirus G constructs was assessed initially generating and using a panel of lyssavirus 
pseudotypes (PTs) representing different isolates from phylogroups I, II and III. The 
ability of PTs to be generated and the ability of standardised sera to neutralise these PTs 
was assessed using both wildtype and mutated glycoproteins as the target for 
neutralisation. PTs were also used to investigate the binding sites of mAbs proposed as 
potential alternatives to RIG. Following assessment of PT neutralisation, both wildtype 
and mutated G proteins were cloned into full length genomes and rescued using reverse 
genetics techniques. Both in vitro and in vivo assessment of virus growth and 
neutralisation was performed. Finally vaccination challenge experiments were conducted 
to evaluate the ability of the neutralisation profile following vaccination with the 
standard rabies vaccines to protect against challenge with recombinant viruses 
containing mutated G proteins.  
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Chapter 2: Materials and Methods 
2.1 Cells and Viruses 
2.1.1 Cell lines and maintenance 
Baby hamster kidney cells (BHK-21), a fibroblastic cell line established from the kidneys 
of Syrian golden hamsters were grown in GMEM (Glasgow Modified Eagles Media) 
(Gibco) supplemented with 10% foetal bovine serum (FBS) (Gibco), 10% tryptose 
phosphate (Gibco), penicillin (100U/ml) and streptomycin (100μl/ml) (Gibco). Human 
embryonic kidney cells (HEK 293T/17), an endothelial cell line established from the 
kidney of a human foetus, were grown in DMEM (Dulbecco’s Modified Eagles Media) 
(Gibco) supplemented with 10% FBS, 4g/L of D (+) glucose (Sigma Aldrich), penicillin 
(100U/ml) and streptomycin (100μl/ml). Tissue culture flasks (Sarstedt) were incubated at 
37°C in a 5% CO2 incubator (Binder). 
 
2.1.2 Culturing cell lines 
Maintenance media was removed from the cell culture flasks and cells were briefly washed 
with sterile Dulbecco’s Phosphate Buffered Saline (DPBS) (Gibco). The DPBS was 
removed from the monolayer and a 4ml aliquot of 0.05% trypsin-EDTA (Gibco) was 
added to the cells. The flasks were incubated at 37°C for 2-5 minutes to detach the cells. 
Once detached, the cells were evenly suspended in 4ml of maintenance medium. Cells 
were either diluted by approximately 1:6 into flasks containing fresh medium for stock 
maintenance or they were counted using a haemocytometer (Improved Neubauer) then 
plated out for transfection, titration or pseudotype assay. 
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2.1.3 Freezing, storing and reviving cell lines 
Cells were stored long term in liquid nitrogen (N2). Preparation for long term storage was 
as follows: a flask of cells for freezing was trypsinised and the cell suspension was 
centrifuged at 500 rpm (34 x g) for 5 minutes. The cell pellet was resuspended in a 90% 
FBS, 10% Dimethyl Sulphoxide (DMSO) mixture at 1ml per 25cm
2
 of cells. The 
suspension was then aliquoted into cryotubes (Nalgene) and placed overnight at -70°C in a 
Mr Frosty cooler (Thermo Scientific). Once frozen the tubes were transferred into liquid 
N2 for storage. In order to revive the cells, tubes were thawed rapidly then gently 
suspended in the relevant medium. Cell suspensions were centrifuged at 500 rpm (34 x g) 
for 5 minutes and the resultant cell pellets were resuspended in 10ml of appropriate 
medium then transferred into a T25 tissue culture flask (Sarstedt). 
 
2.2 Molecular biological techniques 
Plasmid constructs were cloned and grown in E. coli (Max Efficiency DH5α cells 
(Invitrogen); JM109 competent cells (Promega); or TOP10 competent cells (Invitrogen). 
All bacterial preparations were cultured in Luria Bertani (LB) broth at 37°C.  
 
2.2.1 Small scale plasmid preparations 
Single colonies were picked from transformation plates and were grown in 2ml LB broth 
containing the appropriate antibiotic, usually either ampicillin or kanamycin at 100mg/ml 
(Sigma Aldrich) for 12-18 hours. A 1ml aliquot of each of these cultures was transferred to 
a fresh Eppendorf tube and the tubes were centrifuged at 14,000 rpm (21,000 x g) at 4°C 
for 30 seconds. The excess media was removed to leave the bacterial cell pellet. Next, 
300μl of TENS buffer (10mM Tris/Cl, 1mM EDTA, 0.5% SDS and 0.1M NaOH) was 
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added to each tube and the samples were rigorously mixed by vortexing for 10 seconds. 
Then 150μl of 3M sodium acetate (NaOAc) (Sigma Aldrich) was added to each tube and 
the vortexing was repeated. The samples were then centrifuged for 3 minutes. After 
centrifugation the supernatants from each tube were transferred to fresh tubes containing 
1ml of ice cold 100% ethanol. The samples were mixed by inversion then centrifuged for a 
further 3 minutes. DNA pellets were visible and the pellets were washed with 500μl of ice 
cold 70% ethanol by 2 minutes of centrifugation. The ethanol was then removed and the 
pellets left to air dry. The DNA was resuspended in 40μl of Tris-EDTA (TE) containing 
RNaseA (Qiagen) at a final concentration of 25μg/ml. 
 
2.2.2 Large scale plasmid preparations 
HiSpeed plasmid maxi kits (Qiagen) were used according to the manufacturer’s 
instructions for large scale plasmid preparations (maxipreps). Briefly, plasmid DNA was 
re-transformed and cultured overnight in 150ml of LB broth containing the appropriate 
antibiotic. The cells were pelleted before being lysed in alkaline lysis buffer. Cell debris 
was removed by filtration and DNA was bound to the equilibrated Qiagen column. The 
column was then washed in wash buffer, followed by elution of DNA from the column and 
subsequent precipitation in isopropanol. The DNA was then filtered and stored in TE 
buffer at -20°C. 
 
2.2.3 Restriction enzyme digests - preparative 
Preparative digests were performed on different plasmid DNA preparations to prepare 
DNA for ligation. Restriction enzymes were used according to manufacturer’s instructions 
(Promega, UK; New England Biolabs, USA). Up to 10μg DNA was cut in a final volume 
of 50μl.  
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2.2.4 Restriction enzyme digests – analytical 
Analytical digests were performed on plasmid DNA preparations to determine the presence 
and orientation of ligated insert in a DNA sample. Restriction enzymes were used as per 
manufacturer’s instructions (Promega, UK; New England Biolabs, USA). Between 400ng 
and 1μg of DNA was digested in a final volume of 10μl to 20μl.   
 
2.2.5 Agarose gel electrophoresis 
Agarose powder (Helena Biosciences Europe) was used to make 1-2% agarose gels in 1 x 
TAE buffer. 5μl of SYBR safe DNA gel stain (Invitrogen) was added per 100ml of cooled 
dissolved gel. Gels were left to set at room temperature for 30 minutes prior to loading. 6X 
loading dye (Promega) was used along with 1kb DNA ladder (Promega). Gels were run in 
1 x TAE at 120V for 45 minutes.  
 
2.2.6 Low melting point agarose gels 
Bands resulting from preparative digests were separated by running digested DNA on low 
melting point (LMP) agarose gels (Invitrogen) of 0.8-2% to gel purify required DNA 
fragments. DNA bands were visualised under long wavelength UV light and the required 
bands were excised using a sterile scalpel. Excised DNA fragments were then purified 
from LMP gel using the Gfx purification kit (GE Healthcare) according to manufacturer’s 
instructions. 
 
2.2.7 Spectrophotometry 
The concentration of DNA and RNA in solution was measured on a nanodrop ND-2000 
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machine (Thermo Scientific). Prior to all measurements a blank containing the diluting 
agent (TE or H2O) was used to set the zero readings on the nanodrop machine. 1.2μl of 
each sample was measured on the nanodrop and the concentration and purity of nucleic 
acid was measured. 
 
2.2.8 Cloning 
2.2.8.1 Ligation reactions 
Ligations were performed with 20-25ng of vector, with an insert:vector ratio of 1:1, 3:1 or 
5:1, 1μl T4 DNA ligase (Thermo Fisher), 2μl 10x ligase buffer (Thermo Fisher) and water 
to a total of 20μl. Insert DNA, from PCR reactions or purified from gels was used in a 
range of ratios with 3:1 (insert to vector) being used most commonly and alternative ratios 
being used in cases of ligation failure. The ligation was incubated at 16°C overnight but in 
cases of ligation failure the repeat reaction was incubated on ice at room temperature 
overnight. Zero Blunt PCR cloning kit ligations using the pCR-Blunt vector (Invitrogen) 
ligations were performed according to manufacturer’s instructions. 
 
2.2.8.2 Gibson Assembly 
An alternate approach to ligation of insert into vector using standard ligase was adopted to 
obtain certain constructs. Primers were designed to incorporate 19bp overlapping 
sequences containing the required restriction enzyme sequences. These were directed at the 
5’ and 3’ ends of the vector and of the insert. A PCR reaction was carried out to obtain the 
overlapping insert and vector sequences. The reaction conditions used to obtain the insert 
sequences are detailed in section 2.2.10.1 with a variation in incubation, instead using a 
57°C annealing temperature. The reaction to obtain the vector sequence comprised: 10μl 
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5X Q5 High-Fidelity DNA Polymerase buffer, 1μl 10mM dNTPs, 2.5μl forward primer, 
2.5μl reverse primer, 1μl template DNA (vector plasmid diluted 1 in 100), 0.5μl Q5 High-
Fidelity DNA Polymerase, 10μl Q5 high GC enhancer and 18.5μl water to make the 
reaction to 50μl. The reaction was carried using the following cycling conditions: 
 Step 1: 98°C for 30 seconds 
 Step 2: 98°C for 10 seconds 
 Step 3: 57°C for 30 seconds 
 Step 4: 72°C for 30 minutes 
 Step 5: repeat steps 2-4; 34 times 
 Step 6: 72°C for 30 minutes 
 Step 7: hold at 4°C 
Once the overlapping PCR fragments had been obtained they were assembled using the 
following reaction: 2-10μl of the PCR fragments, 10μl of Gibson assembly 2X master mix 
and deionised water to 20μl. This was incubated at 50°C for 15 minutes then 2μl was used 
to transform NEB 5-alpha competent E. coli. 
 
2.2.9 RNA extraction and reverse transcription 
Total cellular RNA was extracted from infected cells using TRIzol reagent (Life 
Technologies) as per the manufacturer’s instructions. 2μl of extracted RNA was used in 
reverse transcription reactions (RTs) to generate cDNA. Superscript III (Invitrogen) was 
used for all RT reactions following the manufacturer’s instructions. Reactions were 
performed with random hexanucleotide primers (RHPs) (Invitrogen) or gene specific 
primers depending on the downstream requirement of the first strand cDNA synthesis 
reaction. 
 
Chapter 2: Materials and Methods 
79 
 
2.2.10 Polymerase chain reaction (PCR) techniques 
2.2.10.1 KOD PCR 
For the amplification of lyssavirus G open reading frames (ORFs) from both first strand 
RT reactions and plasmid DNA, KOD (Novagen) PCR was used. Each reaction used 1μl of 
cDNA (4-8ng/μl), 1.5μl of each primer at 10pmol/μl, 5μl of 10x buffer, 3μl of 25mM 
magnesium sulphate, 5μl dNTPs, 1μl of KOD polymerase and 32μl of water to make each 
reaction up to 50μl. The PCR was run on a PE2720/9700 thermocycler (Applied 
Biosystems) using the following cycling conditions: 
Step 1: 95°C for 2 minutes 
Step 2: 95°C for 20 seconds 
Step 3: 60°C for 20 seconds 
Step 4: 70°C for 20 seconds 
Step 5: repeat steps 2-4; 34 times 
Step 6: 70°C for 10 minutes 
Step 7: hold at 4°C 
The annealing temperature at step 3 was varied according to primer melting temperature 
(Tm). 
 
2.2.10.2 Gradient PCR 
Gradient PCR was used to optimise the generation of PCR products. An Agilent 
Technologies SureCycler 8800 was used to run KOD PCR reactions on temperature 
gradients of approximately 60°C ± 10°C across 6-12 tubes. The annealing temperature 
range was altered depending on primer Tm. 
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2.2.10.3 Overlap extension mutagenesis 
To incorporate nucleotide mutations into antigenic sites within the G ORF, overlap 
extension mutagenesis was performed. Primers to incorporate the desired mutations were 
designed to overlap at the site of mutation by a minimum of 20 base pairs (bp). A first 
round KOD PCR was carried out using primers directed at the start and end of G to create 
a pair of fragments overlapping each region of mutation. The first round reaction cycling 
conditions were as follows: 
Step 1: 95°C for 2 minutes 
Step 2: 95°C for 20 seconds 
Step 3: 60°C for 10 seconds (temperature varied depending on primer Tm) 
Step 4: 70°C for 25 seconds 
Step 5: repeat steps 2-4; 34 times 
Step 6: 70°C for 10 minutes 
Step 7: hold at 4°C 
The pairs of fragments for each site were visualised by electrophoresis and if correct the 
second round KOD PCR reaction (see 2.2.10.1) to overlap the two fragments was carried 
out. The primers directed to the start and end of the G ORF were added to the reaction after 
10 cycles to allow the overlapping fragments to anneal to each other prior to generating a 
complete amplicon. 
 
2.2.11 Sequencing 
Both PCR products and plasmid DNA were sequenced by the Central Sequencing Unit 
(CSU) at the AHVLA. Undiluted PCR product or plasmid DNA was sent to CSU along 
with primers at 1pmol/μl for PCR products or 0.8pmol/μl for plasmids. At CSU the 
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samples were cleaned and run on ABI 3130xl (16 capillary) and ABI 3730 (48 capillary) 
Genetic Analysers to obtain sequence reads. 
 
2.2.11.1 DNASTAR Lasergene 9 core suite 
The SeqMan program was used to align ABI Sanger sequencing produced sequence reads. 
The reads were aligned against an appropriate known glycoprotein sequence in order to 
confirm the sample’s sequence. 
 
2.2.11.2 Vector NTi Advance 11 
Vector NTi (Invitrogen) was used to construct vector maps and for other routine molecular 
biology applications including restriction enzyme digestion prediction and sequence 
annotation. 
 
2.2.11.3 Next Generation Sequencing on Illumina MiSeq Platform 
Double stranded DNA from KOD PCR reactions was purified using AMPure XP magnetic 
beads (Beckman Coulter) and 1ng was used in the Nextera XT DNA sample preparation 
kit (Illumina). A sequencing library was prepared, according to manufacturer’s instructions 
and this was sequenced on the Illumina MiSeq with 2 x 150 bp paired-end reads, according 
to standard Illumina protocols. The resulting reads were mapped to a reference sequence 
using the Burrows-Wheeler Aligner (WBA) (version 0.7.5a-r405) then were visualised in 
Tablet (Milne et al., 2013). A modified SAMtools/vcfutils script (Li et al., 2009) was used 
to generate an intermediate consensus in which any indels relative to the original reference 
sequence were appropriately called. The intermediate consensus sequence was used as the 
reference for subsequent iteration of mapping and consensus calling. 
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2.2.12 Construction of pseudotype plasmids 
The backbone plasmid for pseudotype expression (pI.18- A kind gift from Dr Edward 
Wright, University of Westminster, London) contained a multiple cloning site flanked by 
the Cytomegalovirus immediate early (CMV IE) promoter and transcriptional terminators. 
Plasmid pI.18 was prepared to receive lyssavirus glycoproteins following digestion by 
restriction enzymes KpnI and XhoI. Each representative wildtype (wt) and recombinant 
lyssavirus G protein open reading frame was amplified using primers that incorporated 
KpnI and XhoI restriction enzyme sites for downstream cloning into pre-prepared pI.18. 
Blunt ended KOD polymerase generated lyssavirus G ORF PCR products were initially 
subcloned into pCR-Blunt (Invitrogen). Subclones were checked by restriction digestion to 
ensure insertion of the PCR product into the pCR-Blunt backbone plasmid. Correct 
subclone plasmids were then digested with KpnI and XhoI to release the lyssavirus G 
flanked by the correct restriction sites to enable directional cloning into the KpnI and XhoI 
prepared pI.18 plasmid. The insert was gel purified prior to ligation. Following ligation and 
transformation, small scale DNA preparations were made and successful ligation was 
checked using restriction enzyme digestion. Plasmids containing the correct insert were 
retransformed to enable generation of maxipreps. 
 
2.2.13 SDS-PAGE analysis and Western blotting 
Protein samples were generated by lysis of cells that had been transfected to produce 
pseudotype virus, using Reporter Lysis Buffer (Promega) and a freeze thaw cycle. The 
samples were then run on SDS-PAGE gels (BioRad) and were analysed by 
immunoblotting. The membranes (BioRad) were then blocked using 5% blotting grade 
buffer (BioRad) in TBS-0.2% (APHA, Reagent Production) Tween-20 (Fisher Scientific) 
overnight at 4°C. The primary antibody was added to 3ml blocking buffer and the 
Chapter 2: Materials and Methods 
83 
 
membrane was incubated in this mixture on a R100 Rotatest shaker (Luckham) at 4°C 
overnight. The membranes were then washed three times, each for 15 minutes, in TBS-
0.2% Tween-20. The appropriate secondary antibody (polyclonal rabbit anti mouse 
immunoglobulins/HRP, Dako) was then diluted 1 in 1000 in 10mls of blocking buffer and 
the membrane was incubated in this antibody for 1 hour with constant mixing. The 
membranes were washed, as previously outlined, and the proteins were visualised using the 
ECL plus Western Blotting Detection System (Amersham) as per the manufacturer’s 
protocol. The membranes were exposed to X-ray film (X-Omat LS, Kodak) and the results 
were visualised manually in a dark room using X-ray fixer and X-ray developer solutions 
(Champion Photochemistry).  
 
2.2.14 Particle Tracking 
A NanoSight LM10 machine (Malvern) was used to track pseudotype and virus particles in 
suspension according to the manufacturer’s protocols. Briefly, pseudotype and virus 
preparations were diluted 1 in 100 in BHK media and 300μl was aseptically injected into 
the machine’s specimen chamber until the liquid reached the nozzle tip. Specimens were 
tracked and measured for 60 seconds at room temperature. Data were captured and 
analysed using NanoSight LM10 NTA software (version 3.00). 
 
2.3 Pseudotype techniques 
2.3.1 Transient transfection 
Transfections were carried out with Lipofectamine LTX reagent (Invitrogen) according to 
the manufacturer’s instructions. Briefly, 0.72μg of glycoprotein, 0.72μg of pGagPol and 
1.08μg of reporter plasmid were added per well of a 6 well plate. Transfection reagent was 
Chapter 2: Materials and Methods 
84 
 
optimised for the procedure with a Lipofectamine LTX:DNA ratio of approximately 6:1 
being determined as being optimal for reporter gene expression. The cells were incubated 
at 37°C and 5% CO2 for 48 hours before harvesting the pseudotype virus. 
 
2.3.2 Pseudotype titration 
The titres of harvested PT viruses were determined by 50% tissue culture infective dose 
(TCID50). Each PT was titrated in triplicate in a 96 well flat bottomed tissue culture plate 
(Thermo Fisher). 100μl of BHK media was used per well required and 6 serial 5-fold or 
10-fold dilutions of PT stock were made in BHK media. 50μl of PT was added per well in 
triplicate down the plate. BHK cells were split and diluted to 2x10
5
 cells/ml then 50μl was 
aliquotted per well. The bottom row was left as a cells alone/uninfected control. The plates 
were incubated for 48 hours then the media was removed and replaced with 50μl of a 
mixture of Bright-Glo reagent (Promega) and BHK media in a 1:1 ratio. Luciferase activity 
was measured 2.5 minutes later on a Glomax 96 microplate luminometer (Promega). The 
negative cut off value was defined as the average cells alone luminescence multiplied by 
2.5. The last dilution at which all wells for each PT were positive was used to determine 
the PT titre in TCID50/ml via the Spearman-Kärber method (Aubert, 1996). 
 
2.3.3 Pseudotype neutralisation assay (PNA) 
The pseudotype assay was adapted from the procedure previously described (Wright et al., 
2008). In order to determine the percentage neutralisation of a PT by a specific serum the 
pseudotype virus was diluted to 200 TCID50/50µl. It was then incubated with 50µl of sera 
at 0.5 IU/ml or a range of serum concentrations for 1 hour at 37°C in 5% CO2. In order to 
determine the virus neutralising titre of a serum sample the serum was diluted 1:20 in 
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duplicate in the top two rows of a 96 well plate. Twelve serial 2-fold dilutions of the serum 
were then made down the plate and 50µl of PT at 200 TCID50 was added to each well. The 
plates were then incubated for 1 hour at 37°C in 5% CO2.  In both instances after 
incubation, 50μl of cells from a suspension of 2x105 cells/ml were added per well. The 
plates were incubated for a further 48 hours then the media was removed and replaced with 
50μl of a mixture of Bright-Glo reagent (Promega) and BHK media in a 1:1 ratio. 
Luciferase activity was measured 2.5 minutes later on a Glomax 96 microplate 
luminometer (Promega). For the percentage neutralisation test, the degree of neutralisation 
was calculated as a reduction in the level of luminescence compared to virus not exposed 
to serum. Each assay was carried out in triplicate and a mean average percentage 
neutralisation was calculated. For the serum titre test the 50% end point dilution (where 
complete neutralisation stopped in 50% of the wells) was calculated via the Spearman-
Kärber method (Aubert, 1996). 
 
2.4 Manipulation of full length clones to insert heterologous lyssavirus 
glycoproteins 
The backbone plasmid for full length expression (cSN) contains the full genome for a 
phylogroup I classic rabies virus. cSN was prepared for ligation of lyssavirus glycoproteins 
(G) by restriction enzyme digestion with SmaI and NheI (Promega) to excise the backbone 
phylogroup I G. Each representative wildtype and recombinant lyssavirus G protein open 
reading frame (ORF) was amplified using primers that incorporated HpaI and NheI 
(Promega) restriction enzyme sites for downstream cloning into pre-prepared cSN. Blunt 
ended KOD polymerase (Novagen) generated lyssavirus G ORF PCR products were 
initially subcloned into pCR-Blunt (Invitrogen). Subclones were checked by restriction 
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digestion to ensure insertion of the PCR product into the pCR-Blunt backbone plasmid. 
Correct subclone plasmids were then digested with HpaI and NheI to release the lyssavirus 
G flanked by the correct restriction sites to enable directional cloning into the SmaI and 
NheI prepared cSN plasmid. Following ligation and transformation, small scale DNA 
preparations were made and successful ligation was checked using restriction enzyme 
digestion. Plasmids containing the correct insert were retransformed to enable generation 
of maxipreps.  
 
2.5 Virus rescue 
Rescue of full length clones of CVS and LBV antigenic site swaps and wild type viruses 
were carried out in BHK cells using FuGENE 6 (Promega). Cells were plated at 5.4x10
5
 
cells per well to give 60-70% confluence. Each well was infected with fowlpox T7 (FPT7) 
to provide the T7 RNA polymerase. After one hour of incubation at 37°C the FPT7 was 
removed and each well was transfected with 1μg of pN, 1μg of pP, 1μg of pL and 2μg of 
genome plasmid all under the transcriptional control of the T7 polymerase. Plates were 
incubated for 48-72 hours prior to harvest. 
 
2.5.1 Virus Titration 
The titres of harvested viruses were determined in focus forming units per ml (ffu/ml). 
Each virus was titrated in triplicate in a 96 well flat bottomed tissue culture plate (Thermo 
Fisher). 100μl of BHK media was used per well required and 10µl of virus was added in 
triplicate along row A of the plate. Eight serial 10-fold dilutions of virus were made down 
the plate to row H. BHK cells were split and diluted to 5x10
5
 cells/ml then 50μl was added 
to every well. The plates were incubated for 48 hours then the media was removed and 
replaced with 50μl of 80% acetone (Fisher Chemicals). After 20 minutes fixation at room 
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temperature the acetone fixative was removed and the wells left to completely air dry. 
Once all wells were dry 50µl of a 1:100 dilution of anti-N FITC conjugated mAb 
(Fujirebio) was added to every well and the plates incubated at 37°C for 30 minutes. After 
the incubation the mAb was removed, the cells were washed twice with sterile 0.1M PBS 
and the plates were visualised using a fluorescence microscope to detect cell specific apple 
green perinuclear fluorescence which indicated presence of N protein. The number of foci 
in each well was recorded and the average number of foci in the last row before no foci 
were present was used to determine the ffu/ml of each virus. 
 
2.6 Fluorescent Antibody Virus Neutralisation (FAVN) test 
The neutralising ability of sera was assessed using the FAVN test against CVS virus. Serial 
3-fold dilutions of serum were made in BHK media in a 96 well plate (Corning) using four 
rows per serum. Stock CVS virus was then diluted to 100 TCID50/50µl and 50µl was added 
to every well. The plates were incubated at 37°C at 5% CO2 for one hour. After incubation 
50µl of a suspension of 5 x 10
5
 BHK cells/ml was added to every well and the plates were 
incubated for a further 48 hours. After incubation the supernatant was discarded and the 
cells were fixed with 80% acetone (Fisher Chemicals) for 20 minutes at room temperature. 
The monolayers were air dried then stained with 50µl per well of a 1:100 dilution of 
murine anti-N mAb conjugated to fluorescein isothiocyanate (FITC) (Fujirebio Diagnostics 
Inc.). The wells were then washed twice with 0.1M PBS and visualised using a 
fluorescence microscope. The 50% endpoint dilution (where complete neutralisation 
stopped in 50% of wells) was calculated using the Spearman-Kärber method (Aubert, 
1996). 
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2.7 Immunofluorescence techniques 
2.7.1 Pseudotype visualisation 
Cells grown on 16mm glass coverslips (VWR) that had been either transfected or infected 
were washed three times with 0.1M PBS. The cells were then fixed in 4% 
paraformaldehyde (PFA) (Affymetrix) for 30 minutes. After the cells had been fixed they 
were permeabilised with 0.1% Triton X100 (Sigma-Aldrich) in PBS for 10 minutes. The 
cells were then washed with 0.5% BSA (Sigma-Aldrich) in PBS (Gibco) to block non-
specific binding. The PBS-BSA was aspirated and replaced with an anti-G protein murine 
primary antibody (MyBioSource) diluted 1:50 in PBS-BSA then incubated for 30 minutes. 
The cells were washed three times in PBS-BSA then a goat anti-mouse 568-conjugated 
secondary antibody (red) (Life Technologies) at a 1:200 dilution was added for 20 minutes 
at room temperature. This was washed off with three PBS-BSA washes. The cells were 
then stained with an actin-phalloidin 488-conjugated mAb (Invitrogen) diluted 1 in 50 in 
PBS-BSA for 20 minutes. Following three PBS-BSA washes the coverslips were then 
mounted on glass microscope slides (VWR), cell side down, in aqueous mounting solution 
containing 4′,6-diamidino-2-phenylindole (DAPI) DNA stain (Vectashield, Sigma-
Aldrich). The coverslips were sealed with nail varnish then visualised on a Leica SP8 
confocal scanning laser microscope. 
 
2.7.2 Recombinant virus visualisation 
BHK cells were infected with rescued recombinant lyssaviruses. Following an incubation 
period of approximately 48 hours,  infected cells were fixed in 4% PFA (Affymetrix) for 
30 minutes at room temperature then permeabilised with 0.1% Triton X-100 (Sigma-
Aldrich) for 10 minutes also at room temperature. The cells were then stained to identify 
Chapter 2: Materials and Methods 
89 
 
nucleocapsid aggregates suggestive of lyssavirus presence in order to confirm the success 
of the rescue. Murine anti-N mAb conjugated to fluorescein isothiocyanate (FITC) 
(Fujirebio Diagnostics Inc.) was used at a 1/100 dilution to cover the cell monolayer. The 
plate was then incubated at 37°C with 5% CO2 for 30 minutes. The cells were then washed 
twice with 0.1M PBS and visualised on a Leica L5 microscope in the blue excitation 
wavelength between 475-490 nm. The presence of distinct bright ‘apple’ green 
fluorescence, usually in the perinuclear area of cells confirmed presence of lyssavirus. 
After the N protein had been stained an anti-G protein murine primary antibody 
(MyBioSource) was added at a 1:50 dilution for 30 minutes at room temperature. The cells 
were washed three times in 0.5% BSA (Sigma-Aldrich) in PBS (Gibco) followed by the 
addition of a goat anti-mouse 568 secondary antibody (Life Technologies) at a 1:200 
dilution for 20 minutes at room temperature. This was then removed and the cells were 
washed thrice in PBS-BSA. The coverslips were then removed from the wells, gently 
blotted dry and mounted on glass microscope slides (VWR) in 5µl aqueous mounting 
solution containing 4′,6-diamidino-2-phenylindole (DAPI) DNA stain (Vectashield, 
Sigma-Aldrich). The coverslips were sealed with nail varnish then visualised on a Leica 
SP8 confocal scanning laser microscope. 
 
2.8 Flow Cytometry 
HEK 293Tcells were transfected to produce PT following the procedure in Section 2.3.1. 
Supernatants were harvested and the remaining cell monolayer was resuspended in DPBS 
supplemented with 2% FBS. The cells and the supernatants were stained with an anti-
rabies glycoprotein mAb (MyBioSource) at a dilution of 1/50 for 30 minutes at 4°C. The 
primary antibody was then washed off and replaced with a 568-conjugated goat anti-mouse 
secondary antibody (Invitrogen) at a dilution of 1 in 200. The cells and supernatants were 
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stained in the secondary antibody at 4°C for 30 minutes. The cells and PTs were washed 
and resuspended in 2% FBS DPBS then analysed on a MACSQuant flow cytometer 
(Miltenyi Biotec). 
 
2.9 In vivo studies 
2.9.1 Rabbit Inoculation with PT 
2.9.1.1 Production of Inocula 
A panel of lyssavirus PTs were generated using the procedures detailed in Section 2.3. 
These were then beta-propiolactone inactivated. This involved the addition of beta-
propiolactone at a 1/4000 dilution of the final volume of PT. These were incubated at 4°C 
for approximately 19 hours followed by 1 hour at 37°C. A neutral pH of the inactivated 
PTs was indicated by an orange colour of the media. These inactivated preparations were 
then separated into one aliquot per inoculation and stored at -20°C until reconstitution with 
adjuvant. The adjuvant used in this experiment was Montanide™ ISA 50 V2 (Seppic) at a 
1:1 dilution with inactivated PT. Prior to each inoculation one vial of each inactivated PT 
was thawed and combined with an equal volume of Montanide™ to form an emulsion. 
These were immediately inoculated to avoid sedimentation. 
 
2.9.1.2 Inoculation of Rabbits 
One rabbit per PT, i.e. 10 1 year old female rabbits, were housed together in conditions 
consistent with Home Office regulations for a period of 10 days after arrival onsite at 
APHA and prior to the initial inoculation. Food and water were provided ad libitum along 
with sufficient environmental enrichment. Before inoculation, sites for subcutaneous 
inoculation were shaven and Emla cream (AstraZeneca) was generously applied to these 
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areas for a period of up to 5 minutes. The inocula were then injected at four sites 
subcutaneously followed by two sites intramuscularly at days 0, 21, 28 and 35. On day 43 
all rabbits were anaesthetised, a maximal volume of blood was removed via cardiac 
puncture under terminal anaesthesia. 
 
2.9.1.3 Collection of Sera from Rabbits 
After the blood had been collected from each rabbit this was subjected to centrifugation at 
2500 rpm (860 x g) for 10 minutes, after which the serum was removed from the blood 
pellet. The sera were then heat inactivated at 56°C for 30 minutes then separated into small 
aliquots and stored at -20°C until required. 
 
2.9.2 Vaccination/Challenge in Mice 
2.9.2.1 Mice 
Three to four week old CD1 mice (Charles River) were housed in animal containment 
facilities compliant with current Home Office requirements (PPL 70/7394) with access to 
food and water ad libitum along with appropriate environmental enrichment. Each mouse 
was microchipped using Trovan chips to enable identification. 
 
2.9.2.2 Vaccination of mice 
The human rabies vaccine Rabipur (Novartis) was reconstituted as per the manufacturer’s 
instructions in 1ml of sterile water immediately prior to vaccination of the mice. The 
reconstituted vaccine was then diluted 1 in 20 in sterile filtered deionised water. Mice were 
anaesthetised using isofluorane and vaccine was introduced via intraperitoneal injection of 
500µl to the lower right hand quadrant of the abdomen. Mice were vaccinated on days 0 
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and 14 to ensure a high serological response to vaccination. 
 
2.9.2.4 Blood Sampling by Tail Bleed 
Twenty one days post vaccination a sample of blood was taken from each mouse in order 
to confirm seroconversion following vaccination. The dorsal tail vein of each mouse was 
nicked under anaesthesia using a scalpel blade and the resulting blood was collected in CB 
300 tubes (Sarstedt). Following collection, blood samples were stored at 4°C overnight 
prior to centrifugation at 2500 rpm (860 x g) for 10 minutes after which the serum was 
separated from the blood pellet. These serum samples were heat inactivated at 56°C for 30 
minutes and stored at -20°C until required for virus neutralising antibody detection. 
 
2.9.2.5 Intracranial Challenge with Virus 
Once virus neutralising antibody titre had been determined mice were challenged 
intracranially with 100 ffu/30µl of infectious recombinant viruses at 28 days post 
vaccination. Each challenge group was inoculated with 30µl neat virus directly through the 
cranium into the brain. The mice were housed in groups of 5 per cage and observed twice 
daily for signs of clinical disease. Clinical scores were recorded for each mouse according 
to the clinical signs scale (Appendix III). Any mice showing signs of clinical disease of 
score 3 were immediately anaesthetised, blood collected by cardiac puncture (Section 
2.9.2.6) and subsequently euthanised by cervical dislocation. 
 
2.9.2.6 Blood Collection via Cardiac Puncture 
Mice that showed signs of clinical disease of score 3 and those which survived until the 
termination of the experiment were anaesthetised with isofluorane. Blood was drained 
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directly from the heart by introducing a needle into the chest cavity and collecting the 
blood in a syringe. This was followed by immediate cervical dislocation. The blood was 
then processed to isolate the sera as described for tail bleeding in Section 2.9.2.4. 
 
2.9.3 Pathogenicity Study 
2.9.3.1 Mice 
Three to four week old CD1 mice (Charles River) were housed in animal containment 
facilities compliant with current Home Office requirements (PPL 70/7394) with access to 
food and water ad libitum along with appropriate environmental enrichment. Each mouse 
was microchipped using Trovan chips to enable identification. 
 
2.9.3.2 Footpad Inoculation with Virus 
After acclimatisation to the environment for 5 days prior to inoculation the mice were 
inoculated into the footpad with 1000 ffu/50μl of each virus, except cSN-LBVFSS which 
had a low titre so was inoculated neat; at 200 ffu/50μl. Prior to inoculation the mice were 
anaesthetised with gaseous isofluorane. Once the mice were sufficiently anaesthetised they 
were placed into a holding container with a small hole, through which the left hind limb 
was extended to enable inoculation. Mice were monitored until 28 days post infection. 
Clinical signs were scored and recorded using the clinical scoring system (Appendix III). 
Mice were euthanised via cardiac terminal bleed and cervical dislocation at clinical score 3 
(Section 2.9.2.6). 
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Chapter 3: Construction and characterisation of wildtype and mutant 
forms of lyssavirus pseudotypes 
3.1 Introduction 
The adaptation of pseudotype viruses to express lyssavirus glycoproteins has several 
advantages for utilisation as research tools. Firstly, as previously described, the 
application of PTs to serological work enables the performance of neutralisation assays 
outside of containment facilities. This is of great benefit when working with 
ACDP3/SAPO4 pathogens and the diagnostic application of this technology for rabies 
serology is currently being trialled in resource limited settings. Secondly, the assay 
requires less serum than is required for OIE recommended tests and so is advantageous 
when assessing the serological status of species where only low volumes of sera are 
available, for example bats. Finally, it enables the mutation of the glycoprotein (G) alone 
to assess the effect of the antigenic regions on the ability of different sera to neutralise 
different wildtype and mutant glycoproteins. It is this final feature that is the basis for 
the present chapter. 
 
Plasmids containing both wildtype and mutant G genes were constructed to enable the 
generation of lyssavirus pseudotypes representative of the genus as well as mutants 
containing swaps in the highly immunogenic epitopes described in Section 1.1.2.4.1. 
The discovery of two novel lyssaviruses during this study, Bokeloh Bat Lyssavirus 
(BBLV) and Ikoma lyssavirus (IKOV) also prompted the cloning and generation of G 
plasmids for these two novel viruses. Alongside plasmid construction and transfection to 
generate PTs, the optimisation of transfection conditions is described with data 
demonstrating the variability in titres obtained with different plasmids. 
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3.2 Generation of wildtype lyssavirus pseudotype plasmids 
Numerous lyssavirus pseudotype plasmids were available at the initiation of the project 
through collaboration with Dr Edward Wright (University College London/University of 
Westminster). However, the discovery of two novel lyssaviruses during the project 
meant that pseudotype plasmids were required that contained the open reading frames 
(ORF) for BBLV and IKOV G. To this end, PCR amplicons were generated by overlap 
PCR for both the BBLV and IKOV G ORFs using KOD polymerase. Restriction sites 
(KpnI and XhoI) were incorporated at the 5’ and 3’ end of each ORF through inclusion 
within primer sequences (Appendix II). Both direct digestion of PCR products and blunt 
ended cloning of KOD generated PCR amplicons was performed. Where attempts to 
clone directly digested PCR products failed, G ORFs were excised from blunt end 
cloned plasmids and gel purified before being ligated into prepared vector. Following 
transformation into E. coli., colonies were screened by restriction enzyme digestion and 
clones giving the correct digestion pattern were sequenced to confirm the insert 
sequence. The cloning strategy for the generation of pseudotype expression plasmids is 
detailed in Figure 3.1.  
 
3.3 Construction of single site antigenic mutant PT plasmids 
Antigenic site swap CVS mutants containing single LBV NIG 1965 (lineage B) sites 
were constructed along with the reciprocal swap of LBV to CVS. These mutants were 
generated by overlap extension mutagenesis and site directed mutagenesis and kindly 
donated by Dr. E. Wright at the University of Westminster. These mutants constitute 
swaps between phylogroup I and phylogroup II and can be seen in Figure 3.2.  
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Figure 3.1: The cloning strategy to generate PT expression vectors for BBLV and 
IKOV. Insert DNA is highlighted in red, the pCR-ZeroBlunt vector DNA is in purple 
and the pI.18 vector DNA is in blue. The restriction sites KpnI and XhoI are in green and 
yellow, respectively. 
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Figure 3.2: Schematic representations of each of the CVS and LBV antigenic site 
swap mutant glycoproteins. Where regions contain sequence from CVS they are 
coloured blue whilst sequences from LBV are coloured yellow.  
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3.4 Synthesis and cloning of CVS/LBV full site swap antigenic mutants 
Genes containing a full complement of mutated antigenic sites were synthesised 
commercially as a cost effective alternative to individual site directed mutagenesis 
across the G ORF. Two genes were synthesised: 1) the CVS G gene containing the 
antigenic sites swapped with those of LBV lineage B and; 2) the LBV lineage B gene 
containing the antigenic epitopes swapped with those of CVS. Both synthesised genes 
incorporated the KpnI and XhoI sites at the 5’ and 3’ termini, respectively. The G protein 
DNA was then excised from the synthesised vector with a KpnI and XhoI restriction 
enzyme digest and the resulting fragment was purified and ligated into pI.18. Small scale 
plasmid preparations were made of selected colonies and restriction enzyme mapping 
was utilised to confirm the correct insertion sequence. Two correct small scale DNA 
preparations were then selected for re-transformation and subsequent large scale DNA 
preparation. Sequencing of PCR products of the G ORF from these plasmids were used 
to confirm the G sequence, prior to the use of these in transfection. 
 
3.5 Optimisation of transfection for PT production 
Previous studies had indicated that pseudotype production requires optimisation in each 
laboratory setting (Dr E. Wright, University College London/University of Westminster- 
personal communication) and as such optimisation of the assay was performed to 
maximise the production of high titre lyssavirus pseudotypes  
 
Two transfection reagents were available in the laboratory; FuGENE 6 (Promega) and 
Lipofectamine LTX (Life Technologies) so these two reagents were compared in order 
to identify which produced the highest PT titres. 
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The manufacturer’s recommended amount of each transfection reagent along with 
increasing quantities were added into transfections to produce the CVS PT. Three 
volumes of FuGENE 6: 6, 12 and 18µl and four volumes of Lipofectamine LTX were 
compared: 6, 9, 12 and 15µl. The rest of the protocol followed the manufacturer’s 
instructions. The resulting CVS PTs were titrated on a 5 fold dilution series and the 
TCID50/ml titres were calculated. The results are displayed in Figure 3.3. 
 
The Lipofectamine LTX transfections show a positive correlation between titre and 
volume of transfection reagent used. They do however show a greater level of variation 
at each titre than the FuGENE 6 values. The titres with FuGENE 6 show that the lowest 
PT titre was obtained with 12µl of transfection reagent and this was the lowest titre of all 
obtained (10
3.05
 TCID50/ml). The highest titre using the lowest volume of transfection 
reagent, 6µl, was with FuGENE 6 at 10
3.63
 TCID50/ml; however the titres with FuGENE 
6 decreased after this point, unlike with Lipofectamine LTX. The highest titre obtained 
overall was 10
4.13 
TCID/ml, using 15µl of Lipofectamine LTX and for this reason, this 
reagent at a volume of 15µl was chosen for use in all subsequent transfections to 
generate a panel of PT viruses. 
 
3.6 Production of a panel of lyssavirus PTs 
Once the process of generating pseudotype viruses had been optimised and was reliably 
able to produce PTs with viable titres, work began on production of a range of PT 
viruses. The panel required included a full complement of wildtype, single antigenic site 
swaps (SSS) and full antigenic site swaps (FSS) between CVS and LBV.  
Chapter 3 
100 
 
 
 
Figure 3.3: Optimisation of reaction conditions for the production of viral 
pseudotypes.  
Comparison of CVS PT generated by increasing amounts of either FuGENE 6 or 
Lipofectamine LTX transfection agents. In the FuGENE 6 transfections 0.6ng both 
pGagPol and pGlycoprotein along with 0.9ng pReporter plasmid were transfected. In the 
Lipofectamine LTX transfections 0.72ng both pGagPol and pGlycoprotein along with 
1.08ng pReporter plasmid were transfected. Error bars represent standard deviation (SD) 
about the mean of three replicate in-assay titrations.  
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It also included generation of PTs for a wide range of other wildtype lyssaviruses 
including a selection of RABVs, representatives of all other phylogroup I viruses, single 
isolates of all four lineages of LBV alongside other phylogroup II viruses as well as 
WCBV from phylogroup III and the two novel lyssaviruses, BBLV and IKOV. The 
harvested PTs were titrated via a 5-fold or 10-fold dilution series to obtain a TCID50 
titre, as shown in Figure 3.4. 
 
The titres of the phylogroup I PTs range between 10
3
 and 10
6
 TCID50/ml with CVS and 
DUVV having the highest titres, closely followed by EBLV-2. The rest of the PT titres 
were all very similar at approximately 10
3.7
 TCID50/ml, with KHUV having the lowest 
titre at 10
3
 TCID50/ml. 
 
The titres of the phylogroup II PTs show some variability with LBV A and WCBV 
having the highest titres at 10
6.29 
and 10
6.54 
TCID50/ml, respectively. LBV B, MOKV and 
SHIBV all have similar titres between 10
4
 and 10
6
 TCID50/ml but LBV D shows a titre 
of only 10
1.99 
TCID50/ml. Due to the possibility of variation between individual plasmid 
preparations an alternative LBV D plasmid preparation was generated and the 
transfection was repeated in order to try and improve this PT titre. The PT resulting from 
this repeated transfection and subsequent titration, however remained at the same titre of 
10
1.99 
TCID50/ml which suggested that a feature of the glycoprotein itself may be 
affecting the titre achieved. 
 
The titres of the CVS and LBV PTs varied considerably, regardless of the presence of 
antigenic site mutations. The CVS site swap PT titres were more variable than the LBV 
site swap titres. The LBV PT titres all showed similar titres with most reaching  
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Figure 3.4: Pseudotype titres achieved for a representative panel of lyssaviruses. 
(A) PT titres of representatives of all lyssaviruses in phylogroup I. (B) The titres of 
representatives of phylogroup II in red, phylogroup III in yellow and IKOV in green. (C) 
The titres of all of the CVS and LBV antigenic site swap and wildtype PTs. Error bars 
represent standard deviation (SD) about the mean of three replicate in-assay titrations.  
A 
B 
C 
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approximately 10
5
 TCID50/ml regardless of the antigenic site mutation present except 
LBV to CVS site III which had a lower titre of 10
3.18 
TCID50/ml. In contrast, for the 
CVS PTs some of the antigenic site mutations appeared to have affected the final titres 
achieved. The CVS wildtype and site I PTs showed titres similar to their LBV 
counterparts whereas the CVS site IIa and III PTs had titres dramatically higher than the 
equivalent LBV PTs. 
 
In addition, the CVS to LBV site IV PT reached a considerably lower titre than its 
reciprocal LBV counterpart confirming initial findings with this plasmid (Dr Ed Wright 
– unpublished data and personal communication). The CVSFSS PT also had a very low 
titre and for this reason a number of attempts were made to increase the titre of this PT 
(see Table 3.1). Both FuGENE 6 and Lipofectamine LTX were utilised to determine 
which produced higher titres, in addition an alternative cell type was used for 
transfection; BHKs, but no viable PT was generated and so repeated attempts were made 
with the HEK 293T cells. An alternative plasmid preparation with a higher concentration 
was produced and used in transfection. Transfection of the new construct enabled the 
production of PT, albeit at a very low level. In order to attempt to increase the titre 
increasing amounts of G plasmid DNA were transfected, however, none of these 
alterations were able to produce a viable titre. This suggested that the CVSFSS 
glycoprotein could not be pseudotyped.  
 
Comparing the titres of the single antigenic site swaps of the CVS PTs (Figure 3.4) 
showed that the CVS IIb and IIaIIb PTs also only achieved low titres of 10
1.79
 and 10
2.02 
TCID50/ml, respectively. This suggested that the alteration of the residues that are 
present within the IIb antigenic site may be affecting titre. In an attempt to increase the   
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Table 3.1: Alterations to transfection procedures to attempt successful generation 
of a CVSFSS PT. 
Attempt Cell type 
transfected 
Transfection 
reagent 
Concentration of 
Envelope 
plasmid (µg/µl) 
Quantity of 
Envelope 
pDNA 
transfected 
(µg) 
Titre 
(TCID50/ml) 
 
1 HEK293T-
17 
FuGENE 6 0.36 0.6 10
1.99
 
2 HEK293T-
17 
FuGENE 6 0.36 0.6 10
1.65
 
3 BHK FuGENE 6 0.36 0.6 0 
5 HEK293T-
17 
Lipofectamine 
LTX 
1.00 0.72 10
2.20
 
6 HEK293T-
17 
Lipofectamine 
LTX 
1.00 1.1 0 
7 HEK293T-
17 
Lipofectamine 
LTX 
1.00 1.4 0 
8 HEK293T-
17 
Lipofectamine 
LTX 
1.00 1.8 0 
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CVSFSS titres, reversion of the LBV IIb site mutation back to wildtype CVS was made 
in the CVSFSS constructs using overlap extension mutagenesis. The reversion of LBV 
site II back to CVS in the CVSFSS construct to produce two novel constructs: CVSFSS 
to CVS IIb and CVSFSS to CVS IIaIIb was not successful in rescuing PT titre. In fact 
the titres of the reversion mutants are slightly lower than the original CVSFSS titre of 
10
2.20
 TCID50/ml. The titres of the resulting PTs can be seen in Figure 3.5. 
 
In an additional attempt to increase the titre of CVSFSS along with the low titre LBV D 
PT an alternative transfection strategy was adopted which involved a number of 
alterations to the protocol in Section 2.3.1. Initially HEK293T-17 cells were seeded into 
6 well plates at a lower count than the previous protocol; this time at 5 x 10
5
 cells/ml and 
were grown in OptiMEM (Gibco). The following day the CVSFSS or LBV D G plasmid 
alone were transfected into the cells, using the same quantity of G plasmid and same 
ratio of DNA:transfection reagent as before. Then 48 hours post transfection, the media 
was replaced with fresh OptiMEM and a transfection identical to that in Section 2.3.1 
was performed, but now, the cells were maintained in OptiMEM for a further 48 hours 
post transfection and after this the tissue culture supernatant was collected and the PT 
within was titred as in Section 2.3.2. The titre of the CVSFSS PT did not increase as a 
result of this double transfection, it remained low at 10
1.65
 TCID50/ml. The LBV D PT 
however did increase in titre from 10
1.99 
to 10
2.34 
TCID50/ml. This LBV D titre remains 
fairly low in comparison to other wt PT titres and the CVSFSS titre did not increase at 
all which confirms the possibility that there are features of these two glycoproteins or 
plasmids which reduce the efficiency of incorporation of these glycoproteins into PT 
particles.  
Chapter 3 
106 
 
 
Figure 3.5: Titres of pseudotypes containing mutations to try and increase the titre 
of CVSFSS The CVSFSS PT construct was mutated back to wildtype sequence across 
the site II antigenic site to attempt to increase titre. Error bars represent standard 
deviation (SD) about the mean of three replicate in-assay titrations.  
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3.7 Characterisation of PT particles 
Once the panel of PT viruses had been generated and titres determined, further 
characterisation of these particles was conducted. In order to determine the size of the 
PT particles CVS PT was visualised using a NanoSight instrument (Malvern). This 
instrument is able to visualise particles based on the light scattered when illuminated by 
laser light. The scattered light is tracked from frame to frame by specialised software 
which enables calculation of the particle size based on the assumption of Brownian 
motion in a liquid. Both CVS PT and a β-propiolactone inactivated preparation of 
RABV were measured alongside each other on the NanoSight. The size distribution of 
both preparations is shown in Figure 3.6. 
 
The average size of particles in the inactivated RABV virus suspension was 168.2 nm 
with a standard deviation (SD) of 58.3 nm whereas the spread of particle size in the PT 
preparation was much greater. The average CVS PT particle size was 266.6 nm with a 
SD of 125.2 nm. The size of a rabies virion is known to be approximately 60 nm x 180 
nm (Rupprecht, 1996) and this has been confirmed by the RABV average size of 168.2 
nm. The size of PTs appears to be generally larger than virus particles and much more 
variable. 
 
Having estimated particle size, the expression of G on PT membranes was assessed. 
Initially, flow cytometry was utilised to detect fluorescent antibody tagged PT particles 
alongside the HEK 293T cells which had generated the PTs. Again, as the type species 
for RABV the CVS PT present in harvests from the supernatant of transfected cells and 
HEK 293Ts transfected to produce CVS PT were analysed. Both the CVS PT and CVS 
HEK 293T cells were exposed to a non-fluorescently tagged rabies G specific mAb   
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Figure 3.6: NanoSight measurement of CVS PT and RABV virus particles. 
Suspensions of inactivated RABV and CVS PT were detected. The range of particle 
sizes is shown. 
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alongside tissue culture supernatant (SN) from untransfected cells and untransfected 
HEK 293T cells as negative controls. After incubation with the primary antibody this 
was washed off and replaced with an Alexa Fluor 568 tagged secondary antibody to 
enable indirect staining of the PTs and cells in the red light spectrum. Density plots of 
the events measured can be seen in Figure 3.7. 
 
It was clear that more events were measured with the cell containing samples than with 
the PT containing samples. In addition the forward scatter of cells versus PTs shows that 
PT particles are much smaller than cells, as expected. The staining of the cells was much 
more successful than staining of the PT particles. It was clear that no staining of PT 
particles occurred as the gate over the majority of the population shows the same number 
of events in both the CVS PT and cell SN. In contrast the cell staining showed a clear 
difference between the two different cell samples. The staining of the un-transfected 
cells showed only 0.05% of the gated population positive for fluorescence whereas the 
CVS HEK 293T cell population had 46.39% positive for fluorescence. This suggested 
that the staining of the cells was successful and that approximately half of the samples 
cells were expressing G on their surface which indicated a transfection efficiency of 
approximately 50%. 
 
Once the PT particles and the cells expressing them had been detected by flow 
cytometry, the presence of G on the cell surface was also confirmed by 
immunofluorescence using the same primary and secondary antibodies as used in the 
flow cytometry experiment. A selection of images from the panel of PTs are displayed in 
Figure 3.8. Figure 3.8 A to C show the control staining conducted. It was apparent  
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Figure 3.7: Detection of lyssavirus glycoprotein on cells and PTs by flow cytometry. 
The majority of the cell and PT populations were gated from the total events detected 
and representative dot plots of indirect anti-glycoprotein staining of cells transfected to 
produce CVS PT, CVS PT, un-transfected cells and un-transfected cell supernatant are 
shown. The primary antibody was a murine anti-RABV G mAb (MyBioSource) at a 1 in 
50 dilution and the secondary antibody as goat anti mouse Alex Fluor 568 conjugated 
antibody at a 1 in 200 dilution (Life Technologies).  
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Figure 3.8: Immunofluorescence detection of lyssavirus glycoprotein post 
transfection. (A-C) Untransfected HEK 293T cells. (A) Stained with primary, actin-
phalloidin and DAPI antibodies. (B) Stained with secondary, actin-phalloidin and DAPI 
antibodies. (C) Stained with primary, secondary, actin-phalloidin and DAPI antibodies. 
(D) HEK 293T cells transfected to produce CVS PT, stained with secondary, actin-
phalloidin and DAPI antibodies. (E-F) Transfected HEK 293T cells stained with 
primary, secondary, actin-phalloidin and DAPI antibodies. (E) Cells transfected to 
produce CVS PT. (F) Cells transfected to produce LBV B PT. (G) Cells transfected to 
produce WCBV PT. (H) Cells transfected to produce IKOV PT. All images presented 
are z-stacks. Primary mAb used was anti- RABV G antibody  at a 1/50 dilution 
(MyBioSource), the secondary was Alexa-fluor goat anti mouse mAb (Red) at a 1/200 
dilution (Invitrogen) and DAPI Vectashield (Vectorlabs) was used to stain the cell 
nuclei. The actin-phalloidin mAb (green) was used at a 1/50 dilution (Invitrogen).  
1° 
Chapter 3 
112 
 
that there was no non-specific fluorescence with either the untagged primary antibody 
alone (Figure 3.8 (A)) or the 568-tagged secondary antibody alone (Figure 3.8 (B)), nor 
in combination (Figure 3.8 (C)). Figure 3.8 (D) shows unusual actin-phalloidin staining 
in cells transfected to produce the CVS PT. This unusual actin staining was apparent in 
every transfection image, however the unusual staining was not present in every cell. 
The reason for this effect on actin staining remains unclear. Despite the unusual actin-
phalloidin staining the DAPI and glycoprotein staining were more successful. Figure 3.8 
images E to H show a panel of cells transfected to produce a variety of different 
lyssavirus PTs. The pattern of glycoprotein staining appears to be specific to the surface 
of the HEK 293T cells with some cytoplasmic staining. The cell surface staining was 
particularly evident in the CVS image (Figure 3.8 (E)) however the same pattern was 
evident for the more divergent PTs (Figure 3.8 (F to H)). It was interesting that the 
staining appeared to reduce in intensity with increasing genetic divergence away from 
CVS (Figure 3.8 (E)) as LBV B (Figure 3.8 (F)) is stained more strongly than WCBV 
(Figure 3.8 (G)) and IKOV (Figure 3.8 (H)).  
 
Finally, detection of glycoprotein in transfected cells was assessed by Western blot. The 
same mAb utilised for flow cytometry and immunofluorescence was used to detect G in 
cell lysates.  HEK 293T cells transfected to produce the panel of PTs were lysed and the 
concentration of input cell lysate and dilution factor of the mAb were optimised. A 
dilution of cell lysate 1 in 10 and the mAb 1 in 1000 was found to produce the clearest 
blots (data not shown). Once the mAb had been optimised for use in Western blots the 
panel of cell lysates were run on denaturing gels prior to probing with the mAb and 
subsequent development of the blot. The result of the Western blots can be seen in 
Figure 3.9. 
Chapter 3 
113 
 
 
Figure 3.9: Western blot of a panel of cell lysates from cells transfected to produce 
lyssavirus PTs. The primary antibody was the anti- RABV G antibody  (MyBioSource)  
at a 1/1000 dilution. The secondary was polyclonal rabbit anti mouse 
immunoglobulins/HRP (Dako) at a 1/1000 dilution. The glycoprotein of 65 kDa was 
visible.  
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The lyssavirus glycoprotein is 65 kDa (Maillard & Gaudin, 2002) and this can be seen 
for a number of PTs in Figure 3.9.  
 
These characterisation experiments have shown that PT particles appear to be larger than 
lyssavirus virions and that the glycoprotein of lyssavirus PTs can be detected on the 
surface of transfected cells by both flow cytometry and immunofluorescence. PT 
particles themselves can be detected by flow cytometry but the mAb used in this 
investigation was unable to detect glycoprotein on the surface of PT particles. The same 
mAb was however able to detect wildtype lyssavirus glycoproteins on transfected cells 
by IF and via Western blot. 
 
3.8 Discussion 
A large panel of both wt and mutant lyssavirus PTs has been generated by the use of 
overlap extension mutagenesis, standard ligation cloning techniques and commercial 
gene synthesis. 
 
It is apparent that the titres vary between PTs, regardless of the presence of antigenic site 
mutations. The wildtype PTs do, however tend to achieve higher titres and this may be 
due to the lack of mutations within the G. Several G expressing constructs were unable 
to generate measurable PT titres, including RV61 and RV193 (data not shown) along 
with LBV D and CVSFSS that both gave very low titres. The reason for this remains 
undefined although  several factors may be involved including the potential for variation 
between plasmid preparations with respect to  salt concentrations which may affect the 
transfection efficiency by modulating the membrane rigidity of the liposomal formations 
(Bouvrais, 2012). Multiple plasmid preparations were utilised in repeat attempts to 
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generate LBV D and CVSFSS PTs, both of which produced very low titres however 
these two PTs could not be generated to useable titres. 
 
As described in Section 3.6, attempts to improve the titre of the CVSFSS PT by 
reverting the apparently deleterious site II mutations back to wildtype sequence were 
also unsuccessful (Figure 3.5). The crystal structure of the lyssavirus glycoprotein 
remains undefined which makes interpretation of some of the antigenic site mutant 
titration failures challenging. The absence of a crystal structure for the RABV G 
precludes structural assessment of the impact of antigenic site swaps so it remains 
unclear whether the interactions between sites IIa and IIb play a role in the correct 
folding and proper function of the mature protein. It has been suggested in a proposed 
two-dimensional structure of the rabies glycoprotein that sites IIa and IIb are located in 
close proximity within the primary structure of the protein (Walker & Kongsuwan, 
1999) so perhaps by altering residues in these areas for the CVS to LBV IIa and IIb 
mutants along with the CVSFSS to CVS IIb mutant this affected the  interactions 
between sites IIa and IIb which resulted in incorrect folding. There were also variations 
between titres of many of the CVS and LBV site swap mutants which may also 
correspond to changes in the amino acid sequences and thus protein folding.  
 
Each amino acid has specific physiochemical properties which confer either favourable, 
non-favourable or neutral substitution values if one amino acid is switched for another in 
the same position (Betts & Russell, 2003). The physiochemical substitution scores for 
each amino acid switch between the antigenic sites of CVS and LBV are shown in Table 
3.2. All of the substitution scores were negative, i.e. none of the antigenic site swaps 
were favourable, however some site swaps were less favourable than others. Within   
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Table 3.2: The substitution scores based on physiochemical properties of amino 
acids of the antigenic site swaps between CVS and LBV in an extracellular context. The 
score is identical for the LBV to CVS reciprocal swap. (Betts & Russell, 2003). 
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antigenic site IIb there was only one unfavourable change; the leucine (L) to serine (S) 
switch was marginally unfavourable as L is usually found within the interior of a 
protein, unlike S. However, S is weakly polar and so may be involved in defining a 
proteins’ structure. The substitution in antigenic site IIa was neutral in an extracellular 
context, as with the substitutions in antigenic site I. Antigenic site IV is the smallest 
antigenic site however it has a relatively unfavourable switch of phenylalanine (F) to 
asparagine (N). F is hydrophobic so generally found in the hydrophobic core of proteins 
whereas N is polar so a position on the surface of proteins is more favourable. This may 
explain why the swap was unfavourable as the two amino acids have opposing 
physiochemical properties. Antigenic site III contained the most unfavourable changes. 
The positive polar lysine (K) was switched with the hydrophobic L whilst the other 
positive polar residue, arginine (R) was switched for a negative polar residue, aspartic 
acid (D) thus potentially explaining the unfavourable change as the two residues have 
opposing charges. 
 
These substitution values for each of the antigenic sites may play a role in the folding of 
the glycoprotein and therefore the functionality which may have directly affected 
formation of the PT particles and their viability. Therefore the relationship between the 
substitution values of each antigenic site and the titre of the corresponding PT was 
investigated. The relationship of both the CVS and LBV site swap PT panels with the 
site specific substitution values can be seen in Figure 3.10. 
 
There is no clear correlation between titre and substitution value and both the P and R2 
values for the CVS and LBV data both confirm there is no significant correlation 
between titre and substitution value. This suggests that the physiochemical consequences   
Chapter 3 
118 
 
 
Figure 3.10: The relationship between amino acid substitution value and titre of the 
corresponding antigenic site mutants of both CVS and LBV. The substitution values 
were determined according to (Betts & Russell, 2003) and the correlation was 
determined between each PT titre and the corresponding substitution value using 
GraphPad Prism 6.  
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of the alterations in antigenic site sequences in the mutant PTs did not have an effect on 
the titre. This means that there may be other features of the mutant glycoproteins which 
affect the titre of the resulting PT, for example the residues surrounding the antigenic 
sites may play a role (see Section 6.5). This can be seen in the titres of CVSFSS, CVS to 
LBV IIaIIb and CVSFSS to CVS IIaIIb as all only achieved low titres, despite both CVS 
wt sites IIa and IIb being present. Until the crystal structure of the glycoprotein is 
deduced however, these hypotheses cannot be confirmed. 
 
In vitro characterisation of these PT particles using a range of different techniques was 
conducted and visualisation of PT particles was attempted using both NanoSight 
technology and flow cytometry. The NanoSight data suggested that the sizes of PT 
particles are generally larger than virions and much more variable.  
 
The presence of glycoprotein on the surface of transfected HEK 293T cells was detected 
by flow cytometry which indicated a transfection efficiency of approximately 50%. 
Though PTs could be detected by flow cytometry, the fluorescence staining of the PTs 
was unsuccessful. This may be because the binding epitope of the available mAb 
requires mature conformation for binding. The conformation of this mAb epitope on the 
surface of transfected cells may be different to that on the PT plasma membrane, thus 
resulting in a lack of staining, potentially due to a lack of G expression on the PT surface 
or presentation of G monomers as opposed to trimers.  
 
The protein preparations were run on denaturing gels for Western blot analysis which 
may have affected the epitope of the mAb so it would be interesting to run these lysates 
on a non-denaturing gel to determine whether this affects G staining. In addition an 
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alternative mAb may be used in to stain PTs for flow cytometry as this could be a very 
valuable tool for the assessment of PT particles. Alternatively a lower dilution of the 
mAb could be attempted as although a 1 in 50 dilution was recommended by the 
manufacturer, due to the small number of PT particles measured an increase in mAb 
availability may improve staining. 
 
Regardless, a panel of wildtype and mutated PT particles had been generated and could 
now be assessed using neutralisation assays to evaluate the ability of different sera to 
neutralise the different PT particles (Chapter 4). 
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Chapter 4: Investigation into the neutralisation profiles of a panel of 
lyssavirus pseudotypes 
4.1 Introduction 
A panel of pseudotype particles (PTs) were generated representing glycoproteins from 
each of the lyssavirus species alongside PTs that contain mutations to immunogenic 
antigenic sites within the glycoprotein (Chapter 3). The fact that the current rabies 
vaccines are all based on classical rabies virus strains and are unable to generate a 
neutralising response that protects against all lyssaviruses led to an investigation into the 
ability of hyperimmune sera from immune donors to neutralise the various lyssavirus 
PTs. Here we describe attempts to understand the neutralisation of different PTs by 
hyperimmune sera derived from different species.  
 
4.2 Optimisation of the PNA 
Once the panel of PTs had been generated they were available for assay. Initially the PT 
neutralisation assay required optimisation for use with firefly luciferase; the reporter 
used in this investigation. Two luciferase assay systems were compared; the Luciferase 
Assay System (Promega) and Bright-Glo (Promega). The Luciferase Assay System 
required a substantially more complex setup than Bright-Glo and the read time per plate 
was up to 25 minutes as opposed to just two minutes with Bright-Glo, thus the Bright-
Glo system was adopted for the course of this investigation.  
 
In addition to luciferase assay system optimisation, input of PT virus was also optimised. 
The standard practice in a PT assay is to use a quantified concentration of PT, either 
assayed by relative light unit (RLU) or by titre. This requires the dilution of PT such that 
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the input PT virus is approximately equal. A negative cut-off value was assigned as the 
average RLU of at least 4 wells of cells plus media multiplied by 2.5 (Wright et al., 
2008). Following optimisation of the assay consistent results on back titration were 
achieved by diluting PT to 400 TCID50/ml and then addition of 50µl of this per well. 
This resulted in a fairly consistent back titration of 200 TCID50/ml. A back titration of 
each PT dilution was performed alongside each assay as a control for PT input. If any 
back titres differed substantially from 200 TCID50, the assay was repeated. A further 
control was the addition of PT to cells in the absence of sera to give a value for RLU 
from untreated PT.  This control generated a value from which a percentage 
neutralisation was calculated and compared to those treated with the different test sera. 
A negative dog serum control was also tested to confirm that the reduction in 
luminescence seen with test sera was as a result of specifically neutralising antibodies 
present in the test sera which are absent from naïve dog serum.  
 
4.3 Neutralisation within phylogroup I 
It has been suggested that there is a variable degree of cross neutralising antibody  
response generated following vaccination with standard rabies vaccines and that the titre 
required to neutralise phylogroup I lyssaviruses may vary (Brookes et al., 2006). Since 
this initial publication, novel lyssaviruses that are genetically classified within 
phylogroup I had been discovered and so it was of interest to investigate the ability of 
sera from vaccinated animals and humans to neutralise the full range of these viruses. 
Two types of hyperimmune sera were assessed: WHO serum, an international standard 
sera prepared from blood sampled from vaccinated humans that is used as control sera 
for WHO gold standard diagnostic assays; and VLA serum, a diagnostic control serum 
obtained from a pool of vaccinated dogs used in serological diagnostic tests performed at 
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the Animal and Plant Health Agency, UK, as a control sera for neutralisation tests. Both 
sera were diluted to 0.5 IU/ml which is the WHO and OIE internationally accepted cut-
off titre for protection according to dilutions assessed using live virus in the UKAS 
accredited Fluorescent Antibody Virus Neutralisation test (FAVN). For each PT, the 
preparation of PT was diluted out to 200TCID50/ml and incubated with 50µl of either 
WHO or VLA serum and assayed according to Section 2.3.3. The results of this assay 
can be seen in Figure 4.1. 
 
It is clear that all of the PTs were very strongly neutralised by both the WHO human and 
the VLA dog sera at 0.5 IU/ml so the PT panel were run against 0.1 IU/ml of both sera 
in order to determine whether the cross neutralisation was conserved following a 5-fold 
dilution of control hyperimmune sera (Figure 4.2 A). 
 
All of the phylogroup I PTs were strongly neutralised by both WHO and VLA sera at 
0.1 IU/ml as well as 0.5 IU/ml suggesting that there is a considerable degree of cross 
neutralisation within phylogroup I, both to a protective titre of anti-RABV serum but 
also to an apparently sub-protective but clearly neutralising dilution of serum. 
 
The next stage was to investigate whether there was any cross neutralising capacity by 
phylogroup II and III specific sera against the phylogroup I PTs. The same panel of PTs 
used in Figures 4.1 and 4.2 were run against a panel of rabbit sera directed against LBV 
B, a phylogroup II lyssavirus, WCBV, a phylogroup III lyssavirus and IKOV, a novel 
highly divergent lyssavirus (see Section 5.5). The results of the assay can be seen in 
Figure 4.3.
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Figure 4.1: Neutralisation profile of phylogroup I PTs against 0.5 IU/ml RABV 
specific sera. (A) PT neutralisation assay. WHO serum from vaccinated human and 
VLA serum from vaccinated dogs were diluted to 0.5 IU/ml. (B) Back titrations of each 
PT used in the assay. The dotted line indicates the target titre following PT dilution. 
Error bars represent standard deviation (SD) about the mean of three replicate in-assay 
neutralisation tests.   
A 
B 
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Figure 4.2: Neutralisation profile of phylogroup I PTs against 0.1 IU/ml RABV 
specific sera. (A) PT neutralisation assay. WHO serum from vaccinated human and 
VLA serum from vaccinated dogs were diluted to 0.1 IU/ml. (B) Back titrations of each 
PT used in the assay. The dotted line indicates the target titre following PT dilution. 
Error bars represent standard deviation (SD) about the mean of three replicate in-assay 
neutralisation tests. 
A 
B 
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Figure 4.3: Neutralisation profile of phylogroup I PTs against phylogroup II and 
III specific sera. (A) PT neutralisation assay. LBV B serum represents phylogroup II, 
WCBV serum represents phylogroup III and IKOV serum represents a highly divergent 
lyssavirus. All sera were diluted to 0.5 IU/ml. Error bars represent standard deviation 
(SD) about the mean of three replicate in-assay neutralisation tests. A 2-way ANOVA 
was used to determine any significant differences between neutralisation of each PT by 
the test sera compared to the lack of neutralisation by negative dog serum (0% 
neutralisation by negative dog serum data not shown). Significant differences are 
indicated by asterisks; *p≤0.05, **p≤0.005, ***p≤0.001. (B) Back titrations of each PT 
used in the assay. The dotted line indicates the target titre following PT dilution.  
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The majority of the PTs were not significantly neutralised by any of the three divergent 
sera however ABLV appeared to be significantly neutralised by the anti-WCBV by 76%. 
Likewise BBLV was significantly neutralised by the WCBV by 60.5% and DUVV by 
68%. DUVV was also significantly neutralised by the anti-IKOV by 93% whilst IRKV 
was also significantly neutralised by the IKOV serum by 69%. These data suggest that 
there may be some level of cross neutralisation with sera generated against the most 
divergent lyssaviruses (WCBV and IKOV) being able to neutralise some phylogroup I 
PTs; however the neutralising capacity of divergent lyssavirus specific sera against 
phylogroup I PTs appears to be specific for select PTs as the neutralisation profiles of all 
three sera were not equal across the PT panel.  
 
4.4 Investigation of neutralisation within phylogroup II 
Having observed a high degree of cross phylogroup I neutralisation (Figures 4.1 and 4.2) 
and a degree of neutralisation of some phylogroup I lyssaviruses with sera specific to 
divergent phylogroup II and III lyssaviruses (Figure 4.3) the next stage was to assess the 
ability of phylogroup II specific sera to neutralise PT containing representatives from 
each of phylogroups II and III. This was investigated using a panel of phylogroup II PTs 
and LBV B specific serum (Figure 4.4). Representatives of three of the four lineages of 
LBV were included due to the antigenic divergence between these isolates along with 
the other characterised African lyssaviruses. The result of this assay is detailed in Figure 
4.4. Despite numerous efforts to rescue the titre of the LBV D PT, it did not reach the 
threshold for utilisation in the PNA (Section 2.3.3) and as such could not be included. 
The panel of phylogroup II and III PTs was run against an LBV B specific rabbit derived 
polyclonal serum in order to determine the degree of cross neutralisation.  
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Figure 4.4: Cross neutralisation within a phylogroup II lyssavirus PT panel. (A) PT 
neutralisation assay. PTs representing all members of phylogroup II plus phylogroup III 
WCBV and the highly divergent IKOV were run against an LBV B specific rabbit 
derived polyclonal serum diluted to 0.5 IU/ml. A 2-way ANOVA was used to determine 
any significant differences between neutralisation of each PT by LBV B serum and LBV 
B PT by LBV B serum. Significant differences are indicated by asterisks; *p≤0.05, 
***p≤0.001.  (B) Back titrations of each PT used in the assay. The dotted line indicates 
the target titre following PT dilution. Error bars represent standard deviation (SD) about 
the mean of three replicate in-assay neutralisation tests.  
A 
B 
*** 
* 
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In Figure 4.4 the phylogroup II PTs can be seen in pale blue. There was a strong degree 
of neutralisation of all of these PTs by the LBV B serum which suggested a significant 
degree of cross neutralisation within this group of antigenically and genetically similar 
viruses. WCBV is more divergent than the phylogroup II viruses, having only 54% 
amino acid identity with LBV B, so a low degree of cross neutralisation was expected 
and this was confirmed with WCBV being only 27% neutralised by the LBV B specific 
sera. Likewise the IKOV glycoprotein is more divergent still than WCBV, with just a 
48% amino acid identity with LBV B, so a lower degree of neutralisation was expected, 
however, IKOV was 60% neutralised by the LBV B serum. This degree of neutralisation 
was unexpected although it is significantly lower than the degree of neutralisation 
between PTs within phylogroup II. This experiment confirms that, as observed between 
the viruses in phylogroup I (Brookes et al., 2006; Brookes et al., 2005) there was a high 
degree of cross neutralisation between viruses in phylogroup II. This supports the 
concept of including only one phylogroup I and one phylogroup II lyssavirus 
glycoprotein in any cross protective antigen formulation as these should be able to 
provide sufficient cross neutralisation between all viruses in phylogroups I and II. 
 
4.5 Investigation of cross neutralisation between phylogroups 
Following establishment of the level of cross neutralisation within phylogroups it was of 
interest to determine the level of cross neutralisation between phylogroups. It has long 
been acknowledged that the current rabies vaccines are unable to produce an antibody 
response that can neutralise viruses from other phylogroups efficiently. Most recently, 
with the discovery of Ikoma virus a complete lack of cross reactivity of high titre human 
and pet hyperimmune sera for IKOV has been demonstrated (Horton et al., 2014). 
Alongside this, mice vaccinated with rabies vaccines that seroconverted were also 
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completely unprotected following challenge with IKOV (Horton et al., 2014). In order to 
investigate this further, representatives of each phylogroup were selected on the basis 
that the neutralisation profiles within phylogroups appear to be similar. This panel of 
PTs was then exposed to a range of sera at different concentrations in order to 
investigate any inherent cross neutralisation. 
 
Initial data in Figures 4.1 and 4.3 suggested that 0.5 IU/ml of sera was sufficient to 
neutralise all members of phylogroup I however there was limited cross neutralisation 
with 0.5 IU/ml of phylogroup II and III sera against phylogroup I PTs. For this reason a 
series of increasing concentrations of RABV specific sera were run against the 
representatives of all phylogroups in order to determine whether this induced 
neutralisation of divergent lyssavirus PTs. The results of this PNA can be seen in Figure 
4.5. The sera tested were the same as those utilised previously (WHO and VLA) and due 
to their high concentration these sera could be diluted out to a range of IU/ml to assess 
the ability of increasing concentrations of sera to neutralise each PT. 
 
The percentage neutralisation of each PT was compared to that of CVS for each serum 
dilution using a two way ANOVA test and a level of significance (alpha value) of 0.05. 
Those values which significantly differ from CVS are indicated by asterisks on Figure 
4.5. At each concentration of both WHO and dog serum LBV B neutralisation was not 
significantly different to CVS. The WHO serum was able to neutralise WCBV and 
IKOV to an extent at both 5 IU and 10 IU however at 5 IU the neutralisation of WCBV 
was not significantly different to CVS suggesting substantial neutralisation, though this 
pattern was not continued at 10 IU. The dog serum was not able to significantly 
neutralise either WCBV or IKOV at any concentration however at 10 IU a small degree  
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Figure 4.5: Neutralisation profile of lyssavirus PTs against increasing 
concentrations of hyperimmune sera. (A) PT neutralisation assay. WHO serum was 
obtained as an international reference standard from NIBSC and the dog serum was 
created from a pool of hyperimmune dog sera. A 2-way ANOVA was used to determine 
any significant differences to neutralisation of CVS by each serum. Differences are 
indicated by asterisks; p*≤0.05. (B) Back titrations of each PT used in the assay. The 
dotted line indicates the target titre following PT dilution. Error bars represent standard 
deviation (SD) about the mean of three replicate in-assay neutralisation tests.  
A 
B 
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 of neutralisation was evident with WCBV neutralised by 19% and IKOV by 26% 
respectively. These results suggest that there may be a significant degree of cross 
neutralisation between phylogroups I and II in cases of high antibody titre post 
vaccination, however there is no cross neutralisation of phylogroup III or IKOV by the 
RABV hyperimmune sera. 
 
The degree of cross neutralisation between phylogroups using high titre vaccinee serum 
specific to RABV had been investigated so next the degree of cross neutralisation when 
applying the serological threshold for protection against RABV was investigated 
alongside a ten-fold dilution of sera as described in Figure 4.1 and Figure 4.3 for 
phylogroup I PTs. The same panel of four PTs used in Figure 4.5 were run against serum 
specific to each of the PTs: WHO and VLA gold standard reference sera specific to 
RABV and rabbit serum raised against LBV B, WCBV and IKOV respectively (Figure 
4.6). 
 
A 2-way ANOVA test was used to compare the degree of neutralisation of each PT to 
the percentage neutralisation of PT by its homologous serum i.e. for the LBV specific 
serum, the neutralisation of each PT was compared to neutralisation of LBV. Values 
significantly different to the homologous PT neutralisation are indicated by an asterisk. 
An alpha level of 0.05 was used for each comparison. 
 
At both 0.05 IU and 0.5 IU WHO serum was unable to neutralise LBV B, WCBV or 
IKOV to a similar degree as CVS whereas the VLA serum was able to neutralise WCBV 
to a statistically similar degree as CVS at both 0.05 IU and 0.5 IU. The LBV B serum 
was unable to neutralise any PT substantially at 0.05 IU, even LBV B however at 0.5 IU  
Chapter 4 
133 
 
Figure 4.6: Cross neutralisation between the lyssavirus phylogroups. (A) PT 
neutralisation assay. Each PT was run against a panel of specific sera at a concentration 
of either 0.5 IU/ml or 0.05 IU/ml. A two way ANOVA was used to determine significant 
differences between each PT and the homologous PT versus serum. Significance is 
indicated by an asterisk; *p≤0.05. (B) Back titrations of each PT used in the assay. The 
dotted line indicates the target titre following PT dilution. Error bars represent standard 
deviation (SD) about the mean of three replicate in-assay neutralisation tests.  
A 
B 
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it specifically and completely neutralised LBV B only. The WCBV specific serum 
showed a similar profile to the LBV B serum, only being able to significantly neutralise 
WCBV at both concentrations whereas the IKOV specific serum was able to neutralise 
both CVS and WCBV to a similar extent to IKOV at 0.05 IU. At 0.5 IU whilst CVS was 
still significantly neutralised, WCBV was no longer significantly neutralised but a 
substantial level of neutralisation was maintained and LBV B was also significantly 
neutralised. This suggests that below or at the recognised cut-off for protection of 0.5 
IU/ml vaccine induced sera (WHO and VLA) are unable to neutralise any PTs outside of 
phylogroup I. In contrast IKOV specific serum appears able to neutralise PTs from all 
three phylogroups at 0.05 IU and 0.5 IU, despite being the most divergent lyssavirus 
identified to date. 
 
4.6 Discussion 
The pseudotype neutralisation assays in this chapter have identified a strong level of 
intra-phylogroup neutralisation within phylogroups I and II. The results have also 
suggested a degree of cross neutralisation between IKOV and WCBV though the 
reciprocal reactions showed little to no cross neutralisation. Interestingly, higher 
concentrations of hyperimmune sera demonstrated some cross neutralisation between 
phylogroups I and II. 
 
One element of the data produced by the PNAs in this Chapter is the considerable degree 
of variation between replicates. Every neutralisation was conducted in triplicate however 
the variation in level of luminescence differed substantially between some replicates. 
This is likely a result of the mechanism by which luminescence is detected. Certainly, 
the standard virus neutralisation assays performed when assessing serological status in 
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samples depend on the detection of virus antigen in a sample where antibodies in the test 
sample are unable to neutralise input virus. This WHO and OIE Gold standard 
serological test then relies on reader interpretation of the presence or absence of antigen 
following fixation and staining of the monolayer with a FITC conjugated polyclonal 
antibody preparation directed against the virus N protein. As a result the readout of these 
assays is simply the reciprocal titre at which neutralisation is observed in comparison to 
control sera. In contrast, using the pseudotype neutralisation assay, a measure of 
luminescence is taken following incubation with or without test sera, which by virtue of 
assays dependent on chemiluminescence, will exhibit a much higher degree of 
variability across replicates. As such the PNA can be performed using alternative 
reporter genes such as GFP or β-galactosidase but in this study efforts were made to 
quantify neutralisation. This variation in RLU between replicates has been found in a 
number of other laboratories using this assay system (Dr. Wright University of 
Westminster and Dr Both St George’s University – personal communication) which 
suggests that there is an inherent issue with the luciferase read out of PNAs. This 
variation however is measured and recorded and the advantages of an immediate 
quantitative read out of each well outweigh the disadvantages of the variation observed. 
A study into the reduction of variation between replicates would aid further studies of 
this nature. 
 
In addition to the variation between replicates, the variable back titres of PTs within 
each assay must also be considered. Although efforts were made to ensure a back titre of 
200 TCID50/ml, this was not always achieved and therefore there was a variation in PT 
titre between PTs within assays. This may have affected the neutralisation profiles of 
PTs as a lower than 200 TCID50/ml input could result in more substantial neutralisation 
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than would have resulted had the back titration been closer to 200 TCID50/ml and vice 
versa. 
 
A very strong degree of cross neutralisation within phylogroup I at both 0.5 IU and 0.1U 
was confirmed by PNAs in Figures 4.1 and 4.2. This data is supported by current 
knowledge of phylogroup I viruses however studies have shown varying levels of cross 
neutralisation within phylogroup I, for example the HDCV was able to protect more 
efficiently against CVS and EBLV-2 infection than ABLV or EBLV-1 (Brookes et al., 
2005). In contrast antigenic cartography has shown that ABLV and KHUV appear 
antigenically identical to the RABVs. IRKV, ARAV and EBLV-1 were next most 
similar to RABV followed finally by EBLV-2 (Horton et al., 2010). These contrasting 
studies suggest that the picture of the antigenicity of phylogroup I lyssaviruses is still not 
well defined however the data generated in this investigation provide some insight into 
the utility of the PNA to investigate further the field of cross neutralisation between 
lyssaviruses. 
 
The assay involving the phylogroup I PT panel against sera from divergent lyssaviruses 
shows again the difference between glycoproteins in phylogroup I and appeared to 
suggest that WCBV and IKOV specific serum were able to neutralise some phylogroup I 
PTs to a small extent. This pattern of neutralisation may be a result of the sera used. The 
sera were obtained from rabbits inoculated with inactivated PT preparations (see Section 
5.5) meaning that the sera were polyclonal. This may result in the targeting of a variety 
of areas along the glycoprotein, some of which may be well conserved among all 
lyssaviruses. Although the antigenic sites along the lyssavirus glycoprotein have been 
well defined and do differ between phylogroups, the lack of a crystal structure means 
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that immunogenic domains which rely on the conformation of the protein may not be so 
well understood and it is possible that domains like this are targeted by some antibodies 
in these polyclonal serum preparations. Indeed it is likely that some neutralising 
antibodies are targeted to less divergent domains on the ectodomain of G although until 
an atomic structure for G is generated such areas are difficult to predict. 
 
Following confirmation of cross neutralisation within PTs representing lyssaviruses 
from phylogroup I it was necessary to determine whether there is a strong level of cross 
neutralisation between the members of phylogroup II. PTs representing all viruses in 
phylogroup II were generated, including representatives of three of the four LBV 
lineages. Unfortunately it was not possible to generate sufficient titre for LBV lineage D 
and as such this glycoprotein was excluded from the study. However, with only a single 
isolate of LBV lineage D having been detected evaluation of cross neutralisation 
between the viruses for which PTs were generated is sufficient to gauge the degree of 
cross neutralisation within the phylogroup. There was clear cross neutralisation between 
all members of phylogroup II (Figure 4.4) as well as an unexpectedly high degree of 
cross neutralisation of WCBV and IKOV PTs by the LBV lineage B specific serum. The 
presence of a strong intra-phylogroup neutralising response, within both phylogroups I 
and II has been identified previously (Badrane et al., 2001) so the data in this PNA 
confirms this and extends the existing data to encompass all but one of the currently 
characterised viruses that are grouped within these phylogroups. Furthermore this study 
has given proof of concept for the PNA as an alternative technique for determining cross 
neutralisation as previous studies have been limited to quantifying neutralising responses 
to plasmids containing the phylogroup II glycoproteins as opposed to live virus. These 
previous studies utilised plasmid DNA vectors expressing PV or MOKV glycoprotein 
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sequences under the control of a cytomegalovirus promoter (CMV). These DNA 
preparations were then purified and injected intramuscularly into mice. Although 
specific immune responses were raised to the glycoprotein DNA sequences in these 
plasmids, the antibody responses were characterised by ELISA (Badrane et al., 2001; 
Bahloul et al., 1998). This limits the ability of the study to predict neutralisation as the 
ELISA used was only able to detect binding antibody, it was unable to identify 
neutralising antibody. The PNA used here is able both to identify neutralising antibodies 
and to generate anti-sera against the glycoprotein in a more natural conformation; 
expressed on the surface of a PT particle which may induce antibodies more similar to 
those that might be generated as a result of lyssavirus infection.  
 
The confirmation of this intra-phylogroup cross neutralisation is essential to the 
remainder of this investigation as it means that a construct containing the antigenic 
epitopes of any phylogroup II lyssavirus should be sufficient to neutralise any other 
phylogroup II virus. According to the results in Figure 4.4 it may also be sufficient for a 
small degree of neutralisation of WCBV or IKOV. This suggests that if a pan-lyssavirus 
cross protective candidate was to be developed it would have to contain antigenic 
features from all three phylogroups and perhaps IKOV as well in order to produce 
strongly neutralising antibodies against all currently characterised lyssaviruses. 
 
The further investigations into cross neutralisation between all three phylogroups 
confirmed that antibodies induced by vaccination would provide no protection against 
infection with phylogroup II or III viruses, even at concentrations 20 times greater than 
those which neutralise phylogroup I constructs (Hanlon et al., 2005; Horton et al., 
2014). The possibility however of some cross neutralisation between IKOV and WCBV 
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however is interesting. Currently the classification of IKOV into a phylogroup is 
ongoing however the data from this experiment suggest that it would be best placed in a 
new phylogroup; phylogroup IV. This is due to the lack of a strong neutralising response 
between WCBV and IKOV, unlike the strength of the neutralising responses within the 
other two phylogroups. Despite this, there did appear to be a significant degree of cross 
neutralisation of CVS, LBV B and WCBV by the IKOV specific sera in Figure 4.6. The 
basis for this result is unknown as there have been no published investigations into cross 
neutralisation of IKOV with other lyssaviruses however both IKOV and LBV B are 
African lyssaviruses and there is evidence that WCBV may also be circulating in Africa 
(Kuzmin et al., 2008a) so there may be some antigenic feature which all African 
lyssaviruses share.  
 
The overall finding is that there is strong intra-phylogroup neutralisation but there is 
little inter-phylogroup neutralisation at 0.5 IU/ml. It would be valuable to investigate 
cross neutralisation between phylogroups using sera from different species sources and 
also directed against different vaccine or RABV strains as there may be differences 
between the immune responses to different vaccine strains, for example it was found that 
an animal vaccine; Rabiffa was able to protect dogs against challenge with LBV, 
whereas the HDCV (Imovax) was unable to protect against LBV challenge but was able 
to protect against CVS and DUVV challenge (Fekadu et al., 1988). In addition, the cross 
neutralising capacity of IKOV serum could be further investigated by increasing the 
concentration of serum against a panel of PTs in order to determine whether increasing 
antibody concentration improves its cross neutralising capacity. 
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Chapter 5: Investigating the effect of mutation to antigenic sites within 
the lyssavirus glycoprotein on serological neutralisation 
5.1 Introduction 
An extensive panel of lyssavirus pseudotypes (PT) was generated (Chapter 3) that 
encompassed lyssavirus glycoproteins representative of both wildtype and mutated 
glycoprotein sequences. As a tool to investigate the difference in neutralisation profiles 
of different sera for the lyssavirus glycoprotein a series of antigenic site swap mutant 
glycoproteins were developed containing single and multiple antigenic site swaps 
between a representative rabies isolate (CVS) (phylogroup I) and Lagos Bat Virus 
(lineage B) (phylogroup II).  These isolates were chosen due to the availability of live 
virus, glycoprotein sequence and potently neutralising hyperimmune sera specific for 
each. A panel of single and multiple site swaps was then investigated to evaluate any 
potential role for the different antigenic sites in neutralisation. The antigenic site swap 
mutant PT viruses were assayed against sera specific to both classic rabies virus as well 
as LBV to identify any potentially cross neutralising constructs whilst the panel of 
wildtype PTs comprising phylogroups II and III (described in Chapter 4) was assayed 
against a range of sera from different phylogroups in order to identify any existing cross 
neutralisation between and within divergent phylogroups. Alongside this, sera specific 
for mutated glycoproteins was generated in vivo to enable an assessment of any 
alteration in antigenicity seen following mutation.  
 
5.2 Assessment of the CVS PT Panel 
The first panel of PTs to be assessed by PNA were the CVS to LBV single and full 
antigenic site swaps. The titres of each of the PTs generated in this panel are shown in 
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Figure 5.1. The titres of the CVS panel range from CVS to LBV IIaIIb with the lowest 
titre of 10
3.26
 TCID50/ml to CVS to LBV IIa with the highest titre of 10
7.30
 TCID50/ml. 
There was an approximately 4 log difference between the lowest and highest titres 
however all titres were sufficiently high to enable reliable dilution for input into the 
PNA. As described in Chapter 3 the CVSFSS PT could not be generated to a sufficient 
titre to test (Section 3.6). 
 
Each of the PTs in the CVS panel were run against three different sera. WHO serum was 
obtained from NIBSC and is utilised as the WHO gold standard reference for vaccinated 
humans in current diagnostic tests. VLA serum was obtained from a panel of vaccinated 
dogs and was used as the OIE gold standard reference in diagnostic tests. Both of these 
sera are specific to classic rabies virus in phylogroup I as they were raised against 
vaccine strain RABVs. The third serum utilised was obtained from a rabbit 
experimentally inoculated with β-propiolactone inactivated LBV lineage B PT virus (see 
Section 5.5). As described in Section 2.3.3, three different sera were used to assess the 
neutralisation of the panels of different wildtype and mutated PTs. Each of the three sera 
were diluted to 0.5 IU/ml, following the established dilution series utilised by the 
FAVN, and 50µl of these serum dilutions were exposed to 50µl of diluted PT in 
triplicate. A reduction in the level of luminescence was detected in cases of PT 
neutralisation by the test sera and the percentage neutralisation of each PT by each 
serum was calculated according to the value for luminescence generated by the untreated 
PT (Figure 5.2). The back titrations in Figure 5.2 (B) confirm that all PT input titres 
were close to the target of 200 TCID50/ml so all resulting neutralisation data should be 
reliably comparable. All CVS based PTs including the CVS wildtype PT were almost 
completely neutralised by both RABV specific sera; WHO and VLA which suggests that  
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Figure 5.1: The titres of the panel of wildtype, single and full antigenic site swaps 
between CVS and LBV. Titre was measured in TCID50/ml as determined on BHK-21 
cells. Error bars represent standard deviation (SD) about the mean of three replicate in-
assay titrations. 
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Figure 5.2: CVS antigenic site swap PT neutralisation profiles. (A) The result of the 
CVS panel of antigenic site swap mutants PNA against both phylogroup I specific sera, 
WHO and VLA as well as phylogroup II specific sera, LBV. All sera were diluted to 0.5 
IU/ml. A two way ANOVA was used to determine significant differences between 
neutralisation of each PT and neutralisation of CVS by its homologous WHO and VLA 
sera. Significance is indicated by an asterisk.; *p≤0.05, **p≤0.005, ***p≤0.001. (B) 
Back titrations of each PT used in the assay. The dotted line indicates the target titre 
following PT dilution. Error bars represent standard deviation (SD) about the mean of 
three replicate in-assay neutralisation tests.  
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no single antigenic site swap to that of LBV within the CVS G was sufficient to affect 
phylogroup I neutralisation. The CVS wildtype PT was not neutralised by the LBV B 
serum which confirms a lack of cross neutralisation between these glycoproteins, 
however a number of single and multiple antigenic site swap mutants were neutralised 
by the LBV B specific sera, with those mutants containing LBV site IIb residues being 
neutralised to a significantly similar extent as CVS wt. CVS to LBV IIb was most 
strongly neutralised by 98% followed by CVS to LBV IIaIIb by 80%. CVS to LBV IIa 
was neutralised by 65% however this was significantly different to CVS wt 
neutralisation. This suggests that antigenic site II may play an important role in 
neutralisation of phylogroup II viruses though CVS to LBV I and III were also 
neutralised by 50% and 51% respectively which may suggest that these major antigenic 
sites may also contribute to neutralisation, though not to a significant extent. 
 
The CVS to LBV IV mutant was very strongly neutralised by both the WHO and VLA 
serum whilst being neutralised by only 11% by the LBV B serum. This may suggest that 
site IV plays only a very minor role in neutralisation of phylogroup II viruses as its 
neutralisation profile by the three test sera was very similar to that of CVS wildtype. 
 
Despite numerous attempts with the CVSFSS PT, back titration of virus did not yield 
sufficient virus to indicate that neutralisation was occurring. As such, attempts to study 
the effects of the addition of different sera to the CVSFSS PT were not performed. 
 
5.3 Assessment of the LBV PT Panel 
Having established the neutralisation profile of the panel of CVS mutants against a range 
of phylogroup I and II specific sera, the reciprocal PTs in the LBV to CVS site swap 
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panel were run against the same panel of sera in an exact experimental repeat. The titres 
of the panel of LBV site swap mutants are shown in Figure 5.3 and the result of the PNA 
is shown in Figure 5.4. The titres of the LBV panel of PTs were more consistent than the 
reciprocal CVS PT panel. All titres were approximately 10
5
 TCID50/ml except LBV to 
CVS III which had a lower titre of 10
3.18
 TCID50/ml. Each of these PTs was diluted to an 
endpoint titre of 200 TCID50/ml for input into the PNA (Figure 5.4). 
 
The back titration in Figure 5.4 B shows that all PT dilutions were successful as all back 
titres were close to 200 TCID50/ml. In Figure 5.4 A the results of the PNA show a 
considerable amount of variation for many of the values, overall there seems to be a 
greater amount of variation in the LBV PNA than the CVS PNA. Despite this variation 
there was a clear pattern in the neutralisation profiles observed. The LBV wildtype PT 
was neutralised by the LBV specific sera, as expected however, interestingly the LBV 
wildtype PT was also very strongly neutralised by both of the RABV specific sera which 
contrasts with the CVS wildtype PT result which was not neutralised at all by the LBV 
specific sera. In addition the LBVFSS PT which contains all the antigenic epitopes of 
CVS was also strongly neutralised by both the RABV and LBV specific sera which may 
suggest that there are important neutralising epitopes outside of the defined antigenic 
sites for neutralisation of LBV and that these epitopes may be cross neutralising for 
RABV. The rest of the panel of single antigenic site swap mutants were all also strongly 
neutralised by the LBV specific sera which supports the hypothesis of the importance of 
epitopes outside of the antigenic sites. Those antigenic sites which do, however appear 
to play a role in phylogroup I neutralisation were indicated by PTs which were more 
strongly neutralised by the RABV specific sera than the LBV sera.  
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Figure 5.3: The titres of the panel of wildtype, single and full antigenic site swaps 
between LBV and CVS. Titre is measured in TCID50/ml as determined on BHK-21 
cells. Error bars represent standard deviation (SD) about the mean of three replicate in-
assay titrations. 
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Figure 5.4: LBV antigenic site swap PT neutralisation profiles (A) The result of the 
LBV panel of antigenic site swap mutants PNA against both phylogroup I specific sera, 
WHO and VLA as well as phylogroup II specific sera, LBV. All sera were diluted to 0.5 
IU/ml. A two way ANOVA was used to determine significant differences between 
neutralisation of each PT and neutralisation of LBV by its homologous LBV serum. 
Significance is indicated by an asterisk.; *p≤0.05. (B) Back titrations of each PT used in 
the assay. The dotted line indicates the target titre following PT dilution. Error bars 
represent standard deviation (SD) about the mean of three replicate in-assay 
neutralisation tests.  
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From Figure 5.4 these PTs appear to be LBV to CVS sites I, IIb, IIaIIb and III. LBV to 
CVS site I and LBV to CVS IIb were neutralised by all three sera by over 99% 
suggesting both phylogroup I and II neutralising epitopes were present. LBV to CVS 
IIaIIb was neutralised by WHO and VLA sera by 86% and 98%, respectively and 91% 
by the LBV specific sera. The LBV to CVS III PT was neutralised by the WHO and 
VLA sera by 97% and 99% respectively and the LBV sera by 99%, again suggesting the 
importance of site III in a phylogroup I neutralising response but only neutralisation of 
LBV to CVS IIa by WHO serum was significantly different to LBV wt neutralisation.  
 
The pattern of epitopes identified as holding an important role in phylogroup I 
neutralisation (Figure 5.4) was similar to that identified for phylogroup II neutralisation 
(Figure 5.2). The important antigenic sites appear to include site II (the combination of 
sites IIa and IIb), site I and site III. These epitopes when swapped alone, and also in 
combination with all others appeared to affect the neutralisation profile of the resulting 
PTs.  
 
The finding that LBV PT was neutralised by WHO and VLA sera by 85% and 66%, 
respectively, was unexpected, based on the lack of neutralisation of LBV virus by 
RABV specific sera. This suggests the possibility that the density of G protein on the 
surface of PT particles may affect the ability of sera to neutralise the PT. In order to 
investigate whether this is the case a PNA was set up using a 1 in 10 dilution of the sera 
from the PNAs in Figures 5.2 and 5.4. The result of this assay can be seen in Figure 5.5.  
The assay in Figure 5.5(A) shows CVS and LBV PTs versus the RABV and LBV 
specific sera at a concentration of 0.5 IU/ml. The CVS PT was strongly neutralised by 
both RABV specific sera whilst only 34% neutralised by the LBV specific sera. The  
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Figure 5.5: Assessment of the effect on serum dilution and the neutralisation 
profiles of PTs (A) CVS and LBV PTs against the RABV specific WHO and VLA sera 
and the LBV specific sera at 0.5 IU/ml. (B) CVS and LBV PTs against the RABV 
specific WHO and VLA sera and the LBV specific sera at 0.05 IU/ml. Error bars 
represent standard deviation (SD) about the mean of three replicate in-assay titrations. A 
two way ANOVA was used to determine significant differences between neutralisation 
of each PT by each serum and neutralisation of each PT by its homologous serum. 
Significance is indicated by an asterisk; **p≤0.005.  
A 
B 
** 
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neutralisation profile of the LBV PT again demonstrated neutralisation by each of the 
WHO, VLA and LBV sera by 92%, 96% and 98%, respectively. In Figure 5.4 (B) both 
PTs were run against sera at 0.05 IU/ml and the neutralisation profiles of both CVS and 
LBV PTs reflected the neutralisation profiles seen with the FAVN with the CVS PT 
neutralisation profile matching that of the 0.5 IU/ml assay while the LBV PT was 
neutralised by the WHO and VLA sera by only 33% and 37% respectively whilst being 
98% neutralised by the LBV specific serum however neutralisation of CVS was not 
found to be significantly different to neutralisation of LBV at 0.05 IU/ml.  
 
The results of this assay suggest that there may be less glycoprotein present on the 
surface of the LBV PTs than is present on naturally produced virions and may also be 
possible that there is less G on the surface of the CVS PT due to the expected 
neutralisation profile of LBV only being achieved at a 1 in 10 dilution of the reference 
sera. As a result of this finding, the LBV PNA was repeated with the sera at a 
concentration of 0.05 IU/ml (Figure 5.6). The result of the LBV PNA against 0.05 IU/ml 
of each serum showed a clearer neutralisation profile than the 0.5 IU/ml PNA (shown in 
Figure 5.4). In Figure 5.6(A) the LBV wildtype PT was strongly neutralised by the LBV 
specific serum whilst being poorly neutralised by the WHO serum and not neutralised at 
all by the VLA serum. If the pattern of neutralisation by RABV specific sera verses LBV 
specific sera is used to suggest which antigenic sites may play dominant roles in 
neutralisation, three PTs appeared to affect neutralisation more significantly: LBVFSS, 
LBV to CVS I and LBV to CVS III. These three PTs were neutralised to a greater degree 
by the RABV specific sera than the LBV specific sera which suggests that sites I and III 
play an important role in phylogroup I neutralisation however these neutralisation 
profiles were not significantly different to wt LBV. This selection of sites was similar to   
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Figure 5.6: LBV PNA versus sera at 0.05 IU/ml. (A) The result of the LBV panel of 
antigenic site swap mutants PNA against both phylogroup I specific sera, WHO and 
VLA as well as phylogroup II specific sera, LBV. All sera were diluted to 0.05 IU/ml. A 
two way ANOVA was used to determine significant differences between neutralisation 
of each PT and neutralisation of LBV by its homologous LBV serum. Significance is 
indicated by an asterisk.; *p≤0.05, **p≤0.05.  (B) Back titrations of each PT used in the 
assay. The dotted line indicates the target titre following PT dilution. Error bars 
represent standard deviation (SD) about the mean of three replicate in-assay 
neutralisation tests.  
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that identified in the previous 0.5 IU/ml assay in Figure 5.4. 
 
5.4 Investigation of cross neutralisation between phylogroups 
Chapter 4 demonstrated that within each phylogroup there was considerable cross 
neutralisation but that between phylogroups the ability of sera to neutralise more 
divergent viruses varied.  The next area of interest was to investigate the ability of 
different sera, specific for individual lyssaviruses, to neutralise a panel of lyssaviruses. 
To this end, PT virus was inoculated into rabbits to generate specific neutralising sera 
against viruses for which no sera were available.  
 
A range of ten PTs were selected for inoculation into rabbits based on the availability of 
specific sera (Section 2.9.1). Each of the rabbit derived specific sera were then tested 
against a panel of lyssavirus PTs to assess the potential for cross neutralisation between 
viruses.  
 
Initially, prior to inoculation, the titres of the PTs inoculated into the rabbits were 
determined (Figure 5.7). All PTs were generated to a high titre (>10
6
 TCID50/ml) with 
the exception of PTs for WCBV and IKOV although for both titres were still >10
4
 
TCID50/ml. Once the sera had been generated, each sample was run against its 
homologous PT in order to determine the titre of specific antibodies. The titres of each 
serum sample are shown in Table 5.1.  
 
The sera with the highest tires were CVS to LBV I and LBV lineage A whilst the lowest 
titres were LBV to CVS IIaIIb, LBV lineage B and IKOV. The reason for the variation  
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Figure 5.7: Titres of PTs inoculated into rabbits to produce specific polyclonal sera. 
Solid colour bars represent wildtype glycoprotein PTs and chequered bars represent 
antigenic site mutants. Error bars represent standard deviation (SD) about the mean of 
three replicate in-assay titrations. 
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Table 5.1: Serum titres of each rabbit polyclonal serum generated against a range 
of inactivated PT viruses. Titres are given both in International Units per ml and 
reciprocal titre i.e. 50% end point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Rabbit Sera Titre (IU/ml) Reciprocal Titre 
CVS 512.0 40959.9 
CVS to LBV I 2048.0 163839.6 
LBV to CVS I 362.0 28962.9 
LBV to CVS IIaIIb 16.0 1280.0 
LBVFSS 1448.2 115851.4 
LBV A 2896.3 231702.4 
LBV B 8.0 640.0 
LBV C 362.0 28962.9 
WCBV 90.5 7240.7 
IKOV 22.6 1810.2 
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between the serum titres was unknown so the protein concentration of each inocula 
(inactivated PT prep) was determined via spectrophotometer and absorbance at the 280 
nm wavelength. A standard curve was constructed using a series of known 
concentrations of BSA in PBS and the resulting curve was then used to approximate the 
protein concentration of each of the inocula. The standard curve generated is shown in 
Figure 5.8. The concentration of each inoculum was determined from the curve and the 
results are displayed in Table 5.2. 
 
The protein concentrations of all inocula were similar with the lowest being WCBV at 
3.66 mg/ml and the highest being CVS at 5.11 mg/ml. In order to determine which 
factor had the greatest influence on serum titre, statistical analyses were used to compare 
the serum titre values with both the PT titre and the protein concentration of each 
inocula. An alpha level of 0.05 was used for all statistical tests. The serum titre did not 
correlate with PT titre r(10) = -0.04359, p = 0.9048 and although there was a slightly 
stronger positive correlation of serum titre with inoculum protein concentration, this 
relationship remained insignificant r(10) = 0.3265, p = 0.3571. The variation in serum 
concentrations following inoculation was therefore likely related to animal to animal 
variation. 
 
Once the serum concentration of each sample had been determined using the PNA a 
confirmation of each serum titre was conducted via FAVN. A function of the FAVN test 
is that only CVS virus is used which means that any sera generated against divergent 
lyssavirus PTs may not cause neutralisation of the phylogroup I CVS virus. Despite this, 
each rabbit derived serum was run against CVS PT on a standard PNA and against live 
CVS virus on a standard FAVN assay in order to identify any significant differences  
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Figure 5.8: A standard curve of absorbance at 280 nm constructed using a series of 
known concentrations of BSA diluted in PBS. This curve was used to determine the 
protein concentrations of a panel of inactivated PT preparations by extrapolation of their 
absorbance to their concentration. The absorbance of each solution was measured in 
triplicate and standard deviation error bars generated.  
 
 
  
Chapter 5 
157 
 
Table 5.2: Estimated protein concentrations for each PT preparation. The protein 
content of each inoculum that was used to inoculate rabbits in order to generate specific 
sera was determined by absorbance at 280nm with reference to a standard curve of 
absorbance (Figure 5.8). 
 
Inoculum Protein Concentration (mg/ml) 
CVS 5.11 
CVS to LBV I 4.88 
LBV to CVS I 4.75 
LBV to CVS IIaIIb 4.77 
LBVFSS 5.06 
LBV A 4.99 
LBV B 5.01 
LBV C 4.99 
WCBV 3.66 
IKOV 3.71 
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between the serum titres determined by the two methods. The tires of each of the ten 
serum samples as determined by both PNA and FAVN are shown in Table 5.3. A paired 
Student’s t-test was performed on the titres determined by both PNA and FAVN in order 
to determine whether there was any significant difference between the values produced 
by each assay t(3) = 1.54, p = 0.05. There was no significant difference between the 
pairs which confirms that the PNA method of determining serum titre is as accurate as 
the gold standard FAVN test and lends support for the titres of the sera generated against 
divergent lyssavirus PTs as these could only be calculated by PNA due to a lack of 
availability isolates for each of the live divergent viruses. Additionally no correlation 
was found between the protein concentration of inocula and the resulting anti-serum 
titre; R
2
 = 0.09, p = 0.311. 
 
Once accurate serum titres of each of the rabbit derived sera had been determined an 
investigation into the neutralisation profiles of the antigenic site swap sera was 
conducted. The CVS to LBV I, LBV to CVS I, LBV to CVS IIaIIb and LBVFSS 
specific sera were run against wildtype CVS and LBV PTs at 0.5 IU/ml (Figure 5.9). 
The CVS to LBV I serum neutralised the CVS PT but also neutralised the LBV PT by 
47%. In a reciprocal experiment the LBV to CVS I serum completely neutralised the 
LBV PT but the CVS PT was only neutralised by 7% which was to a lesser degree than 
the reciprocal serum was able to neutralise LBV. Interestingly the LBV to CVS IIaIIb 
serum neutralised the CVS PT more strongly than the LBV PT; by 93% and 64% 
respectively. Finally, the LBVFSS specific serum neutralised both CVS and LBV PTs to 
a similar extent; 51% and 56% respectively. All of these neutralisation profiles were  
significantly different to neutralisation by negative dog serum except neutralisation of 
CVS PT by LBV to CVS I serum.  
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Table 5.3: Titres of polyclonal rabbit sera against CVS by PNA and FAVN. (A) 
Serum titres of rabbit derived polyclonal serum against inactivated PT preparations 
determined by standard PNA. (B) Serum titres of rabbit derived polyclonal serum 
against inactivated PT preparations determined by standard FAVN. 
(A) PNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) FAVN 
 
 
 
 
 
 
 
  
Rabbit Sera Titre (IU/ml) Reciprocal Titre 
CVS 512.0 40959.9 
CVS to LBV I 4.0 320.0 
LBV to CVS I 0.50 40.0 
LBV to CVS IIaIIb 1.0 80.0 
LBVFSS 4.0 320.0 
LBV A No neutralisation No neutralisation 
LBV B No neutralisation No neutralisation 
LBV C No neutralisation No neutralisation 
WCBV No neutralisation No neutralisation 
IKOV No neutralisation No neutralisation 
Rabbit Sera Titre (IU/ml) Reciprocal Titre 
CVS 631.2 25904.27 
CVS to LBV I 276.9 11363.98 
LBV to CVS I 0.13 5.20 
LBV to CVS IIaIIb 0.87 35.53 
LBVFSS 7.79 319.81 
LBV A 0.13 5.2 
LBV B 0.13 5.2 
LBV C 0.17 6.8 
WCBV 0.13 5.2 
IKOV 0.13 5.2 
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Figure 5.9: Rabbit derived antigenic site mutant sera PNA. (A) The four sera 
directed against antigenic site swap mutants were diluted to 0.5 IU/ml and run against 
wildtype CVS and LBV PTs. A 2-way ANOVA was used to determine any significant 
differences between neutralisation of each PT by the test sera compared to the lack of 
neutralisation by negative dog serum (0% neutralisation by negative dog serum data not 
shown). Significant differences are indicated by asterisks; *p≤0.05 (B) Back titrations of 
each PT used in the assay. The dotted line indicates the target titre following PT dilution. 
Error bars represent standard deviation (SD) about the mean of three replicate in-assay 
neutralisation tests.  
Chapter 5 
161 
 
5.5 Discussion 
The PNA system was successfully optimised and used to conduct a variety of 
neutralisation experiments exploring the relative importance of each of the antigenic 
sites in a phylogroup specific neutralisation response as well as investigating the degree 
of cross neutralisation across different phylogroups. 
 
From the site swap assays three antigenic sites were highlighted as being potentially 
important for both a phylogroup I and II neutralisation response. The CVS to LBV assay 
suggested those sites involved in phylogroup II neutralisation. Antigenic site II mutants 
were most strongly neutralised by both RABV and LBV specific sera indicating their 
essential role in neutralisation. Antigenic site I and III mutants also showed an alteration 
in their neutralisation profile by LBV specific sera however these mutants were less 
strongly neutralised than the site II mutants indicating these may play a more minor role. 
 
A different neutralisation profile was evident for the reciprocal LBV to CVS site swaps 
as the data suggested that sites I and III were of potential importance however there was 
a lack of significance in these neutralisation profiles which must be considered when 
interpreting the patterns of neutralisation. The LBV wildtype PT was shown to 
potentially express a reduced amount of G on its surface than the CVS PT which meant 
that a reduction in the concentration of serum exposed to the LBV PT panel resulted in a 
clearer neutralisation profile. The reason for a reduced concentration of G on the LBV 
PTs is unknown however this may result from a lack of control of expression of G on the 
transfected cell surface or the absence of a stabilising interaction with the matrix protein 
within the PT particle. It may also simply be a reflection of the transfection efficiency or 
variation in the number of cells in the wells. Despite this, the results of both the 0.5 
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IU/ml and the 0.05 IU/ml PNAs suggest that a phylogroup I specific neutralising 
response may depend more heavily on antigenic sites I and III whereas a phylogroup II 
response is more dependent on antigenic site II. There is little evidence in the literature 
defining the importance of individual antigenic sites in lyssavirus neutralisation however 
what data exists is focussed on RABV viruses of phylogroup I in mice. This data 
indicates that sites II and III are the most important for a CVS neutralising response in 
H-2
d
 mice (Benmansour et al., 1991). The importance of these two sites as well as site I 
is also supported by the finding that a large number of neutralising anti-glycoprotein 
mAbs are specifically directed towards these sites (Lafon et al., 1983). The data 
collected in this investigation highlighting the importance of sites I and III in a 
phylogroup I neutralising response is therefore supported by the currently available 
evidence. 
 
Now that the three sites which appear to play the most important role in phylogroup I 
and II neutralisation have been proposed this can direct the selection of potentially cross 
neutralising candidates. The full antigenic site swaps are an obvious choice as these 
contain all of the main immunodominant epitopes of each glycoprotein however, from 
this data it is possible that a mutant containing antigenic sites I and III of CVS and site II 
of LBV would be the most promising cross protective candidate. Unfortunately due to 
time constraints the generation of this mutant was not possible. However the generation 
of such a mutant would be a very interesting direction in which to take any future work. 
 
The inclusion of two different RABV specific sera in this investigation; WHO and VLA 
was interesting as these are sourced from two different species; WHO from humans and 
VLA from dogs. The WHO serum is generated from a pool of human vaccinees. 
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However, production of this serum is problematic and relies on obtaining sera from 
individuals that may have been vaccinated with different inactivated preparations of 
rabies virus. This factor may have an impact on the neutralisation profile of this serum as 
there are numerous variations between different RABV strains prepared for vaccine 
generation although they are at least conserved across the major antigenic epitopes 
investigated in this study. The WHO serum is obtained from the WHO bank as an 
international reference serum. In contrast, the VLA serum is generated from a pool of 
vaccinated dogs for use within the APHA diagnostic laboratory. VLA serum is not 
available as an international standard however the concentration of rabies specific 
antibodies in each ampoule is carefully controlled and measured using the prescribed 
OIE standard techniques for assessment of neutralising antibodies in sera. As with the 
WHO serum, the exact vaccination history of each dog included in the VLA pool is 
unknown. Despite this, these sera represent key reagents for diagnostic evaluation and as 
such their utilisation in this study is well founded. 
 
Both sera are directed against classic RABV isolates and as such their neutralisation 
profiles were expected to be similar. This was the case with most of the results however 
for a limited number of antigenic site mutant PTs there was a distinct difference between 
the degrees of neutralisation by the two RABV specific sera. The LBV to CVS IIa PT 
was more strongly neutralised by the WHO human serum than the VLA dog serum 
whereas the LBV to CVS IV PT was more strongly neutralised by the VLA serum than 
by the WHO human serum. This suggests there may be a difference between human and 
dog immune responses to the distinct antigenic sites and these differences may stem 
from a difference in the major histocompatibility complex (MHC) genes between 
species. Both humans and dogs have three classes of MHC genes however dogs have 
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two additional class I genes compared to humans and these are found on chromosomes 7 
and 18 (Yukhi et al., 2007). This difference in number of class I MHC genes may have 
impacted the humoral response as studies in dendritic cells (DC) show that RABV is 
presented by class I MHCs in mice (Irwin et al., 1999). Though there is no direct 
evidence to demonstrate RABV presentation by MHC class I in dogs or humans it can 
be supposed that RABV would be presented by the endogenous pathway due to the 
absence of virus in blood and other extracellular compartments. Therefore the 
differences between canine and human humoral responses may be responsible for the 
variations seen in the neutralisation profiles of the sera derived from these differing 
species. 
 
Overall a clear combination of antigenic sites playing an essential role in phylogroup I 
and II neutralisation has been identified, despite the variation in the results clear patterns 
were evident which led to the identification of antigenic sites I, II and III as those most 
important in lyssavirus neutralisation. 
 
A further area of interest was the selection of a panel of PTs to generate a panel of 
polyclonal sera from rabbits. The PT panel was selected based on the availability of 
existing sera as well as the inclusion of a selection of antigenic site swap PTs which had 
been identified as promising cross protective candidates. Regulations surrounding the 
inoculation of genetically modified material into rabbits dictated that each PT was 
inactivated prior to inoculation into rabbits and as such an adjuvant was included to 
increase the local immune response and subsequent seroconversion. All rabbits 
seroconverted satisfactorily enabling the provision of sera specific for each of the novel 
PTs. A PNA assessing each serum sample against its homologous PT demonstrated that 
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the rabbits inoculated with CVS to LBV I, LBVFSS and LBV A had raised a 
particularly strong neutralising antibody response. Other titres were lower although the 
basis for these differences remains undefined although it is possible that individual 
differences in immune response between rabbits generated the diversity seen. Despite 
the strain of New Zealand White rabbits being an inbred strain there have been instances 
of immune variation in inbred laboratory models (Sellers et al., 2012). 
 
It has previously been shown that PT viruses are able to cause strong seroconversion in 
mice without prior inactivation, sufficient to induce protection against wildtype 
challenge virus (Powell et al., 2012; Tao et al., 2013) so it is of interest that in this study 
seroconversion was obtained in rabbits inoculated with inactivated PT. The sera obtained 
from these rabbits were then used to predict protection using the in vitro PNA.  
 
An initial experiment, primarily to validate the method of antibody quantification by 
PNA in comparison with FAVN determined the antibody titre of each serum against 
CVS PT or live virus. The results indicated that there was no significant difference 
between titres determined by PNA or FAVN which validated the use of the PNA for this 
purpose as well as highlighting some cross neutralisation of CVS by a number of 
different sera. As expected CVS serum most strongly neutralised the CVS wt PT and 
live CVS virus. However, CVS to LBV I and LBVFSS sera also strongly neutralised 
CVS. This is interesting as both contain the antigenic sites of CVS, except CVS to LBV 
I lacks CVS site I, which suggests that these mutations confer a considerable level of 
neutralisation by CVS specific serum which implies these sera would be able to 
neutralise many other phylogroup I viruses. This also confirmed that the LBVFSS 
construct is susceptible to neutralisation by phylogroup I specific sera so if it retains 
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susceptibility to phylogroup II sera this would be a very promising cross neutralising 
construct. 
 
Further investigation into the neutralising capabilities of these rabbit derived site swap 
sera suggested that the antigenic site swaps had altered the neutralisation profiles with 
respect to sera generated against wildtype viruses. The results of the site swap sera 
versus wildtype CVS and LBV PTs acted as a reciprocal experiment of the site swap 
PTs versus RABV and LBV specific sera. Comparison of the results from the reciprocal 
assays shows a different pattern of neutralisation in each. The CVS to LBV I serum 
versus CVS and LBV PTs shows a very similar neutralisation profile to the reciprocal 
assay using the antigenic site swapped PT whereas the LBV to CVS results were less 
similar. The LBV to CVS PT panel suggested that sites I and III were most important 
but the LBV to CVS I serum did not neutralise CVS PT whereas the LBV to CVS IIaIIb 
serum did. This suggests that site II is more important than site I in a neutralising 
response. The LBVFSS serum was able to neutralise both CVS and LBV PTs by 
approximately 50% which is in contrast to the ability of both RABV and LBV specific 
sera to strongly neutralise LBVFSS PT. The differences between these neutralisation 
profiles may be due to innate differences between human, rabbit, dog and mouse 
immune responses as the antigenic sites were originally mapped using murine antibodies 
(Lafon et al., 1983) whereas the sera used in this investigation originated from a range of 
different mammalian species which may respond to antigens in a different manner to 
each other. It would be valuable to run the site swap rabbit sera against LBV virus in a 
modified FAVN assay in order to determine whether the neutralisation profiles between 
LBV PT and LBV virus are statistically similar, as was shown with CVS PT and virus. 
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Chapter 6: Investigation of neutralisation by antigenic site directed 
mAbs 
6.1 Introduction  
A further application of the PNA using antigenic site swap PTs is their utility in the 
potential characterisation of monoclonal antibody epitopes. The lyssavirus glycoprotein 
is the main immunogenic component of the virus as it is the only viral protein expressed 
on the virion surface. This means that many neutralising antibodies are directed towards 
this protein and many specifically towards the antigenic sites as these are the proposed 
immunodominant regions (Section 1.1.2.4.1).  
 
Monoclonal antibodies have recently been proposed as an alternative to rabies 
immunoglobulins (RIG) (Section 1.2.2) (Both, 2013; Muller et al., 2009) for the passive 
immunisation of humans following the suspicion of a bite from a rabid animal. RIG is 
composed of polyclonal antibodies from either horses or humans. The current procedure 
for PEP involves administration of RIG in and around the wound site utilising a 
dose:weight ratio of 20 IU/kg for HRIG and 40 IU/kg for ERIG. As a result for each 
potential exposure a large amount of RIG may be required. Importantly, it is estimated 
that between 10-16 million people receive PEP annually (Bourhy et al., 2010; Warrell, 
2010). This poses significant disadvantages in that human serum requires multiple 
downstream processes in order to reduce the risk of transmission of blood-borne 
infectious disease. In addition, the production of ERIG has been discontinued by many 
international manufacturers due to ethical issues raised by animal protection groups. 
This means that supply relies on regional manufacturers e.g. in Thailand. The most 
significant disadvantage, however is the very high cost of RIG; HRIG at $100-250 per 
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dose and ERIG at $25-50 per dose (Knobel et al., 2005; Muller et al., 2009). These high 
costs preclude the use of RIG in areas of Africa and Asia where it is most needed.  
 
Due to these constraints with RIG, the potential application of monoclonal antibodies 
(mAbs) as an alternative is very attractive. This approach would utilise antibodies that 
are directed towards the lyssavirus glycoprotein, often targeting specific antigenic sites 
along the glycoprotein. For many mAb preparations, the epitope binding regions have 
not yet been determined and so the potential for antigenic variation and the significance 
of variation on the ability of mAbs to neutralise virus has not been assessed. However, 
due to the immunodominance of the antigenic sites within G, they are often the target of 
potently neutralising mAbs. To test this, and evaluate mAb binding sites for some 
commonly used mAbs the panel of PTs containing antigenic site swaps were used to 
assess the ability of different mAbs to neutralise them. 
  
The panel of mAbs investigated in this study is shown in Table 6.1. mAbs E559 and 62-
7-13 have already been acknowledged by the WHO as potential mAbs for use in PEP 
(Muller et al., 2009) whilst mAb D1 is currently only used in a serological diagnostic 
capacity in a commercially available enzyme linked immunosorbent assay (ELISA) 
(Fournier-Caruana et al., 2003). mAb D8 was produced at APHA and has been shown 
by fluorescent antibody virus neutralisation test (FAVN) to specifically neutralise 
DUVV so for this reason has been excluded from inclusion in potential therapeutic 
cocktails. However the epitope that D8 binds to on the glycoprotein has not yet been 
defined and so it was included in the study. 
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6.2 Utilisation of a panel of PTs to investigate binding sites for monoclonal 
antibodies 
The panel of antigenic site swapped PTs between phylogroups I and II generated in 
Section 3 was used to investigate the potential binding regions of a panel of mAbs, some 
of which have defined antigenic sites within the proposed epitopes of the lyssavirus 
glycoprotein. As none of the antibodies to be investigated were able to neutralise 
phylogroup II lyssaviruses by FAVN (David Selden- personal communication and 
(Muller et al., 2009)) the glycoproteins with antigenic site swaps between phylogroups I 
and II were used to assess the specificity of the different monoclonal antibodies.  
 
Each of the monoclonal antibodies had previously been proposed to target different 
antigenic epitopes on the glycoprotein. Earlier studies had suggested that E559 targeted 
antigenic site II (Muller et al., 2009) so all PTs containing mutations in antigenic site II 
were tested against this mAb. Likewise, cross neutralisation studies have suggested the 
62-7-13 mAb targets antigenic site I so this mAb was tested against all PTs with 
antigenic site I swaps. Finally, D1 was tested against all PTs with antigenic site III 
swaps. Details of each mAb used in this investigation are given in Table 6.1. The results 
of the PNAs are shown in Figure 6.1. The titre of each of the mAbs was determined via 
FAVN and the dilution required to give 0.5 IU/ml was calculated. The value of 0.5 
IU/ml was selected as this is the OIE and WHO approved threshold antibody titre that 
confers protection against infection with RABV. It is therefore used as a standard in all 
OIE and WHO gold standard serological tests.  Each dilution of 0.5 IU/ml was then 
carried out and the titres confirmed on a subsequent FAVN. The PTs were then exposed 
to mAbs at these dilutions and the degree of neutralisation of each PT was calculated   
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Table 6.1: Technical information for the panel of mAbs utilised in this 
investigation. ERA – Evelyn Rokitniki Abelseth SAD derived RABV strain, PV – 
Pasteur virus, a RABV strain, IgG – immunoglobulin isotype G. Adapted from (Muller 
et al., 2009). 
 E559 62-7-13 D1 D8 
Proposed 
Antigenic site 
recognised 
II I III Unknown 
Method for 
determining 
epitope 
Sequencing (following 
generation of an 
escape mutant) 
Cross 
neutralisation 
Unknown Unknown 
Antigen ERA G Whole ERA 
Whole 
PV 
Whole 
DUVV 
Fusion partner P3-X63Ag8 
Sp2/0–Ag14 
myeloma 
Unknown 
NS1 
myeloma 
IgG subtype IgG 1 IgG 2b IgG 1 Unknown 
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Figure 6.1: Neutralisation of antigenic site swap PTs by a panel of mAbs at 
0.5IU/ml. (A) neutralisation profile of antigenic site I swap PTs against mAb 62-7-13. 
(B) Neutralisation profile of antigenic site II swap PTs against mAb E559. (C) 
Neutralisation profile of antigenic site III swap PTs against D1. (D) Back titrations of 
each PT used in the assay. The dotted line indicates the target titre following PT dilution. 
Error bars represent standard deviation (SD) about the mean of three replicate in-assay 
neutralisation tests. A one way ANOVA was used to determine significant differences 
between neutralisation of each PT by each mAb and neutralisation of CVS by each 
mAb. Significance is indicated by an asterisk; *p≤0.05.  
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as a function of the reduction in luminescence in the presence of mAb as opposed to 
luminescence in the absence of mAb. 
 
Antigenic site I is the proposed epitope of 62-7-13 (Both et al., 2013) and this has been 
confirmed by its neutralisation profile against antigenic site I PTs (Figure 6.1 (A)). CVS, 
a phylogroup I lyssavirus was 99% neutralised by 62-7-13, as were LBV to CVS site I 
and LBV to CVS full antigenic site swaps. All of these PTs contain the phylogroup I 
antigenic sites, with this being the only phylogroup I sequence in the LBV to CVS I 
construct. In contrast the wildtype LBV PT as well as the CVS to LBV site I PT were 
only very weakly neutralised, by 15% and 7% respectively. Both of these constructs 
contain a phylogroup II antigenic site I sequence which was clearly not neutralised by 
62-7-13. Due to the CVS to LBV site I PT being so poorly neutralised, this indicated 
that 62-7-13 targets specifically and solely the phylogroup I antigenic site I as no other 
PTs underwent any considerable level of neutralisation. The ability to use phylogroup II 
G containing PTs with just the phylogroup I antigenic sites enabled confirmation of the 
data proposed previously by (Both et al., 2013). 
 
In contrast to the clearly specific 62-7-13 CVS site I epitope, the results of the 
assessment of E559 binding and neutralisation were more complex (Figure 6.1(B)). The 
wildtype CVS PT was neutralised by only 21%, despite having the same sequence in 
antigenic site I as the ERA strain (Table 6.2) against which E559 was generated. The 
LBV to CVS site IIaIIb PT was strongly neutralised by 82%, however, which does 
suggest that the phylogroup I antigenic site II plays a role in E559 neutralisation. This 
was confirmed by the LBV to CVS full antigenic site swap PT being 52% neutralised 
however LBV to CVS IIa was only 16% neutralised which suggests that antigenic site  
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Table 6.2: Alignment of CVS, ERA and LBV lineage B antigenic sites. Residues in 
red differ from the CVS sequence. This highlights the close sequence similarity between 
the RABV strains; CVS and ERA and the divergence of phylogroup II LBV sequence. 
Virus Site IIb Site IIa Site I Site IV Site III 
CVS GCTNLSEFS KRA KLCGVL FH KSVRTWNEI 
ERA GCTNLSGFS KRA KLCGVL FR KSVRTWNEI 
LBV GCGTSSVFS KKS TLCGKP NR LKVDNWSEI 
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IIb plays a stronger role in E559 neutralisation than IIa. This role of site IIb was 
confirmed by the reciprocal PT swaps as the CVS to LBV IIa PT, which still contains 
CVS site IIb, was 71% neutralised. The CVS to LBV IIb PT however appeared to be 
more strongly neutralised than the IIa swap which reduces the certainty of the role of 
CVS IIb in E559 neutralisation. 
 
The neutralisation profile of mAb D1 against all of the antigenic site III swap PTs 
suggests that site III may not be a target of D1 (Figure 6.1 (C)). Only the CVS wildtype 
PT was completely neutralised by D1. All of the remaining site III PTs were not 
neutralised at all or to low levels. The LBV to CVS III and LBVFSS PTs both contain 
the CVS antigenic site III however these were only very weakly neutralised, by 1% and 
4% respectively. These degrees of neutralisation are similar to those of wildtype LBV 
and CVS to LBV III which both contain the antigenic site III of LBV which suggests 
site III may be necessary for D1 neutralisation but is not sufficient; other sequences are 
required. 
 
6.3 Escape from neutralisation by the proposed mAb panel 
The cocktail of mAbs being considered by the WHO as a potential alternative to current 
RIG therapy, E559 and 62-7-13 have been shown in general to be able to neutralise 
RABV viruses (Section 6.2 and (Muller et al., 2009)) however there have been instances 
where certain phylogroup I viruses have been demonstrated to escape neutralisation by 
these mAbs (Muller et al., 2009). Data from Section 6.2 suggested that mutations to 
CVS antigenic site I inhibited neutralisation by mAb 62-7-13 and mutations to site II 
influence E559 neutralisation, thus the sequences of antigenic sites I and II in a number 
of viruses known to escape neutralisation were examined in order to identify any 
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specific residues which may determine neutralisation. The viruses and their antigenic 
site sequences can be seen in Table 6.3. 
 
A critical role for residue Lys 245 in 62-7-13 neutralisation was identified (Both et al., 
2013) and it was found that an escape mutant of E559 had mutations of Leu to Arg at 57 
and Lys to Glu at 217 (Muller et al., 2009). All three of these residues are located in 
antigenic sites: 245 in site I and 57 and 217 in site II. It was therefore postulated that any 
mutations at these positions would affect neutralisation by the respective mAbs. It can be 
seen from Table 6.3 that both PV and EBLV-1 were not neutralised by 62-7-13 and it 
was clear that both contain mutations at position 245 with Glu and Arg residues in place 
of Lys, respectively. This confirms the critical role of Lys 245 as well as explaining the 
lack of neutralisation of PV, EBLV-1 and all PTs containing LBV antigenic I. 
 
Kelev is a strain of RABV and has been repeatedly shown to escape neutralisation by 
E559 (Muller et al., 2009). From Table 6.3 it was clear that Kelev contains mutations in 
site II at the same positions as the E559 escape mutant. This suggests that these residues 
may have a critical role in E559 neutralisation, however the USA Bobcat isolate had the 
same sequence in site II as both CVS and PV which were neutralised by E559. This 
suggested that there may be epitopes outside of antigenic site II which play a role in 
E559 neutralisation and it may be that these mutations affect the conformation of site II 
as it is the only discontinuous epitope on the lyssavirus glycoprotein so is likely to be the 
most susceptible to be affected by mutations resulting in conformational changes. 
Despite the Bobcat isolate neutralisation profile against E559, the significance of the 
residues at positions 57 and 217 in the Kelev RABV strain was further investigated. An 
isolate of Kelev was available in the laboratory so a series of PCR products were  
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Table 6.3 : Sequence of antigenic sites and neutralisation profiles of a panel of 
viruses which escape neutralisation by the current mAb cocktail being considered by 
WHO as an alternative to current serological therapies. Residues in red differ from CVS-
11 which is neutralised by both mAbs in the cocktail. 
Virus 
Site I 
(245-250) 
62-7-13 
Neutralised 
Site IIa 
(217-
291) 
Site IIb 
(53-61) 
E559 
Neutralised 
CVS-11 KLCGVL Y KRA GCTNLSGFS Y 
PV QLCGVL N KRA GCTNLSGFS Y 
Kelev, Israel KLCGVL Y TRA GCTNRSEFS N 
Bobcat, USA KLCGVL Y KRA GCTNLSGFS N 
EBLV-1, 
Germany 
RLCGVL N KKA GCTTLTPFS Y 
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generated from different sources of Kelev: from infected mouse brain homogenate and 
from an infected tissue culture cell pellet. Previously next generation sequencing (NGS) 
using the 454 platform had identified four different variants of Kelev, each with a 
different combination of aa at positions 57 and 59 (Denise Marston – unpublished data). 
The variation at these sites was of interest due to their presence in antigenic site IIb so in 
order to determine whether the same variants were present in the mouse brain 
homogenate or the cell pellet PCR reactions were set up to generate the entire G ORF as 
product. These 1.5 kb PCR products were sequenced using the MiSeq platform 
(Illumina) in house at the APHA Central Sequencing Facility and the results were 
analysed using Tablet (version 1.14.10.20). The consensus sequence used to map the 
reads was the glycoprotein ORF of rabies virus isolate RV2324 (KF154998.1). 
 
A number of nucleotide (nt) variants were identified in the cell pellet product whereas 
only one nt variant was found in the mouse brain PCR products. The variant identified in 
all PCR products was a T to G at position 170. This nt variant was identified in 99.9% of 
all mouse brain reads and 72.4% of all cell pellet reads suggesting that this variation is 
under substantial selective pressure. In addition to the nt 170 variant in the cell pellet, a 
variant consisting of a C to T substitution at position 169 was identified in 32.2% of all 
reads. There were also a limited number of variants with a G to A substitution at position 
175 and some with an A to G substitution at position 176. All of these variations are 
within antigenic site IIb and result in amino acid changes in the glycoprotein sequence.  
 
The significance of the substitutions at positions 169 and 170 is that these determine 
which aa will be present at position 57 in the glycoprotein; the precise residue which 
appears to influence E559 neutralisation. The C to T substitution at 169 in combination 
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with the T to G substitution at 170 results in a tryptophan residue at aa 57 whereas the 
170 substitution alone results in an arginine residue at aa 57. The consensus sequence of 
Kelev along with CVS, PV and EBLV-1 contain a leucine residue at position 57 whereas 
those viruses which escape neutralisation by E559; the Kelev isolate from this 
investigation along with MOKV and IKOV (David Selden – unpublished data) contain 
arginine, glutamate and glycine residues at position 57, respectively. This therefore led 
to the hypothesis that leucine 57 plays a critical role with regard to mAb E559 
neutralisation. 
 
6.4 Neutralisation profile of mAb D8 
The epitope of mAb D8 has not yet been defined however preliminary virus 
neutralisation assays suggest that D8 is only able to neutralise DUVV, the virus against 
which it was generated. In order to investigate further the neutralisation profile of this 
mAb it was run against a panel of PTs representing every lyssavirus to determine 
whether it is able to cross neutralise any other PTs. The result of this PNA can be seen in 
Figure 6.2. 
 
mAb D8 showed the expected neutralisation profile against DUVV PT. Despite DUVV 
being a phylogroup I lyssavirus this anti-DUVV mAb shows a very limited 
neutralisation capacity against any other phylogroup I PT, unlike the RABV specific 
sera in Chapter 4. The only phylogroup I PT showing significant neutralisation by D8 is 
BBLV which was 88.5% neutralised. The MOKV PT was 72% neutralised and this was 
the only other PT that showed more than 50% neutralisation. Interestingly both LBV B 
and IKOV showed no significant difference in neutralisation when compared to DUVV 
using a one way ANOVA as both were 45% neutralised.  
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Figure 6.2: Neutralisation profile of mAb D8 against a full panel of wildtype 
lyssavirus PTs. (A) PT neutralisation assay. mAb D8 was diluted to 0.5 IU/ml and a one 
way ANOVA compared neutralisation of each PT to neutralisation of DUVV. 
Significant differences are indicated by an asterisk. Error bars represent standard 
deviation (SD) about the mean of three replicate in-assay neutralisation tests. A one way 
ANOVA was used to determine significant differences between neutralisation of each 
PT by D8 and neutralisation of DUVV by D8. Significance is indicated by an asterisk; 
*p≤0.05. (B) Back titrations of each PT used in the assay. The dotted line indicates the 
target titre following PT dilution.   
A 
B 
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Due to the insignificant neutralisation of the CVS PT by mAb D8 and the significant yet 
limited neutralisation of LBV B this mAb was not run against the antigenic site swap 
panel of PTs as in Figure 6.1. 
 
6.5 Discussion 
Knowledge surrounding the ability of monoclonal antibodies to bind epitopes within the 
glycoprotein is of great significance when considering the potential for antibody 
mediated escape and the role of mAbs as a replacement for RIG. Such information is of 
particular importance where the evaluation of neutralising antibodies is concerned as the 
potential for escapes mutant generation has significant implications on the potential 
utility of mAbs in a cocktail for the replacement of RIG. The neutralisation profiles of 
the mAbs investigated here do not entirely match with published data on proposed 
epitopes. There may be a number of reasons for this, however, the lack of a crystal 
structure for the rabies, or any lyssavirus glycoprotein, significantly hinders 
interpretation of whether the structure of Gs in mutated PT particles has been altered 
potentially affecting binding and neutralisation. A number of estimations as to the effect 
of individual amino acids (aa) within the protein may be generated by looking at the 
physiochemical properties of the amino acids both within the CVS and LBV antigenic 
sites as well as residues adjacent to these sites. Any changes in residues within sites may 
alter the physiochemical interactions between residues within the protein, thus affecting 
the structure and subsequently recognition by site specific mAbs. The aa sequence of the 
antigenic sites in both wildtype and the antigenic site swap mutants along with the 
physiochemical properties of the adjacent residues are shown in Figure 6.3.  
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Figure 6.3: Alignment of CVS-11 and LBV RV1 wildtype glycoprotein sequences 
along with reciprocal antigenic site swap sequences made in GENEDOC. Residues 
are shaded according to their physiochemical properties. Antigenic sites are marked in 
black boxes and positions at which a physiochemical swap occurs have been highlighted 
by arrows.  
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The GENEDOC alignment software assigned physiochemical properties according to 
those proposed by (Dickerson & Geis, 1969) and the amino acid properties assigned by 
(Betts & Russell, 2003) were also used to interpret the effects of aa changes. Antigenic 
site IIb contains two residues at which a switch in physiochemical properties of the 
amino acids is altered by the antigenic site switch. The aliphatic leucine (L) in CVS is 
switched to a tiny serine (S) and the negatively charged glutamate (E) is switched to a 
small valine (V) in the antigenic site swap. It has already been established however that 
these switches are only weakly unfavourable in terms of physiochemistry (see Table 3.2) 
but the folding of this antigenic site may be affected by the alteration in the adjacent 
amino acids. The residues upstream of the antigenic site retain very similar 
physiochemical properties between the CVS and LBV backbones however downstream; 
there is a switch from a hydrophobic methionine (M) in the CVS backbone to a small 
valine (V) in the LBV backbone. This may result in a conformational change due to the 
size difference between the two amino acids however both are hydrophobic so similar 
interactions should be maintained. Upstream of antigenic site IIa there is a switch from a 
positive arginine (R) in CVS to a small threonine (T) in LBV. Though threonine is 
marginally polar, the main difference between these two residues is that threonine is C-
beta branched so contains two, rather than one, non-hydrogen substituent on the C-beta 
carbon. This results in a larger than average amino acid residue and indeed threonine is 
very rarely found in alpha helices but commonly found in beta-sheets. In contrast, due to 
the polar nature of arginine this residue commonly forms salt bridges with negatively 
charged residues to create hydrogen bonds which confer stability to the protein. 
Downstream of antigenic site IIa there are more physiochemical changes as the region 
becomes more hydrophobic in the LBV backbone. The hydrophobic methionine residues 
in LBV at this site would reside on the interior of the protein whereas the serine and 
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threonine residues in the corresponding positions in CVS are not hydrophobic. Serine is 
a small slightly polar residue which can be found on the interior of proteins, like 
methionine however as mentioned, threonine is a larger than average residue due its C-
beta branch and is unlikely to reside in alpha helices. This gives some insight into the 
potential structures which have been altered in the site swap mutants. For example this 
may help explain the unexpected neutralisation profile of E559 as this was proposed to 
recognise antigenic site II however it did not seem to show a profile consistent with this. 
If the alteration in the backbone had indeed affected the structure of this discontinuous 
epitope then the CVS to LBV PTs would be expected to have been more strongly 
neutralised than the LBV to CVS PTs. This pattern does seem to be present with both 
the CVS to LBV site IIa and IIb PTs being very strongly neutralised. In confirmation, 
both the LBV to CVS IIa and IIb PTs were less strongly neutralised than their reciprocal 
counterparts which suggests that the alteration in the residues surrounding these 
antigenic sites did have a noticeable effect on the ability of E559 to recognise and 
neutralise these mutants. This may also suggest that it is the combination of antigenic 
sites IIa and IIb of CVS that is essential for E559 neutralisation as the LBV to CVS 
IIaIIb PT was 82% neutralised which suggests that the sequence of the combination of 
antigenic sites IIa and IIb remains of strong importance for E559 neutralisation, even if 
the surrounding residues and hence the structure of the discontinuous site may differ. 
Interestingly, E559 is capable of binding to phylogroup II lyssavirus G proteins as 
evidenced by its ability to detect LBV and MOKV G in immunofluorescence (Finke, S. 
personal communication), however it is unable to neutralise these lyssaviruses. This may 
indicate multiple binding residues on G of which some are important in neutralisation. 
The fact that the escape mutant generated by E559 contains two amino acid mutations; 
one in site IIb and the other in site IIa indicates that site II does play a role in binding 
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and neutralisation by this mAb. In addition to this, NGS data showed a consistent variant 
at nt 170 which encodes aa 57 within antigenic site IIb which further supports the role of 
site IIb in E559 neutralisation and highlights the need for further investigation of its 
epitope as this may have significance for the WHO’s continued investigation of this 
mAb as part of a novel therapeutic cocktail.  
 
The neutralisation profile of 62-7-13 was as expected with only PTs containing the CVS 
site I sequence being neutralised. The physiochemical features of the residues 
surrounding antigenic site I differ only very slightly between CVS and LBV which may 
explain the accuracy of the mAb. There is a switch of two hydrophobic methionines (M) 
in CVS to two aromatic phenylalanines (F) in LBV downstream of site I, however 
phenylalanine is strongly hydrophobic, as is methionine so these switches are unlikely to 
have affected the protein folding, thus site I was specifically targeted by 62-7-13. 
 
The interest in mAb D1 stems from its use in the current rabies specific ELISA. It has 
been shown to recognise antigenic site III in native but not β-mercapto-ethanol and/or 
sodium dodecyl sulphate (SDS) treated G. It has been shown to have a strong 
neutralising potency towards RABVs: CVS, Pasteur virus (PV) and Pitman-Moore virus 
(PM) and also towards EBLV-2 in virus neutralisation assays (Fournier-Caruana et al., 
2003) so may have some potential for use in a therapeutic cocktail. However, D1 was 
only able to neutralise the wildtype CVS PT. The lack of neutralisation of PTs 
containing CVS antigenic site III by mAb D1 may be explained by the considerable 
alteration in the physiochemical properties of the residues downstream of site III 
between the CVS and LBV backbones. Upstream of site III there are very few changes 
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in physiochemical properties however nine residues downstream of site III there are a 
number of changes to the physiochemical features of the glycoprotein. The small valine 
(V) in CVS is switched for an aliphatic isoleucine (I), however, both of these residues, 
like threonine are C-beta branched so the impact of this switch is unlikely to cause any 
alteration in the protein structure. Following this likely insignificant switch there are a 
number of glycine (G) residues in CVS which are not present in LBV. This may have a 
significant impact on the folding of the protein as glycines contain a small hydrogen in 
their side chain, as opposed to carbons in all the other amino acids. This means that 
glycines confer a much greater amount of conformational flexibility than other amino 
acids as they can reside in areas of the protein which would be impossible for other 
amino acids. There may be a tight turn downstream of antigenic site III in CVS, due to 
the G residues which cannot be present downstream of the LBV site III and this may 
have had a severely detrimental effect on the structure/availability of antigenic site III. It 
has been proposed that antigenic site III forms a loop-like structure on the surface of the 
lyssavirus glycoprotein (Benmansour et al., 1991) and this structure may be due to the 
presence of the glycines, enabling this tight turn. Thus, when the glycines are no longer 
present within the LBV to CVS site swap, the usual loop like conformation of site III is 
no longer possible resulting in mAb D1 being unable to recognise and bind to its usual 
epitope. 
 
Overall it appears that the residues surrounding the antigenic sites play as an important a 
role in antigenic site formation as the sequences of the antigenic sites themselves. This 
has been demonstrated by the alteration in physiochemical properties of the glycoprotein 
both up and downstream of antigenic sites II and III between CVS and LBV resulting in 
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potentially altered presentation of these antigenic sites which may have had a negative 
impact on the ability of site specific mAbs to recognise or access their epitopes. The fact 
that the physiochemical properties of the glycoprotein around antigenic site I differ 
minimally between CVS and LBV may have enabled the expected neutralisation profile, 
which was seen in this experiment and this lends support to the importance of residues 
surrounding the antigenic sites in the formation and presentation of mAb epitopes. In 
addition the current limited data on the critical residues for 62-7-13 and E559 
neutralisation has been supported by this investigation. The lack of neutralisation of any 
PT or virus containing a mutation at residue 245 by 62-713 was previously demonstrated 
(Both et al., 2013). The residues 57 and 217 identified as potentially essential to E559 
neutralisation (Muller et al., 2009) were shown to be mutated in Kelev and were also 
mutated in the site II antigenic site swap mutants however the lack of neutralisation of 
the Bobcat isolate which contained wildtype residues at positions 57 and 217 and the 
lack of neutralisation of the CVS wildtype PT by E559 put the significance of these two 
residues into question. The NGS data however provides support for the critical role of 
leucine 57 in E559 neutralisation though further investigation into the epitopes of both 
E559 and D1 is required in order to confirm their specificities. 
 
The neutralisation of the mAb D8 was also investigated against a panel of PTs 
representing all of the currently identified lyssaviruses. Initial virus neutralisation assays 
had shown D8 potently neutralised DUVV (unpublished data) however no investigation 
into its epitope had been conducted. The PNA (Figure 6.2) showed that D8 was able to 
significantly neutralise BBLV along with some of the other African lyssaviruses 
however it showed no potency against any phylogroup I PTs except BBLV which 
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suggests that the strong intra-phylogroup I neutralisation seen with vaccine induced 
polyclonal sera (Figures 4.1 and 4.2) may not be representative of all sera raised against 
each phylogroup I virus. Further investigation into the cross neutralising capacity of sera 
raised against all phylogroup I viruses against all other phylogroup I viruses/PTs would 
be valuable. 
 
It was interesting that many of the African lyssavirus PTs were neutralised by D8 as a 
similar pattern was seen with IKOV specific polyclonal sera. This again may suggest 
that the African lyssaviruses share some antigenic features which likely reside outside of 
the defined antigenic sites.  
 
Due to the limited neutralisation of CVS by D8 it was unlikely that any antigenic sites 
on CVS would comprise the epitope of D8, in addition LBV B was only 45% neutralised 
suggesting it did not contain any significant epitope for D8. This result means that the 
epitope for D8 likely lies outside of the currently defined antigenic sites however an 
assay including D8 against the CVS PNA panel may yield some information into the 
ability of D8 to neutralise LBV as the CVS PTs contain only the antigenic sites of LBV, 
thus if any were to be neutralised by D8 it would be highly likely that this neutralisation 
would have resulted from recognition of that particular LBV antigenic site as it has been 
shown that D8 is unable to neutralise CVS. 
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Chapter 7: Construction and characterisation of full length clones in 
vitro and in vivo 
7.1 Introduction 
In order to confirm the neutralisation results obtained using the PNA, a panel of 
recombinant full length clones were generated for subsequent neutralisation experiments 
with the aim of preparing these constructs for use in vaccination/challenge experiments 
in vivo. The data obtained from the PNA suggested that wildtype CVS and LBV clones 
alongside the full antigenic site swaps: CVSFSS and LBVFSS would be the most 
informative in the first instance. These recombinants were generated in the context of a 
vaccine strain RABV, cSN where the cSN glycoproteins were exchanged for the 
heterologous glycoproteins of interest. The functionality of successfully rescued clones 
was determined in vitro prior to inoculation of viable clones into vaccinated and 
unvaccinated mice to determine protection against challenge and pathogenicity of each 
virus. 
 
7.2 Construction of full length clones 
The full length cSN clone contains a number of restriction sites which enable 
manipulation of the genome (Figure 7.1). The G gene is flanked by SmaI and NheI 
restriction sites. Due to the presence of a SmaI site within the pCR Blunt vector 
(Invitrogen) used for subcloning, an alternative blunt ended restriction enzyme site was 
engineered upstream of the G genes, HpaI. This site was not present in either the 
subclone or full length clone. HpaI recognises a 6 nucleotide sequence; the same length 
as that of SmaI so does not result in any frame shifts and also generates a blunt end like 
SmaI so the blunt to sticky ended ligation was maintained. The HpaI and NheI   
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Figure 7.1: Graphic illustration of cSN, the full length cDNA copy of the RABV 
genome. All restriction enzyme recognition sites within the plasmid sequence which 
enable manipulation of the genome are highlighted. Mutated or wildtype glycoproteins 
of interest were introduced into the cSN backbone via HpaI/PmeI and NheI restriction 
enzymes. Digestion of the intact cSN plasmid with SmaI and NheI generated two 
fragments; the 14,195 bp backbone and the 1572 bp glycoprotein in lanes 1-3. The 
ladder is 1kb DNA ladder (Promega).
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restriction enzyme sites were engineered via PCR to flank each of the mutated and 
wildtype lyssavirus G genes that were produced (see Section 3) (primer sequences in 
Appendix I). 
 
The cloning strategy was the same for all produced G constructs (Figure 7.2). Firstly 
cSN was digested with SmaI and NheI to remove the G gene. The now linear cSN 
plasmid minus the G gene was then purified by LMP agarose gel electrophoresis. 
Meanwhile the insert constructs were directly digested by HpaI and NheI. After 
purification of the cSN vector, the pre-digested G constructs were then inserted into the 
vector by ligation.  
 
This approach of directly ligating the PCR product into the vector was unsuccessful for 
all of the G constructs so an additional step of subcloning each of the inserts into a 
commercially available blunt ended vector was attempted. The PCR products resulting 
from the addition of the HpaI and NheI restriction enzyme sites flanking the G gene 
were ligated into the pCR Blunt vector. These ligations were then transformed into 
MAX Efficiency® DH5α-T1R competent cells (Invitrogen) in the presence of the 
selective antibiotic, kanamycin. Putative positive clones were purified by the small scale 
plasmid preparation technique and confirmed by restriction enzyme mapping. Plasmid 
DNA from confirmed positive small scale DNA preparations was then produced in large 
amounts using the maximum scale plasmid preparation kit. The purity and concentration 
of the resulting large scale DNA preparations were measured on a spectrophotometer 
(Section 2.2.7).  Following this, 10µg of each large scale plasmid preparation was 
digested with HpaI and NheI to excise the G insert from the blunt vector. Following 
digestion, the inserts were purified by LMP gel electrophoresis and the resulting insert   
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Figure 7.2: Cloning strategy for HpaI/NheI glycoprotein into full length clone. The 
strategy for cloning CVS, CVSFSS, WCBV and IKOV into cSN. The wildtype cSN 
glycoprotein is highlighted in blue, the cSN vector DNA is in orange, pCR-ZeroBlunt 
vector is in green and the glycoprotein insert is in yellow. 
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preparations were ligated into the pre-digested cSN vector. The ligation reactions were 
transformed into MAX Efficiency® DH5α-T1R competent cells (Invitrogen) in the 
presence of the selective antibiotic, ampicillin. Small scale plasmid mini preparations 
were generated for putative positive clones and these sequences were confirmed by 
restriction enzyme mapping and sequence analysis. Plasmid DNA from confirmed 
positive small scale preparations was grown up into large scale preparations and the 
purity and concentration of the resulting preparations was measured on a 
spectrophotometer. Three positive maxi preparations from three separate positive 
colonies were generated for each full length clone. This strategy was successful in the 
generation of the CVS, CVSFSS, WCBV and IKOV full length clones however despite 
multiple attempts, the LBV and LBVFSS clones could not be correctly constructed. 
 
In an attempt to generate full length clones containing LBV and LBVFSS via ligation an 
alternative blunt end restriction enzyme site was selected, PmeI. This restriction enzyme 
recognises an 8 nucleotide sequence, unlike SmaI and HpaI which both recognise a 
sequence of 6. This meant that two amino acids from the cSN backbone, within the 
intergenic region were converted into the first two residues of the PmeI site during the 
primer design, in order to avoid the addition of nucleotides. This new restriction enzyme 
site was engineered upstream of the LBV and LBVFSS G genes via PCR. These PCR 
products were then ligated into the subclone vector and the previous cloning strategy 
was then repeated. This alteration of the restriction enzyme sites showed no 
improvement in the generation of these clones so an alternative cloning strategy was 
then attempted. 
 
Gibson Assembly (NEB) involves the generation of overlapping PCR products in order 
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to construct the clones (Figure 7.3). Primers were designed using an online tool provided 
by NEB (NEBuilder) to incorporate the PmeI and NheI sites up and downstream of the 
G genes. These primers overlapped with an additional set which would encompass the 
rest of the cSN backbone. PCR products successfully generated using these primers were 
subsequently incorporated into an assembly reaction and the results of these assemblies 
were transformed into NEB 5-α competent E. coli cells. Small scale plasmid 
preparations were generated for putative positive clones and the sequences of these were 
confirmed in the same manner as those by conventional cloning; restriction enzyme 
mapping and sequence analysis. Large scale plasmid maxi preparations were generated 
for positive clones and their purity and concentrations were determined. Again three 
maxi preparations were generated for each clone. This method of Gibson Assembly was 
able to generate the two remaining full length clones; LBV and LBVFSS in cSN. 
 
7.3 Rescue of viruses from cDNA 
The rescue of the recombinant full length clones using the reverse genetics technique 
was conducted as described in Section 2.5, see Figure 1.4. The purest plasmid maxi 
preparation of each full length clone was selected, along with the wildtype cSN full 
length clone as a positive control. These were transfected at a concentration of 0.3μg 
into FP-T7 infected BHK cells using FuGENE 6 (Promega) along with four helper 
plasmids: pN (0.8μg), pP (0.4μg), pG (0.4μg) and pL (0.4μg) in 24 well plates. This 
passage was designated as passage 1 (P1). After 3 days the cells and supernatants were 
harvested and transferred onto 50% confluent BHKs in 12 well plates. Due to the lack of 
visible cytopathic effect upon infection by lyssaviruses, an aliquot of 200µl from each of 
the freshly seeded 12 well plates was transferred into 96 well plates, in duplicate.  
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Figure 7.3: Cloning strategy via Gibson Assembly (NEB) for glycoprotein into full 
length clone. The strategy for cloning LBV and LBVFSS into cSN. The wildtype cSN 
glycoprotein is highlighted in green, the cSN vector DNA is in orange, and the 
glycoprotein insert is in blue. 
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Following a further 72 hour incubation; P2, the 96 well plates were fixed in 80% acetone 
then subsequently stained with an anti-N FITC conjugated monoclonal antibody 
(Fujirebio) to assess the proportion of cells that were positive for antigen. All of the 
rescues at this stage showed a number of positive cells. These were cells showing bright 
apple green, perinuclear granular fluorescence. The P2 cells and supernatant from the 12 
well plates were transferred onto 50% confluent BHKs in 6 well plates. Aliquots into 96 
well plates were again carried out. After 72 hours incubation; P3, the 96 well plates were 
fixed and stained. At P3 the CVS rescues suggested approximately 100% cells were 
positive for antigen. The WCBV cells were approximately 70% and IKOV 
approximately 30% positive. The LBVFSS wells showed a number of positive cells 
whereas the CVSFSS and LBV wells showed only a small number of positive cells and 
no visible foci of infection could be detected. In order to increase the volume of each 
virus, the cells and supernatants from the 6 well plates were transferred onto 50% 
confluent BHKs in T25 flasks. After a further 72 hour passage, designated P4, cSN-CVS 
was 100% positive for antigen, cSN-LBVFSS showed multiple positive cells but no foci 
of infection, cSN-LBV and cSN-CVSFSS showed a limited number of positive cells but 
no foci and cSN-WCBV and cSN-IKOV both showed multiple foci of infection. The 
cells and supernatants were split in half across two fresh T75 flasks and these were 
incubated for 72 hours. After the incubation the flasks were frozen at -80°C in order to 
lyse the cells to release the maximum yield of virus. The flasks were subsequently 
thawed and the cells and supernatants were separated by centrifugation. The 
supernatants of each virus rescue were inoculated onto 50% confluent BHKs in T75 
flasks and RNA was extracted from the remaining cell pellets. In order to confirm the 
correct sequence of each of the rescues at this fifth passage the RNA was used to 
generate cDNA which was then used as a template in G specific KOD PCRs. The 
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resulting products were all of the expected size; 1.5 kb so were subsequently sequenced 
with G specific primers. The correct sequence of each rescue was obtained, confirming 
that no contamination had occurred.  
 
Due to the low level of cells positive for antigen in the cSN-CVSFSS and cSN-LBV 
rescue wells at P3-5, a repeat transfection; P1 was set up with alternative full length 
clone maxipreps of both cSN-CVSFSS and cSN-LBV alongside cSN-CVS as a positive 
control. These were blind passaged to P2 at which point the corresponding 96 well plate 
was fixed and stained to detect fluorescence. Again very few cells were positive for 
antigen but despite this a further three passages were conducted, up to P5, however the 
number of positive cells at each passage consistently failed to increase, suggesting that 
the growth/viability of these viruses was severely restricted. A subsequent rescue 
attempt with passage up to P3 was also unsuccessful. In a final attempt to generate 
viruses from these plasmids some supernatant from the initial P1 rescue attempt was 
inoculated onto a fresh batch of BHK cells. The cells and supernatants were passaged up 
to P4 where cSN-CVSFSS again consistently failed to produce any more than 10 
positive cells. At this point the decision was made to stop any further attempts to 
generate cSN-CVSFSS due to time constraints. In contrast cSN-LBV at P4 showed a 
cluster of positive cells so passage of cSN-LBV was continued. At P6 one single focus 
of infection was visible. The cells and supernatant were split into thirds across three 
fresh T75 flasks and after 72 hours incubation these P7 cells showed 10 separate foci of 
infection. It was expected that P8 would show 100% of cells positive however only one 
focus of infection was present. For this reason an aliquot from P7 that had been stored at 
-80°C was used to inoculate fresh cells in a repeat of the previous P8 passage however 
after 72 hours incubation this passage also failed to produce multiple foci of infection. 
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The cells and supernatants were passaged up to P10 without the presence of any more 
than one focus of infection so due to time constraints further passage or rescue attempts 
of cSN-LBV were abandoned. 
 
In contrast, the cSN-CVS showed 100% cells positive for antigen at P5 so after a freeze 
thaw cycle the cells and supernatant were separated by centrifugation. The supernatant 
was then stored in 1ml aliquots at -80°C prior to titration. The remaining viruses were 
further passaged until all reached 100% positive cells. cSN-IKOV reached 100% at P6, 
cSN-WCBV at P7 and cSN-LBVFSS at P9. 
 
Once all viable viruses had been generated and the presence of N protein had been 
confirmed at each passage the viruses were inoculated onto BHK cells which are highly 
permissive for lyssavirus infection. After 72 hours incubation the cells were fixed with 
PFA, permeabilised with triton X-100 and the cells were stained for actin-phalloidin, 
nuclei and glycoprotein using a rabies glycoprotein specific mAb (MyBioSource). A 
representative image of immunofluorescence staining is shown in Figure 7.4. 
 
7.4 Titration of recombinant viruses 
Once all four viable recombinant viruses had been successfully grown to 100% infection 
the supernatants were titrated. Alongside the recombinants a sample of wildtype cSN 
was also titrated. The titres achieved are shown in Table 7.1. 
 
The titre of wildtype cSN was the highest at one log greater than cSN-WCBV. cSN-
IKOV had a titre similar to that of cSN-WCBV whereas cSN-CVS was considerably 
lower. This was unexpected as cSN-CVS appeared to grow faster than cSN-WCBV and   
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Figure 7.4: Assessment of glycoprotein distribution in recombinant cSN-IKOV 
virus infected cells. (A) Nuclei are stained blue; DAPI (VectaShield); (B) the RABV G 
protein is stained with Alexa Fluor 488 conjugate (Green); (C) the actin cytoskeleton is 
stained red (phalloidin conjugate-568); (D) and the merged images indicate that the 
glycoprotein (G) is present both associated with the endoplasmic reticulum/Golgi in the 
perinuclear region of the cytoplasm as well as being present on the cell plasma 
membrane. 
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Table 7.1: Titres of rescued recombinant viruses and wildtype cSN. 
Virus Titre (ffu/ml) 
cSN 3.3x10
6
 
cSN-CVS 8.5x10
4
 
cSN-LBVFSS 4.0x10
3
 
cSN-WCBV 3.3x10
5
 
cSN-IKOV 1.3x10
5
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cSN-IKOV. The lowest titre was that of cSN-LBVFSS and this mirrored the time taken 
for this recombinant to reach 100% infection as it required 9 passages to reach this point. 
 
7.5 Growth kinetics of recombinant viruses 
The titres of each of the rescued viruses had now been calculated so the growth kinetics 
of these could now be determined in vitro. Due to the low titres of both cSN-CVS and 
cSN-LBVFSS a single step growth curve was not possible to conduct for all viruses so a 
multiple step growth curve using a multiplicity of infection (MOI) of 0.01 was 
performed.  
 
The growth kinetics of the viruses can be seen in Figure 7.5. There was a striking 
difference between the growth curve of wildtype cSN and the recombinant viruses 
(Figure 7.5 A). cSN did not start at zero ffu/ml but grew to a peak titre of 8.35x10
8
 
ffu/ml at 72 hours post infection (hpi) whereas the peak titre of the next most successful 
virus; cSN-WCBV was 2.92x10
5
 ffu/ml at 96 hpi. All viruses except cSN-LBVFSS were 
detectable by 18 hpi. cSN-LBVFSS was detected from 24 hpi at a very low level of 
4.85x10
1
 ffu/ml until it disappeared by 96 hpi. The end point titre of cSN-IKOV was 
5.33x10
4
 ffu/ml which is slightly lower than that of cSN-WCBV whereas cSN-CVS 
reached an end point of just 1.17x10
3
 ffu/ml after gradually reducing from its peak titre 
of 5.84x10
3
 ffu/ml at 24 hpi. 
 
The patterns of growth of each of the viruses also differed. It appeared that the growth of 
cSN was reducing by 96 hpi as its titre had slightly reduced from 72 hpi. Likewise cSN-
CVS appeared unable to maintain a productive infection as its titre consistently 
decreased after 24 hpi. In contrast cSN-WCBV and cSN-IKOV both appeared to be   
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Figure 7.5: Growth kinetics of recombinant lyssaviruses in vitro. (A) Multiple step 
growth curves of each virus starting from MOI 0.01. The time course was undertaken 
twice, at each time point virus titres were determined in triplicate on BHK cells. The 
mean of the combined results are displayed. The error bars represent the SD about the 
mean of each titre. (B) Proportion of cells positive for antigen. cSN, cSN-WCBV and 
cSN-IKOV reached 100%, unlike cSN-CVS and cSN-LBVFSS.   
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increasing in titre over time as both peaked at 96 hpi. This suggests that both of these 
viruses grow at a slower rate than the wildtype. Aliquots of culture supernatants were 
collected at the designated time points and virus titres were determined on BHK cells in 
triplicate. The time course was undertaken in duplicate for all five viruses. 
 
The trend of each virus is replicated in the percentage of cells positive for antigen at 
each time point (Figure 7.5 (B)). cSN-LBVFSS had the lowest number of antigen 
positive cells at each time point however the proportion of positive cells increased 
slowly to a peak at 96 hpi, unlike the titre of virus in the supernatant. Likewise, though 
cSN-CVS only reached an end point of 50% positive, the proportion of positive cells 
steadily increased from 0 hpi, unlike the titre in the supernatant which decreased from 24 
hpi. cSN, cSN-WCBV and cSN-IKOV all reached 100% positivity with cSN at 48 hpi 
and the recombinants at 96 hpi. Although cSN-WCBV and cSN-IKOV both reached 
100% positivity by the end time point neither reach a titre equal to that of cSN which 
was also 100% positive by the final time point.  
 
The titres of each of the viruses (Table 7.1) indicated the trend seen in the growth 
kinetics experimentation. cSN had the highest titre; and grew to the highest titre in the 
growth curve and reached 100% positivity before any other virus. cSN-WCBV and cSN-
IKOV both had similar titres and showed very similar curves as well as % cells positive 
at each time point. cSN-CVS had a lower titre than the previous two recombinants and 
this was reflected in its growth kinetics, just as cSN-LBVFSS had the lowest titre and 
failed to establish a productive infection. This suggests the efficiency of cell to cell 
spread of the recombinant viruses was reduced in comparison to cSN. This also lends 
support to these findings as the trends remain the same in each experiment. 
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7.6 In vivo assessment of recombinant viruses 
7.6.1Vaccination of mice prior to intra cranial (i.c.) challenge 
In order to determine the degree of protection afforded by available vaccines against the 
recombinant viruses, a group of mice were vaccinated with a current human rabies 
vaccine; Rabipur (Novartis). Mice were vaccinated via the intra peritoneal (i.p.) route 
with 500μl of a 1 in 20 dilution of vaccine (approximately 0.06 IU in 500μl) on day 0 
and then again, with the same vaccine dose on day 14. On day 21 post vaccination blood 
samples were collected via tail bleeds and sera were isolated (Section 2.10.2.4). Each 
serum sample was run on a partial dilution series PNA (Section 2.3.3); starting at a 1 in 
20 dilution, due to the very low volume of serum obtained from a mouse tail bleed, 
finishing at a 1 in 640 dilution. This enabled determination of whether the mice had 
seroconverted to a titre comparable to the WHO standard 0.5 IU/ml serum. The sera 
from the two groups of mock vaccinated mice were pooled and all serum samples from 
vaccinated mice were titrated individually, except for three individuals where a 
sufficient volume of serum for input into the PNA was not obtained.  
 
The WHO control serum sample had a reciprocal titre of 639.99. The mock vaccinated 
pool 1 had a titre of 79.99 and the mock vaccinated pool 2 had a titre of just 11.31 
indicating that none of these mock vaccinated mice had seroconverted. Four mice 
seroconverted to the same titre as the WHO control; 639.99 and 51 of the mice 
seroconverted so strongly that there was neutralisation to the end of the scale suggesting 
that these 57 mice had titres greater than 905.09. Two of the vaccinated mice did not 
seroconvert to the WHO control level, both reached just 22.62. Unfortunately there were 
insufficient sera remaining to repeat these two samples however their microchip 
numbers were noted. 
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7.6.2 Survival of vaccinated mice challenged i.c. with virus 
Once the seroconversion of the vaccinated mice had been confirmed, all groups, both 
vaccinated and mock vaccinated were challenged i.c. with 100 ffu/ml of each virus in 
30μl. Ten vaccinated mice and 5 mock vaccinated mice were challenged with each virus. 
The viruses inoculated were: cSN, cSN-CVS, cSN-LBVFSS, cSN-WCBV, cSN-IKOV 
and an isolate of LBV lineage B virus due to the lack of recombinant cSN-LBV. All 
mice were challenged 28 days post initial vaccination. 
 
Mice were left until 21 days post challenge then survivors were terminated and cardiac 
bleeds taken. The survival curves of the mock vaccinated and vaccinated mice are shown 
in Figure 7.6. 
  
7.6.3 Pathogenicity of recombinant lyssaviruses 
In addition to the vaccination/challenge experiment a study into the pathogenicity of 
each of the recombinant viruses in naïve mice was conducted. Three to four week old 
mice were peripherally inoculated into the footpad (f.p.) (Section 2.10.3.2).  
 
These mice were monitored for 21 days post peripheral inoculation, with clinical 
assessment twice daily. Any mice reaching clinical score 3 (Appendix III) were 
terminated. The pathogenicity of the recombinant viruses and LBV was then compared. 
The survival curve to 21 dpi data is shown in Figure 7.7.  
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Figure 7.6: Survival curve of mice challenged i.c. (A) The survival curve to day 21 
post infection of mock vaccinated mice n = 5 per virus. (B) The survival curve to day 21 
post infection of mice vaccinated with Rabipur n = 10 per virus. Each mouse was 
challenged with 100 ffu/30μl of virus via the intra cranial route. 
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Figure 7.7: Survival curve of mice challenged peripherally. Each mouse was 
challenged with 1000 ffu/50μl of virus via the foot pad, except the low titre cSN-
LBVFSS which was inoculated neat at 200 ffu/50μl. n = 5 per virus. 
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The survival curves of mock vaccinated mice challenged i.c with virus (Figure 7.6 (A)) 
showed that all of the mock vaccinated mice died by day 7 with the median survival of 
cSN-CVS, LBV and cSN-WCBV at 6 dpi and cSN and cSN-IKOV at 7 dpi. All of the 
cSN-LVFSS mock vaccinated mice survived with no clinical signs at day 21. 
 
The survival of mice vaccinated with Rabipur (Figure 7.6 (B)) showed all mice 
challenged with a virus containing a phylogroup I G protein had survived to 21 dpi 
alongside the cSN-LBVFSS challenged mice which also all survived to day 21. In 
contrast 20% of the mice challenged with LBV had survived to day 21 whereas all those 
mice challenged with cSN-WCBV and cSN-IKOV had died by 7 and 8 dpi respectively. 
 
The mice challenged peripherally by the six viruses showed a different trend to those 
inoculated intra cranially. On day 8 dpi 40% of the cSN-CVS challenged mice had died 
and 20% of both LBV and cSN-IKOV challenged mice had died. The remaining cSN-
CVS, LBV and cSN-IKOV mice all survived to 21 dpi whereas all mice challenged with 
cSN, cSN-LBVFSS and cSN-WCBV survived to 21 dpi. 
 
 7.7 Discussion 
A panel of antigenic site swap and divergent lyssavirus glycoproteins in a vaccine strain 
backbone has successfully been generated. Despite correct plasmid sequences and 
multiple rescue attempts only four of the six clones could be rescued successfully. The 
growth kinetics of these viable viruses was investigated with the aim of using these 
viruses to challenge vaccinated mice post vaccination. 
Two plasmids consistently failed to produce viable virus; cSN-CVSFSS and cSN-LBV. 
The failure of cSN-CVFSS to rescue or grow to a detectable level mimics the finding 
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from the PNA as this glycoprotein failed to produce sufficient PT for use in PNAs. This 
suggests that the mutations made to the antigenic sites have irreparably affected the 
functionality of this glycoprotein. There may have been substantial alteration to the 
folding of the CVSFSS G or alterations in its glycosylation pattern which reduced or 
blocked its ability to form viable viruses and PTs. The failure of cSN-LBV to rescue was 
not predicted from the PT data as the LBV PT grew to consistently high titres. In an 
attempt to determine the cause of the failures of these two viruses, a structural model of 
the CVS and LBV wildtype glycoproteins as well as the antigenic site swap mutants in 
both monomeric and trimeric form was predicted, from a published structure. 
 
To enable this SWISS-MODEL was utilised to identify any existing viral structures that 
shared identity with lyssavirus sequences. The model identified was the prefusion form 
of the VSV spike glycoprotein (Roche et al., 2006). VSV G shares 27.5% identity with 
CVS and 31.0% identity with LBV at the amino acid level (AlignX). This level of 
identity is low to use as a template however in the absence of any lyssavirus G structural 
data there is no available alternative. Template-target alignments were generated in 
SWISS-MODEL followed by a predicted model from the resulting alignments. A 
monomeric model was automatically generated in preference to the trimeric form due to 
the lack of sequence identity; however a trimeric form was then generated, despite the 
SWISS-MODEL prediction. The trimeric models all had substantially lower Global 
Model Quality Estimation (GMQE) scores than the monomeric models signifying their 
lower accuracy however; as all of these models are predictions their accuracy cannot be 
improved without a more suitable model as a template. Once the models had been 
generated in SWISS-MODEL they were manipulated in PyMOL (version 1.3r1) in order 
to highlight the areas of the protein of most interest to this investigation. The monomeric 
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form of the lyssavirus G is shown in Figure 7.8. The antigenic sites are depicted in the 
surface conformation in order to highlight the area of each site which is expressed on the 
surface of the protein. The remainder of the protein is depicted in the stick form. From 
the top view of each monomer, antigenic sites I, IIa, IIb and III are visible on the CVS 
and CVSFSS models. For LBV and LBVFSS the models differ  as antigenic site IIa 
appears to be almost entirely concealed by site IIb, i.e. there is much less of the IIa 
epitope present on the surface of the LBV and LBVFSS glycoproteins than CVS and 
CVSFSS. This may be interpreted in several ways. Firstly, this may suggest that the 
alteration of the antigenic site sequences is not sufficient to drastically alter the location 
of the antigenic sites on the mature protein as the patterns on the surface of CVS and 
CVSFSS remain similar, despite the sequences differing and the same pattern is evident 
with the LBV and LBVFSS models. Secondly, this alteration in the accessibility of 
antigenic sites may indicate that the positioning of antigenic sites on the G surface, and 
any masking of antigenic sites through mutation, may affect the importance each site 
plays in a cross neutralising response. From the PNA data with the single and full 
antigenic sites swaps in Chapter 5 it was found that sites I and III were important in a 
phylogroup I neutralising response and site II was important in a phylogroup II 
neutralising response. This may be related to the conformation of the sites as site I is 
displayed in a fairly similar conformation on all models in Figure 7.8. However site III 
differs between models predicting the wildtype CVS and Gs containing mutations with 
G proteins containing a phylogroup I site III (e.g. CVS and LBV FSS) having fewer site 
III residues exposed on the surface than those containing the phylogroup II site III. This 
may be significant in the recognition of this epitope. Indeed, from the site III specific D1   
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Figure 7.8: Model of monomeric lyssavirus glycoproteins. Antigenic site I is in 
yellow, antigenic site IIa is in blue, antigenic site IIb is in red, antigenic site III is in 
orange and antigenic site IV is in pink. The glycoprotein has been modelled using the 
prefusion VSV G (Indiana strain) as a template on the SWISS-Model server. The 
resulting model was subsequently manipulated and images created in PyMOL. The 
glycoprotein of each lyssavirus is shown in the same orientation to enable direct 
comparison. All four are shown as viewed from above, from the front of the model (as 
displayed in both modelling programmes) and from the back so that all 4 antigenic 
epitopes are visible.  
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mAb data in Chapter 6 it was evident that this site specific mAb was only able to 
neutralise wildtype CVS, it failed to neutralise LBVFSS suggesting that the 
conformation of this epitope, not simply the correct sequence, plays an essential role in 
recognition of antigenic site III. 
 
The suggestion that antigenic site II may play an important role in phylogroup II 
neutralisation may be related to its conformation on the glycoprotein surface, as site II is 
displayed in a very different conformation on LBV backbone models than those 
generated with a CVS backbone. Site IIa appears to be less visible on the protein surface 
in phylogroup II models which may suggest that site IIb is in fact the immunodominant 
epitope. This is supported by the data from the CVS to LBV PNA (Figure 5.2) which 
shows that CVS to LBV IIb was more strongly neutralised by the LBV specific serum 
than any other construct. CVS to LBV IIaIIb was next most strongly neutralised 
followed by CVS to LBV IIa. All of these results together with the prediction model in 
Figure 7.6 suggest that site IIb, and or the interaction between site IIa and IIb would 
form an essential component of a phylogroup II neutralising construct. 
 
The pattern of antigenic sites displayed on the surface of the trimeric form (Figure 7.9) 
of the lyssavirus glycoprotein models differs from that of the monomer. However the 
reduced accuracy of the trimeric model cannot be ignored when attempting to interpret 
this trimeric structure. The positioning of site IIa and IIb on the predicted CVS and LBV 
monomeric structures is no longer valid on the trimeric models for either G and as such 
it is difficult to interpret this data with respect to the potential roles of antigenic sites in 
virus neutralisation. In the absence of a more suitable structure, when examining the 
predicted trimeric model it is clear that antigenic sites I, II and III are all present on the   
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Figure 7.9: Model of trimeric lyssavirus glycoproteins. Antigenic site I is in yellow, 
antigenic site IIa is in blue, antigenic site IIb is in red, antigenic site III is in orange and 
antigenic site IV is in pink. The glycoprotein has been modelled using the prefusion 
VSV G (Indiana strain) as a template on the SWISS-Model server. The resulting model 
was subsequently manipulated and images created in pyMOL. The glycoprotein of each 
lyssavirus is shown in the same orientation to enable direct comparison. All four are 
shown as viewed from above, and from the front so that the interaction between each 
chain is visible.  
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tip of the ectodomain and access to these sites appears relatively unrestricted by the 
trimeric conformation. This may explain why these three sites play the most important 
roles in neutralisation. In contrast, though antigenic site IV is present on the surface, 
access to this site may be restricted by its position in the groove between two chains of 
the trimer. This location may inhibit access of many antibodies to this site, thus reducing 
its impact in the neutralising response. Antigenic site III is located in closest proximity 
to neighbouring chains which suggests it may be most negatively impacted by any 
alterations in trimerisation. This may explain the previous finding that site III specific 
mAb D1 was only capable of neutralising the CVS wildtype PT as folding of the trimer 
in the other PT preparations may have differed. In fact it has been proposed that D1 can 
only recognise the trimeric form of glycoprotein (Jallet et al., 1999) which supports this 
finding as any alteration in the construction of the trimer would affect mAb binding. 
 
Overall the models produced here provide limited insight into the location of antigenic 
sites on the lyssavirus glycoprotein however they have yielded some interesting 
explanations for previous findings of this investigation. The fact that sites IIa and IIb are 
in very close proximity to each other on the surface of these models lends support for 
some accuracy in this prediction as previous predictions have also placed the two 
distinct regions of this discontinuous epitope close together in the 3D structure of the 
glycoprotein. Until a crystal structure of RABV or any other lyssavirus G is resolved 
however any interpretations from this model remain limited (Dr Gaudin – personal 
communication). Despite this these predictions provide an opportunity to evaluate 
experimental findings. 
 
The structural predictions have not provided significant insight into the reason for the 
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cSN-LBV virus rescue failures. However, one factor that may have affected virus rescue 
was the stability of this plasmid. As described previously cSN-LBV was problematic to 
generate, requiring alternative cloning techniques to construct the correct plasmid. It was 
hypothesised at the stage of bacterial transformation that the glycoprotein insert itself 
may have been toxic as bacteria transformed with the cSN-LBV ligations consistently 
failed to produce colonies post transformation. In addition, once Gibson Assembly had 
eventually yielded a correct plasmid, the maximum scale plasmid preparation had a 
lower DNA concentration than other full length plasmids which suggests that the 
bacteria were unable to grow to the usual capacity. This observation may therefore be 
applicable to the consistent failure of mammalian BHK cells to support production and 
infection of viruses containing this potentially toxic glycoprotein insert. In addition, 
throughout the numerous rescue attempts and repeated passages it was observed that 
BHK cells transfected to produce cSN-LBV and BHK cells exposed to TCSN from cSN-
LBV transfected cells grew very poorly compared to cells infected with other 
recombinant viruses. This may again indicate a level of toxicity specific to this construct 
however due to time constraints a more detailed investigation into the cause of cSN-
LBV failure was not possible. 
 
The cSN growth curve did not start from zero ffu/ml suggesting either some input virus 
remained after washing or it was able to initiate a detectable infection after just one hour 
of adsorption. The other viruses that were rescued successfully all grew to titres 1 to 3 
logs lower than the wildtype cSN. This suggests that the insertion of heterologous 
glycoproteins into the cSN backbone affects the growth capacity and cell to cell spread 
of the resulting viruses, most significantly for cSN-LBVFSS. This low titre correlates 
with the growth kinetics data in Figure 7.5 as cSN-LBVFSS had the slowest growth and 
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the lowest peak titre. It is possible that the mutations in the antigenic sites of the 
glycoprotein rescued its ability to grow as the wildtype cSN-LBV construct consistently 
failed. It may be that the presence of the CVS antigenic sites in the LBVFSS construct 
reduced the potential toxicity of the construct or rescued the folding or glycosylation of 
the protein (Chapter 8). cSN-CVS has the next lowest titre and end point titre on the 
growth curve. This was unexpected as CVS G has the closest homology to the cSN G so 
it was expected that this switch would have the least impact on the resulting virus. In 
fact the highly heterologous WCBV and IKOV G inserts produced higher titre viruses. 
This same pattern is seen in the PT titration data as CVS PT consistently grew to lower 
titres than WCBV or IKOV PTs. Within the context of a cSN based infectious virus the 
differing titres of these constructs may be a result of the interaction between the 
heterologous glycoprotein and the matrix protein to form the structure of the virus 
particle. The precise nature of the interaction between these two viral proteins remains 
undefined however it has been shown for a number of  Mononegavirales including 
Respiratory Syncytial virus and VSV that M interacts directly with G to enable high 
efficiency viral budding from host cells (Enami & Enami, 1996; Ghildyal et al., 2005; 
Lyles et al., 1992). It has also been shown that the interaction between the rabies G and 
M proteins enables efficient budding of viral particles (Mebatsion et al., 1999). It is the 
cytoplasmic domain of the G protein which has been shown to play the key role in this 
interaction (Genz et al., 2012; Ghildyal et al., 2005) so an alignment of the 
transmembrane and cytoplasmic domains of cSN and the other lyssavirus glycoproteins 
was made to look for sequence homology which might explain the success of some 
viruses over others. This can be seen in Figure 7.10.Certainly, if the titre of the viruses 
was directly related to the homology between the cSN and heterologous G it would be 
expected that cSN-CVS would have the highest titre of the recombinants, followed by   
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Figure 7.10: Alignment of glycoprotein transmembrane and cytoplasmic domains. 
The alignment was made in GENEDOC. The wildtype G sequences used in construction 
of recombinant lyssaviruses are shown against the sequence of the backbone 
glycoprotein; cSN. 
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cSN-LBV. This is not the case which suggests that the homology between glycoprotein 
and matrix protein is not the sole determinant of successful virus rescue. 
 
Despite cSN-WCBV and cSN-IKOV growing to higher titres than cSN-CVS and cSN-
LBVFSS there was still difference between the growth kinetics of the recombinants and 
the wildtype cSN. It is clear that the replacement of the cSN G with a heterologous 
lyssavirus G, despite a close sequence homology between the wildtype and the inserted 
G, has a detrimental effect on the ability of the virus to grow and in some cases even 
inhibits the virus from initiating a productive infection. This is similar to findings from a 
previous study which incorporated the G proteins from EBLV-1 and EBLV-2 into cSN. 
This study found that both recombinant viruses grew to substantially lower end point 
and peak titres than cSN, however the titres of the recombinants were higher than those 
of the parental EBLV-1 and EBLV-2 wildtype viruses (Marston et al., 2013). This 
suggests that a further study into the growth kinetics of the recombinant viruses 
generated in this investigation in comparison with their wildtype virus counterparts 
could reveal the reason for the success of cSN-WCBV and cSN-IKOV over cSN-CVS as 
perhaps CVS virus grows to a lower titre in vitro than WCBV or IKOV. Although 
wildtype IKOV is available at APHA, WCBV is not so comparisons cannot be made. 
 
The data from the survival curves indicated some substantial differences between 
survivorship in intra cranially challenged vaccinated and unvaccinated individuals. The 
cSN-CVS, LBV and cSN-IKOV viruses appeared to be most pathogenic when 
inoculated intra cranially into naïve individuals as these viruses had the shortest median 
time post infection to 0% survival. cSN and cSN-WCBV followed by just 1 day whereas 
all cSN-LBVFSS challenged mice remained healthy at the end of the experiment. This 
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pattern was conserved in the peripherally inoculated mice also as cSN-CVS, LBV and 
cSN-IKOV all showed 60-80% survival whereas all other viruses showed 100% survival 
by 21 dpi. This was reflected in the growth kinetics as cSN-LBVFSS grew at the slowest 
rate of all the recombinant viruses so it can be postulated that infection in vivo may also 
result in clinical signs days after those caused by other viruses. In addition, the 
vaccinated cSN-LBVFSS challenged mice were all healthy at day 21 but the role of 
vaccination in this result cannot be determined. In contrast there were clear differences 
between survival of vaccinated and unvaccinated mice challenged with other viruses; all 
unvaccinated mice challenged with cSN and cSN-CVS had died by 7 dpi whereas all 
vaccinated mice challenged with these viruses survived. This confirms published data 
(Brookes et al., 2006) and data from Chapters 4 and 5 which describe strong cross 
neutralisation between phylogroup I viruses. 
 
The survival of mice, vaccinated or unvaccinated with LBV, cSN-WCBV and cSN-
IKOV also supports existing data describing a lack of protection against divergent 
lyssaviruses from vaccine induced immunity (Hanlon et al., 2005). Both vaccinated and 
unvaccinated mice challenged with cSN-WCBV survived until 7 dpi and the same 
pattern was evident with the cSN-IKOV mice as 100% unvaccinated died on day 6 post 
infection and 90% of the vaccinated mice had died by 7dpi with the remaining 10% 
surviving just one more day to die on day 8 post infection. This confirms the total lack 
of protection afforded by rabies vaccines against these divergent lyssaviruses. 
Interestingly however 20% of the vaccinated mice challenged with LBV remained 
healthy at 21 dpi which suggested that the vaccine had induced a small degree of 
protection. This is reflected in a previous finding where dogs were protected against 
challenge with LBV after they had been vaccinated with Rabiffa vaccine. It would be 
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interesting to compare the sequences of the RABV strains used to generate both Rabiffa 
and Rabipur (used in this experiment). Additionally, data in Chapter 5 suggested that the 
WHO polyclonal serum from vaccinated humans was able to induce substantial (80-
90%) neutralisation of LBV PT which may explain the survival of a small percentage of 
the LBV challenged mice, in addition these mice had very strongly seroconverted post 
vaccination. Interestingly the WHO serum is isolated from a pool of human sera, all 
having seroconverted to a human vaccine strain and the vaccine used in this experiment, 
Rabipur, is a human vaccine so this may suggest that some of the RABV strains used to 
generate human rabies vaccines have the capacity to generate a protective response in a 
small proportion of LBV B infections. 
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Chapter 8: Discussion 
 
The utility of PTs in the investigation of the neutralisation profiles of dangerous 
zoonotic pathogens such as the lyssaviruses has been demonstrated. The panel of PTs 
enables investigation of the lyssavirus glycoprotein in situations where the live virus is 
unavailable and the presence of PT can be quickly identified by reporter gene readout, 
without the need for time consuming antibody based detection methods or the 
requirement of specialist containment facilities. However, at least for some lyssaviruses, 
including both wildtype and mutated glycoproteins, viable PTs could not be generated 
suggesting that the transfection process requires further optimisation. The variation in 
the rescue efficiencies and titres of PT viruses may be a result of differences in the 
quality of the plasmid preparations used to generate these constructs (Bouvrais, 2012). 
 
The attempts to characterise some PT preparations suggested that there is great 
variability between PT particles in a population. The sizes of the PT particles appear to 
be larger, on average than virus particles and their greater range of sizes suggests a more 
pleiomorphic morphology than virus particles. In order to characterise lyssavirus PT 
particles it would be advantageous to be able to visualise them by electron microscopy in 
order to compare their morphology with that of lyssaviruses. It was also not possible to 
measure fluorescence of PTs directly using flow cytometry, despite the scatter of PTs 
being measurable. This was likely due to an alteration in the epitope of the mAb utilised 
in the flow cytometry experiment. In order to determine whether PTs can be directly 
measured an alternative mAb, also directed to the glycoprotein should be selected. This 
would enable an estimation of the concentration of G proteins expressed on the surface 
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of the PT population and also enable a qualitative estimation of the size differences 
between groups of particles in the population.  
 
A downstream effect of the apparent variability within PT populations is a marked 
variation between replicates in the neutralisation assays. This variation was evident in 
the standard deviation around the mean percentage neutralisation of many PTs by the 
large range of sera tested. There are approximately 400 trimeric glycoprotein spikes on a 
rabies virion (Da Poian et al., 2005) however the number of trimers on a PT particle is 
undefined. In order to increase the reliability of PNAs, the expression of glycoprotein 
trimers on PTs must be determined. This will enable a more accurate comparison 
between neutralisation data from both PTs and viruses. 
 
A strong level of intra phylogroup I cross neutralisation was confirmed, in support of the 
current data from virus neutralisation studies and vaccine protection data (Brookes et al., 
2006; Hanlon et al., 2005). The degree of cross neutralisation was found to be very 
strong with just 0.1 IU/ml hyperimmune sera strongly neutralising all phylogroup I PTs. 
Data from virus neutralisation assays defined a threshold of 0.5 IU/ml to be protective 
against lyssavirus infection however, in light of the 0.1 IU/ml finding from PNAs it 
would be of use to conduct a similar assay with live viruses in order to determine 
whether 0.1 IU/ml remains protective. This may impact on vaccination dosing regimens 
as current regimens require a series of vaccinations on days 7, 21 and 28 which requires 
a substantial level of commitment from patients and often these schedules are not 
adhered to (Sudarshan et al., 2012; Wilde, 2007). If a lower titre of antibody is found to 
be protective against all viruses in phylogroup I, perhaps the number of doses in current 
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PEP regimens can be reduced which would provide effective protection to a greater 
proportion of patients and have substantial economic benefits. 
 
There also appears to be a strong level of intra phylogroup II cross neutralisation with a 
marked lack of cross neutralisation with phylogroup III and IKOV. This degree of 
neutralisation within phylogroup II has been previously demonstrated (Badrane et al., 
2001) however this has not been investigated in such depth as neutralisation within 
phylogroup I. This investigation has highlighted the presence of a high degree of cross 
neutralisation of phylogroup II PTs with sera directed against LBV lineage B however 
further neutralisation assays using sera directed against the other members of 
phylogroup II would be beneficial to more accurately characterise the degree of 
neutralisation present. 
 
Due to the high level of neutralisation within phylogroup I, as demonstrated by 
hyperimmune sera from both humans and dogs this suggests that the antigenic features 
of a RABV (as the backbone of all current vaccines) should be sufficient to induce 
antibodies capable of neutralising all other phylogroup I viruses. Likewise, due to the 
neutralisation of all phylogroup II PTs by LBV B sera, the antigenic features of the LBV 
B G protein should be sufficient to induce protective antibodies against all other 
phylogroup II viruses. A combination of the antigenic features of both CVS (a RABV) 
and LBV B should therefore be sufficient to induce protection against all viruses in both 
phylogroups I and II, however it is likely this construct would not be able to induce 
complete protection against viruses outside of these phylogroups. It therefore follows 
that a true pan-lyssavirus protective construct would contain antigenic features of 
WCBV and IKOV as well as CVS and LBV B. This is due to the divergence of WCBV 
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and IKOV away from CVS and LBV resulting in antibodies raised against these 
divergent viruses being unable to completely neutralise CVS and LBV B PTs and vice 
versa. 
 
Now that one representative G protein from phylogroups I and II have been found to 
sufficiently represent all other members of their respective phylogroups the precise 
antigenic features of these glycoproteins which are responsible for the induction of 
protective immunity have potentially been defined. Previous studies into the antigenicity 
of the RABV G suggested that antigenic sites II and III were most immunogenic (Jallet 
et al., 1999; Lafon et al., 1983) and the results of this investigation confirm this as well 
as highlighting the role of antigenic site I in neutralisation. The models generated in 
Chapter 7 suggest that sites I, II and III are all present on the tip of the glycoprotein 
spikes so provide unrestricted access to antibody interactions. This goes some way to 
explaining the reason for the importance of these individual antigenic sites in a 
neutralising response however until a crystal structure is resolved; the speculation over 
the location and impact of the antigenic sites remains unsupported. 
 
The antigenic site swap PNAs also highlighted variability in glycoprotein expression 
between different PT populations. It appeared that the LBV backbone PTs may express a 
lower concentration of G protein on the surface than the CVS PTs. This was due to the 
neutralisation profile of the LBV PT as it was strongly neutralised by 0.5 IU/ml RABV 
specific sera as well as 0.5 IU/ml LBV specific sera whereas the CVS wt PT was only 
neutralised by the 0.5 IU/ml RABV specific sera and not at all by the 0.5 IU/ml LBV 
specific sera. Upon dilution of the test sera 10-fold the neutralisation profile of the LBV 
PT was closer to the pattern expected from virus neutralisation data (David Selden – 
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unpublished data). This therefore lead to the hypothesis that there was less G present on 
the LBV PT which lead to its increased susceptibility to neutralisation by heterologous 
sera as a result of immunogenic epitopes outside of the antigenic sites. The reason for 
this reduction in the concentration of G on the LBV PTs is unknown and requires further 
investigation. A valuable experiment would utilise electron microscopy to gold label the 
glycoproteins on the surface of CVS wildtype PTs, LBV wildtype PTs and inactivated 
CVS and LBV viruses. This would enable visualisation of the viral and PT particles to 
compare morphology as well as determining any differences between the levels of G 
expression on the different particles. Alternatively, once a mAb is identified which is 
able to label PT for flow cytometry, this could be used to compare populations of PT and 
virus based on the mean fluorescence intensity of each population which is directly 
related to the amount of G expressed on the viral envelopes. 
 
The reason for the apparent reduction in G expression on the LBV PTs is unknown 
however the link between this and the repeated failure of the cSN-LBV virus to grow 
may be significant. The defining feature of glycoproteins is glycosylation. The 
lyssavirus G proteins are N-linked glycosylated at asparagine (N) residues which are 
contained within specific glycosylation sequons. These sequons consist of asparagine-X-
serine/threonine sequences where X can be any amino acid except proline (Shakin-
Eshleman et al., 1992).The RABVs contain three glycosylation sequons at asparagines 
56, 266 and 338 (Shakin-Eshleman et al., 1992). The LBV glycoprotein however lacks 
N 56 so contains only two glycosylation sites and amino acid 56 is within antigenic site 
IIb. It has been shown that N 56 is not efficiently glycosylated in the presence of 
complete sequons at positions 266 and 338 however in the absence of these sequons N 
56 is sufficient for transport and expression of G on the cell membrane. The absence of 
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this glycosylation site in the LBV PT and the IIb mutants may impact the intracellular 
transport, antigenicity and the stability of the glycoprotein (Shakin-Eshleman et al., 
1992; Shakin-Eshleman et al., 1993). As well as this it has been shown that regions of a 
protein downstream from sequons can influence their glycosylation (Shakin-Eshleman et 
al., 1993) so the mutations in sites III and IV may have had some effect on 
glycosylation. These studies however were conducted in cell free systems so 
glycosylation may have been more or less effective than in cell based systems. In 
addition glycosylation may differ between cell types in vitro and efficiency likely differs 
in vivo also. This makes it difficult to define the precise effect of glycosylation but may 
explain the lack of G on the LBV PT and even the toxicity or failure of the cSN-LBV 
virus to rescue. 
 
Progress has also been made into characterising the epitopes for a panel of apparently 
antigenic site specific mAbs. The antigenic site of mAb 62-7-13 had been previously 
characterised (Both et al., 2013) and data from this investigation confirmed its 
specificity and the critical role of aa 245 in neutralisation. The epitope for E559 was less 
well defined however evidence from this investigation has highlighted the potential 
importance of leucine 57 as a critical residue for E559 neutralisation. The virus 
neutralisation data points towards a critical role for leucine 57 however the PNA did not 
provide such strong evidence. This was because the wildtype CVS PT was not strongly 
neutralised by E559 whereas live CVS virus is neutralised. The reason for the 
discrepancy here may be an altered display of G protein on the PT surface, as opposed to 
that found on the surface of a viral particle however this hypothesis requires further 
investigation, as previously described. In addition antigenic site II is the only known 
discontinuous conformational epitope on the lyssavirus glycoprotein which means it is 
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likely to be most susceptible to changes in folding or structure of the G protein, therefore 
any differences between the stability of the G protein in virus particles and PT particles 
(due to the lack of interaction with M protein) is likely to affect the conformation of 
antigenic site II and therefore may affect its neutralisation profile. 
 
Despite the unexpected neutralisation profile of the wildtype CVS PT, the other site 
swap PTs were consistent with site IIb and therefore leucine 57 playing a role in E559 
neutralisation. In order to investigate this hypothesis further by expanding on initial 
previous work (Muller et al., 2009) the Kelev G protein should be incorporated into PT 
particles. This would enable site directed mutagenesis to generate the observed 
mutations at positions 169 and 170 to determine which mutation and which amino acid 
plays the most critical role in E559 neutralisation. These mutations should then be 
incorporated into Kelev virus glycoprotein and reverse genetics utilised to rescue these 
mutated viruses in order to confirm data from the PNAs. These future investigations may 
have substantial impact if key residue of the E559 epitope is defined as it is still under 
consideration by the WHO as a component of a potential therapeutic mAb cocktail (Both 
et al., 2012; Muller et al., 2009). 
 
A panel of recombinant viruses was generated using reverse genetics techniques. 
However, some viruses rescued more successfully than others, likely due to differences 
in the heterologous glycoprotein substitutions. No cSN-CVSFSS virus could be 
generated from a full length genome plasmid containing the correct sequence for this 
recombinant. However, the PT expressing this G protein was also unsuccessful, perhaps 
because it lacked the glycosylation site at amino acid 56 which would normally be found 
in the wildtype CVS G protein. The cSN-LBV virus was also unsuccessful, again it 
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lacked the asparagine residue at position 56 which although didn’t appear to affect PT 
generation so substantially, may have had a more detrimental impact in the context of 
the RABV cSN backbone as this would have contained N 56 in its wildtype G protein.  
It was surprising therefore that IKOV and WCBV rescued successfully and grew to 
higher titres than cSN-CVS as IKOV and WCBV do not have N56 whereas CVS does so 
it is likely some other factor is affecting the success of these recombinant viruses. It was 
found previously that a lack of success of a recombinant virus was linked to the success 
of the parental virus of the glycoprotein in question. cSN-EBLV-2 showed a marked 
reduction in growth although interestingly the parental wildtype EBLV-2 virus grew to 
an even lower titre (Marston et al., 2013). This suggests that future work should be done 
to repeat the growth kinetics experiment in Chapter 7 alongside wildtype viruses where 
available including: CVS, WCBV & IKOV to determine whether the recombinant virus 
growth curves reflect the wildtype virus growth curves as this may help to explain the 
differences between the activities of the recombinant viruses generated in this 
investigation. 
 
Clearly the utilisation of PTs and reverse genetics to study the neutralisation within the 
genus can help to understand the relationships between viruses within the genus and 
provide tools to further investigate the cross neutralisation afforded by responses to 
different glycoproteins. The lack of vaccine protection afforded by the current rabies 
vaccines against several members of the genus is of importance to both human and 
animal health. Frustratingly, whilst the data generated in this study are of interest, in the 
absence of a crystal structure for the rabies glycoprotein, it is difficult to make firm 
conclusions regarding the importance of different regions on the glycoprotein.  
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Appendices 
Appendix I: Solutions and reagents 
Tissue culture media: 
BHK Media 
500ml BHK-21 GMEM  
50ml heat inactivated foetal bovine serum (FBS) Australian origin  
50ml Tryptose phosphate solution  
5ml penicillin/streptomycin solution to 100U/ml penicillin and 100μl/ml streptomycin  
 
HEK293-T 17 Media 
500ml DMEM  
50ml heat inactivated foetal bovine serum (FBS) Australian origin  
15ml D (+) glucose solution to 4g/L  
5ml penicillin/streptomycin solution to 100U/ml penicillin and 100μl/ml streptomycin  
 
Bacterial cell culture media: 
Luria –Bertaini (LB) Broth 
10g tryptone 
5g yeast extract 
10g sodium chloride (NaCl) 
950ml deionised water and autoclave to sterilise 
Ampicillin or kanamycin to 100mg/ml 
 
LB Agar 
10g tryptone 
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5g yeast extract 
10g NaCl 
15g melted agar 
Deionised water to 1l and autoclave to sterilise 
Ampicillin or kanamycin to 100mg/ml 
 
Molecular biological buffers: 
TENS Buffer 
10ml 1M Tris-HCL (pH 8.0) 
2ml  0.5M EDTA 
50ml 10% SDS 
100ml 1M NaOH 
Distilled water to 1l and autoclave to sterilise 
Store at 37°C 
 
TE Buffer (Tris-EDTA) 
2ml 1M Tris-HCL (pH 8.0) 
400μl 1mM EDTA 
Sterile water to 200ml 
 
TAE Buffer (Tris-acetate EDTA) (50X) 
242g Tris base 
57.1g glacial acetic acid 
100ml 0.5M EDTA 
Distilled water to 1l and autoclave to sterilise 
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Western blotting reagents: 
12% separating gel 
12 ml 30% Acrylamide (29:1) 
11.25ml 1/1.5M Tris (pH 8.8) 
 300μl 10%SDS 
6.5ml water 
200μl 10% APS 
50μl TEMED 
 
Stacking gel 
1.7ml 30% Acrylamide (29:1) 
1.25ml 1M Tris (pH 6.8) 
100μl 10%SDS 
7ml water 
100μl 10% APS 
30μl TEMED 
 
Transfer buffer 
25mM Tris 
190mM glycine 
20% methanol 
 
TBS-Tween 20 
20mM Tris (pH 7.5) 
150mM NaCl 
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0.2% Tween 20 
 
Blocking buffer 
100ml TBS-Tween 20 
5% milk powder 
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Appendix II: List of Primers 
A list of all primers used in this investigation is shown. 
Name Sequence Melting 
Tempera
ture (°C) 
BBLV G for GATCATGGTACCGCCACCATGCCAACTCAAGCCGTCCT 86.9 
BBLV G rev GATCATCTCGAGCTAAGCTTGACCTCCTGCAT 76.1 
WCBV G PT 
For 
GCGCGCGGTACCGCCACCATGGCTTCCTACTTTGCG 89.8 
WCBV G PT 
Rev 
GCGCGCCTCGAGTTATTGGGCAGTTTGTC 80.6 
CVS G PT For GCGCGCGGTACCGCCACCATGGTTCCTCAGGTTGTT 88.6 
CVS G PT Rev GCGCGCCTCGAGTTACAGTCTGATCTCACCTC 80.2 
LBV D PT For TATATATAGGTACCGCCACCATGAGTTACTCGATTTCAACACC 76.7 
LBV D PT Rev TATATATACTCGAGTTAGGCATTTGAGGAGCCCTTG 72.6 
BBLV int G for GAGACTGCAAAATGGTGC 59.4 
BBLV int G rev AAGTCATGAATGTTCACC 52.6 
IKOV G for TATATAGGTACCGCCACCATGGCTCAGTTGGTCACTTTGG 81.1 
IKOV G rev TATATACTCGAGCTAGAATGCAGAACTCTTGTAA 67 
IKOV G int for CGACCCTCAGGATGTGTTCCA 69.6 
IKOV G int rev AATTTAACTGTGTGTTTGTTC 53.3 
LBV G (RV1) 
for 
GCGCGCGGTACCGCCACCATGAGTCAACTAAATTTGATACTCT 84.6 
LBV G (RV1) 
rev 
GCGCATCCCGGGGCCACCATGAGTCAACTAAATTTGATACTCT 85.1 
CVS G site swap 
checks for 
ACGATACCAGACGAACCTGG 63.9 
CVS G site swap 
checks rev 
TAACTGAAGATTTCAACAACTCC 58.8 
LBV G site swap 
checks for 
AATTCCTGAAAAGATAGG 50.4 
LBV G site swap 
checks rev 
ACATCAACAAATTCATCGGCATCACC 72 
pI.18 for GGTGGAGGGCAGTGTAGTCT 63.2 
pI.18 rev GAAGACACGGGAGACTTAGT 57.4 
CVS to LBV I 
rev 
AGGCTTTCCACATAACGTGAGCC 69.1 
LBV to CVS I 
rev 
TAGTACCCCACATAATTTCAGTTTAC 60 
LBV to CVS IV 
for 
ACTTTCACATAGATGAAGTTG 53.3 
LBV to CVS III 
for 
TAAAAGCGTTCGCACTTGGAATGAAATAC 71.0 
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LBV to CVS III 
rev 
ATTCCAAGTGCGAACGCTTTTATAATGAACG 73.4 
CVS G Transfer 
into FL For 
TATATATACCCGGGAAAGATGGTTCCTCAGGTTC 73.4 
CVS G Transfer 
to FL Rev 
TATATATAGCTAGCCAGTCCTTATCACAGTCTGATCTCACCTC
C 
74.8 
LBV G Transfer 
into FL For 
TATATATACCCGGGAAAGATGAGTCAACTAAATTTG 69.7 
LBV G Transfer 
to FL Rev 
TATATATAGCTAGCCAGTCCTTATCAGACATTAGAGG 67.6 
CVS G transfer 
into FL HpaI 
For 
TATATATAGTTAACAAAGATGGTTCCTCAGGTTC 65.5 
LBV G transfer 
into FL HpaI 
For 
TATATATAGTTAACAAGATGAGTCAACTAAATTTG 61.1 
LBV G into FL 
PmeI for  
TATATATATATATATAGTTTAAACAAGATGAGTCAACTAAATT
TG 
62.7 
LBV G into FL 
XbaI rev 
TATATATATATATATATCTAGACAGTCCTTATCAGACATTAGA
GG 
63.6 
gib cSN rev CTGTTTAAACGGTCTTTTGAGGGATGTTAATAG 69.3 
gib LBV into 
cSN for 
CATCCCTCAAAAGACCGTTTAAACAGATGAGTCAACTAAATTT
GATACTC 
77.8 
gib LBV into 
cSN rev 
TAGCCAGTCCTTACAGTCAGACATTAGAGGTACCC 73.0 
gib cSN for CTGTAAGGACTGGCTAGC 54.9 
WCBV G 
transfer into FL 
HpaI For 
TATATATAGTTAACAAGATGGCTTCCTACTTTGC 65.5 
WCBV G 
transfer into FL 
NheI Rev 
TATATATAGTCAGCACCTTGTTATTGGGCAGTTTGTC 71.8 
IKOV G 
transfer into FL 
HpaI For 
TATATATAGTTAACAAGATGGCTCAGTTGGTCAC 30.5 
IKOV G 
transfer into FL 
NheI Rev 
TATATATAGTCAGCAACCCACTAGAATGCAGAACTCTTG 30.7 
CVSFSS to CVS 
IIa for 
AGA GGGAAGAGAGCATCCAAAGG 67.7 
CVSFSS to CVS 
IIa rev 
CCTTTGGATGCTCTCTTCCCTCT 67.7 
CVSFSS to CVS 
IIb for  
TGAAGGATGTACCAACCTGTCCGAGTTCTCCTACATGGAAC 80.7 
CVSFSS to CVS 
IIb rev  
GTTCCATGTAGGAGAACTCGGACAGGTTGGTACATCCTTCA 80.7 
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Appendix III: Generic Scoring System for Mice Inoculated with 
Lyssaviruses 
This scoring system was used to monitor and score all mice used in the experiments for 
this thesis. The scoring was conducted by members of both the Animal Services Unit 
and Wildlife Zoonoses and Vector Borne Disease Research Group at both daily 
assessments of the animals. 
Clinical Score Clinical Signs 
0 No effect 
1 
Twitching in inoculated limb (in certain strains) 
 
Ruffled fur 
 
Hunched back 
 
Paralysis in inoculated leg 
2 
Spasms (in certain strains) 
 
Affected gait 
(slow or circular movements) 
3 
Hind quarter Paralysis 
 
Severe spasms (in certain strains) 
4 Progressive paralysis 
5 Prostration, permanent recumbency 
Death 
 
 
 
